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Abstract 
Designer benzodiazepine is the term used when referring to benzodiazepines, which 
have been available for recreational use since the late 2000s. Some designer 
benzodiazepines are prescribed in other countries and became popular in the UK as 
a drug of abuse, others were investigated as medicines in the 1960s and 1970s but 
were never brought to market. A few designer benzodiazepines are novel drugs 
created solely for the recreational market. Originally sold as ―research chemicals‖ or 
―legal highs‖ they circumvented the law by having small structural differences to the 
traditional benzodiazepines and sold in packages containing the disclaimer ―Not for 
Human Consumption.‖ The introduction of the Psychoactive Substances Act 2016 
(PSA) put new UK legislation in place to control the distribution and manufacture of 
any compound that is ―capable of producing a psychoactive effect,‖ this captured the 
designer benzodiazepines as well as other ―legal highs‖. This legislation works in 
conjunction with the current Misuse of Drugs Act 1971 (MoDA), thereby legislating 
against a distinct list of drugs in the MoDA and any drug producing a psychoactive 
effect in the PSA. 
While there is now clarity of the legal status of these drugs, the scale of use in 
different sub-populations in Scotland, before and after, this legislation is unknown. 
There is little literature exploring how commonly designer benzodiazepines are 
detected in post-mortem cases from both drug related and non-drug related deaths. It 
has been demonstrated that etizolam is a common finding in drug-related deaths in 
Scotland but there is a lack of data regarding the designer benzodiazepines that 
emerged after etizolam. This makes toxicological interpretation and the decision to 
include the drug in the cause of death very difficult for toxicologists and pathologists, 
respectively, as there is a lack reference ranges to consult. Similarly the scale of use 
in living populations who are required to abstain from drugs for reason such as 
treatment or incarceration is unknown. The initial legality and the belief they may 
evade detection by simple screening tests make the designer benzodiazepines an 
attractive option.  
Two Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) methods were 
developed in order to test the different sub-populations. The urine method developed 
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was a qualitative screen and was validated for use. The blood method developed was 
used to quantify the designer benzodiazepines and was validated for use. 
A total of 2,582 samples were analysed from the different sub-populations. Of these, 
893 were urine samples from living participants and 1691 were blood samples from 
deceased individuals. All blood samples were from the post-mortem (PM) cohort and 
369 (22%) of the cases were positive for the designer benzodiazepines tested. 
Diclazepam was detected in 212 cases and gave a median concentration of 0.017 
mg/L (n=157, 0.005 – 0.211 mg/L), Delorazepam was detected in 339 cases and 
gave a median concentration of 0.043 mg/L (n=311, 0.005 – 1.50 mg/L), 
Lormetazepam was detected in 144 cases and gave a median concentration of 0.010 
mg/L (n=85, 0.005 – 0.18 mg/L), Flubromazepam was detected in 18 cases and gave 
a median concentration of 0.66 mg/L (n=15, 0.01 – 2.30 mg/L), Pyrazolam was 
detected in 9 cases and gave a median concentration of 0.033 mg/L (n=6, 0.008 – 
1.10 mg/L). These concentrations can assist in the toxicological interpretation of these 
drugs.  
The urine samples, which were screened for a wider range of benzodiazepines, were 
from three different cohorts. These were made up of individuals being admitted to or 
liberated from one of the seven Scottish Prison Service (SPS) facilities included in 
this study, individuals under the supervision of a Drug Treatment and Testing Order 
(DTTO) through the Scottish Drug Court (SDC) system in Glasgow and patients 
undergoing psychiatric treatment from NHS Greater Glasgow and Clyde Forensic 
Directorate (NHS GGC FD). The analysis found that 55% of the 73 urine samples 
from the SDC were positive, 41% of the 725 SPS urine samples were positive and 
there were no positive samples found in the 95 NHS GGC FD urine samples.  
The results of the studies show that benzodiazepines and designer benzodiazepines 
are widely used in the Scottish population. The individuals from the SDC and NHS 
GGC FD were able to refuse to take part in the study or able to abstain before their 
known drug test date. The SPS samples only gives a snapshot of those being 
admitted to or liberated from prison, which is not a reflection of the general inmate 
population and not every post-mortem case was tested for designer benzodiazepines. 
However despite these limitations, key information about the scale, nature and blood 
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concentrations of the designer benzodiazepines being abused in Scotland was 
gained. 
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1. Introduction to Benzodiazepines and Designer Benzodiazepines 
1.1. Introduction 
The use of benzodiazepines has been a long-term problem in Scotland. In the 
1980s, temazepam was the most widely abused prescription drug in the UK 
(Ashton, 2002) and in 1990s Scotland, there was a brief trend of removing it from 
its gel capsule to combine with other drugs for injection. Scottish drug users are 
known to take ―supratherapeutic‖ or mega doses of benzodiazepines as it can 
increase the high from heroin and increase intoxication when used together. 
(Johnson, Barnsdale and McAuley, 2016) An audit of drug prescribing in NHS 
Greater Glasgow and Clyde in 2013 found that 25% of opioid users were 
prescribed one or more benzodiazepine type drugs. (Johnson, Barnsdale and 
McAuley, 2016) It seems that Scottish drug users have always sought out the use 
of benzodiazepines, therefore when a wave of novel benzodiazepines were legally 
for sale in Scotland from 2010 onwards, these were an attractive addition to the 
drug using population. Some of these drugs were completely new preparations, 
others had been patented in the 1960s and 70s but never fully investigated or 
brought to market. In the years that followed the Scottish drug landscape changed 
rapidly with the availability of new ‗legal‘ drugs. These changes presented 
challenges for not just the users and their families but the treatment services, 
policymakers and the laboratories that were responsible for detecting these drugs.  
This work will investigate the use of some of these designer benzodiazepines in 
blood from deceased individuals and in urine of living participants from a 
population with a history of drug use, a population under psychiatric treatment and 
individuals leaving or entering the Scottish prison system. The drugs investigated 
in post-mortem blood were diclazepam and two of its metabolites (delorazepam 
and lormetazepam), pyrazolam and flubromazepam. This analysis dealt with 
active post-mortem cases and was part of the wider toxicological investigation. 
These drugs were chosen, as there was increasing evidence from various 
agencies such as the police and online searches that these drugs may be getting 
abused in Scotland. The urine screen used was more encompassing with 22 
analytes included to give a fuller picture. 
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1.2. History of benzodiazepines 
The first benzodiazepine discovered was chlordiazepoxide, which was synthesised 
accidentally by Dr Leo Sternbach. It was initially placed in storage with no further 
investigation until it was rediscovered and submitted for pharmacological 
evaluation during a laboratory clean up in 1957. It was found to have hypnotic, 
sedative and anti-strychnine effects. The structure was identified as a 1, 4-
benzodiazepine and it was introduced into clinical use in 1960. (Ban, 2006; Lader, 
1991)  Creating new benzodiazepine analogs showed promise that a new, safer 
alternative to the addictive barbiturates had been discovered. Benzodiazepines 
appeared to be non-addictive unlike barbiturates as initial trials showed the users 
were not asking for an increased dose. (Ban, 2006; Lader, 1991)  
Diazepam, now the most well-known benzodiazepine was introduced 1963 and 
became the most popular benzodiazepine worldwide in the 1960s and 1970s. 
(Mehdi, 2012) 
Table 1 shows the introduction of benzodiazepines into the UK pharmaceutical 
market. Some of the drugs displayed in the table are no longer available on 
prescription in the UK, alprazolam is an example of this. It is still commonly 
prescribed in the USA. Ketazolam and flunitrazepam are also no longer prescribed 
in the UK. Flunitrazepam and especially the brand name Rohypnol have a 
negative connotation in popular culture as an untraceable ‗date rape‘ drug.  
Table 1: UK introduction of benzodiazepines 
Drug Name Brand Name Year introduced 
Chlordiazepoxide Librium 1960 
Diazepam Valium 1963 
Nitrazepam Mogadon 1965 
Oxazepam Serenid 1966 
Lorazepam Ativan 1972 
Temazepam Euhypnos 1977 
Clobazam Frisium 1979 
Ketazolam Anxon 1980 
Lormetazepam Noctamid 1981 
Flunitrazepam Rohypnol 1982 
Alprazolam Xanax 1983 
Table amended from Lader 1991 (Ban, 2006; Lader, 1991)
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1.2.1. The emergence of designer benzodiazepines 
The term New (or Novel) Psychoactive Substances (NPS) is defined by the 
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) as ‗a new 
narcotic or psychotropic drug, in pure form or in preparation, that is not controlled 
by the United Nations drug conventions, but which may pose a public health threat 
comparable to that posed by substances listed in these conventions'. (EMCCDA) 
NPS are often called designer drugs and are usually, but not exclusively, structural 
analogues designed to mimic the effect of a traditional drug of abuse while 
circumventing the legislation. (Wohlfarth and Weinmann, 2010; Stephenson and 
Richardson, 2014)  
In 2007, the EMCDDA expanded its early warning system (EWS) scope to include 
all NPS; this saw a dramatic increase in compounds reported to the EMCCDA 
each year.  
According to the EMCDDA, phenazepam was the first designer benzodiazepine to 
hit the recreational market in 2007 and from around 2012 phenazepam and 
etizolam were sold by online retailers as ‗research chemicals,‘ (EMCDDA., 2015) 
See figure 1 for a timeline of designer benzodiazepines and when they were 
reported to the EMCDDA.  
 
Figure 1: EMCDDA timeline of reported designer benzodiazepines. 
(EMCDDA, 2015) 
From around 2012/2013, stores in city centres across Britain, known as ‗head 
shops‘, would also stock these research chemicals. Stimulants and synthetic 
cannabinoids were available alongside the designer benzodiazepines in these 
shops and online. Figure 2 shows two packets of designer benzodiazepines 
purchased in a shop in Edinburgh in November 2014. The packaging of the drugs 
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states ‗Not for human consumption‘ which at the time was a way to avoid providing 
any information about the use of the drug or the harms and circumvent trading 
standards legislation. (Stephenson and Richardson, 2014) A report in 2016 placed 
the UK as the second highest country (after the USA) of dark net vendors selling 
illegal drugs. (Kruithof, 2016) Etizolam, diclazepam, flubromazepam, phenazepam 
and pyrazolam are the most frequent designer benzodiazepines reported to the 
EMCDDA. Etizolam, diclazepam, flubromazepam and phenazepam make up 80% 
of the European drug seizures of designer benzodiazepines since 2005.  
 
Figure 2: Designer benzodiazepine packets purchased in a head shop in 
Edinburgh in 2014 
 
Designer benzodiazepines have existed for decades before they became a drug 
sold for recreational purposes, Table 2 shows the year each designer 
benzodiazepine was first patented and the year it was reported to the EMCDDA 
EWS. Due to this, the term NPS should be thought of as newly misused or newly 
available on the drug market as these substances are often not inherently new, 
some are prescribed in other countries. The availability of these drugs was 
concerning for drug treatment services, the NHS and toxicology laboratories. 
These drugs were potentially evading their detection and causing unknown harms 
to the drug using population.  
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Table 2: Designer benzodiazepine patent date and date reported to EMCDDA 
Drug Year patented Year reported to EMCDDA 
Phenazepam 1974 2007 
Etizolam 1978 2011 
Pyrazolam 1979 2012 
Diclazepam 1964 2013 
Flubromazepam 1962 2013 
Nifoxipam 1985 2014 
Flubromazolam 1978 2014 
Clonazolam 1971 2014 
Deschloroetziolam 1998 2014 
Metizolam 1988 2015 
Table amended from Manchester et al (Manchester et al., 2018) 
Google trends is a service which analyses the popularity of Google search terms 
in a geographical location and in any selected period of time. Figure 3 shows the 
trends for phenazepam, etizolam, diclazepam and flubromazepam from the 
beginning of 2012 to the beginning of 2019 in Scotland. Etizolam is the most 
popular drug searched and its popularity peaked in September 2014. February 
2012 was the peak of phenazepam searches, diclazepams‘ search peak was 
August 2015 and flubromazepams‘ was October 2014. Most of the other designer 
benzodiazepine had very little data on Google trends so have not been included.  
 
Figure 3: Google trends data showing the search popularity of four designer 
benzodiazepines over a 7-year period 
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1.3. Prescribing benzodiazepines 
Benzodiazepines have been used effectively for many clinical reasons such as 
anxiety, depression, stress, withdrawal therapy from drugs and alcohol, treatment 
of seizures, treatment of sleep disorders, palliative care, pre/post-operative care 
and as muscle relaxants. (Mehdi, 2012) Benzodiazepines are grouped into short, 
medium and long acting characterised by the half-life of the parent drug. A long-
acting benzodiazepine such diazepam has a half-life of 20 to 50 hours, a medium 
acting such as lorazepam has a half-life of 10 to 20 hours and a short acting 
benzodiazepine such as midazolam a half-life of 1 to 4 hours. The duration of 
action determines their clinical use. The long to medium acting drugs are useful in 
treatment of anxiety, as this tends to be a reoccurring condition. The short acting 
benzodiazepines are used in anaesthesia and palliative care, as they are not 
required for a lengthy time. 
The apparent safe nature and their usefulness in treating multiple conditions led to 
a huge rise in prescribing benzodiazepines; in 1980 around 80 billion doses of 
benzodiazepines were consumed each day worldwide. (Tyrer, 1980) In April 2013, 
NHS Greater Glasgow and Clyde issued guidance to ban prescribing 10 mg 
diazepam doses (known as ―blue vallies‖) and recommended 2 mg instead, This 
was also a way to determine fake ―blue vallies‖ from prescription ones however 
yellow or white fakes were also then produced. Users in Glasgow often take many 
tablets at the one time and a lower dose is therefore safer. (NHS Greater Glasgow 
& Clyde Area Drug and Therapeutics Committee, 2013) This reinforces the high 
abuse potential of benzodiazepines in Glasgow and the attempts local authorities 
have put in place to try and curb that abuse.  
Benzodiazepines are useful for treating conditions such as mild anxiety however 
prescribing them to individuals with severe mental illnesses such as schizophrenia 
and bipolar disorder can exacerbate the symptoms such as anxiety and 
depression. A study found that individuals with a mental health disorder and a 
substance abuse history are unlikely to refrain from drug abuse when prescribed 
benzodiazepines and are likely to abuse them. The study was made up of 203 
patients who were assessed through yearly follow up interviews over six years, 
43% of participtants were prescribed benzodiazepines at the time of at least one 
assessment. Relying on interviews can lead to under reporting and as they were 
conducted yearly, intermittent benzodiazepine use may have been missed 
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nevertheless alternative approaches to managing symptoms should be sought for 
these individuals. (Brunette et al., 2003) The mismanagement and over-
prescribing of benzodiazepines by health care professionals within acute mental 
health settings is also reportedly a concern. This can lead to tolerance, addiction 
and can be dangerous when used in combination with other CNS depressants. 
(Duxbury and Baker, 2004) 
The benzodiazepines, diazepam, temazepam, oxazepam, nitrazepam, lorazepam, 
lormetazepam, loprazolam and chlordiazepoxide were all dispensed in Scotland in 
2017/18. (Information Services Division Scotland, 2018) Diazepam was the most 
commonly dispensed (879,177 times) and lormetazepam the least dispensed 
(2,533 times) over the year period. Figure 4 shows how many times each 
benzodiazepine was dispensed in Scotland in 2017/2018. Whilst this doesn‘t give 
information on how many people received these drugs, it gives some scale to how 
many legitimate prescriptions of these drugs there were. 
 
Figure 4:Number of benzodiazepines dispensed in Scotland in 2017/2018 
 
1.4. Abuse of benzodiazepines 
 Opioid users frequently also misuse benzodiazepines; this can be to increase 
the high from the opioid(s) or to self-medicate to treat withdrawals or psychological 
issues. It has been shown in the ample evidence summarised in the review by 
Jones et al how opioids and benzodiazepines are commonly co-abused and that 
2,533 
5,076 
6,932 
13,354 
16,857 
56,078 
60,640 
103,912 
122,035 
879,177 
Lormetazepam
Loprazolam
Oxazepam
Chlordiazepoxide
Clobazam
Clonazepam
Nitrazepam
Lorazepam
Temazepam
Diazepam
 
 
8 
the intensity and duration of opioid drugs can be prolonged by the concomitant use 
of benzodiazepines, (Jones, Mogali and Comer, 2012) studies have especially 
focused on benzodiazepine use in those on opioid replacement therapy. 
Methadone users reported stronger highs and euphoria when used with diazepam 
however this was a small study of only five patients (Spiga et al., 2001) Greater 
and prolonged respiratory depression was observed when midazolam was given 
intravenously with buprenorphine then one drug alone in rodents, this was 
determined by sampling the arterial gases and pH. (Gueye et al., 2002) This 
indicates injecting benzodiazepines along with opioids may be particularly 
dangerous however oral administration is the most common way to consume 
benzodiazepines. (EMCDDA., 2015)  
Intelligence on the drugs being seized by the police on the street can give an 
indication on what drugs are being abused. This can be a very valuable resource 
in dynamic drug markets as it provides a relevant snapshot and often informs what 
drugs forensic laboratories should analyse for. The number of any type of drugs 
seized from year to year can vary dramatically; in 2016/2017 2.2 million 
benzodiazepine tablets were seized in Scotland by police. (Scottish Government., 
2019) In 2017/2018 Police Scotland seized 321,000 diazepam or other 
benzodiazepine tablets, this number does not include etizolam. The number of 
etizolam tablets seized was 240,000. Figure 5 shows the percentage of drug 
seizures in 2017/2018 in Scotland, this data demonstrates that benzodiazepine 
tablets are a common drug to find on Scottish streets, the presence of 
benzodiazepines that are not diazepam on the street may be the more significant 
information rather than the absolute number of seized drugs.  
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Figure 5:Percentage of drugs including diazepam and etizolam in Police Scotland 
drug seizures 2017/2018  
(reproduced with permission under the Open Government License 
http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/) 
 
Another way to gauge the extent of benzodiazepine use or abuse is to assess its 
prevalence and how it compares to the other drugs detected in driving populations. 
One study investigating the post-mortem blood results of drivers in fatal collisions 
from 2012 to 2015 in Scotland found that benzodiazepines was the third most 
common drug group found after cannabis and opioids. This benzodiazepine 
finding was in 12% of the cases examined (n=14 out of the 118 cases examined). 
Diazepam was found in 13 out of 14 cases; once in combination with phenazepam 
(a designer benzodiazepine) and in one case phenazepam was found on its own. 
Due to benzodiazepines being a common drug of abuse in Scotland and a lack of 
prescription information for diazepam, it was not clear if these cases were from 
illicit or therapeutic use. (Hamnett et al., 2017) Another driving study in Scotland 
noted a dramatic increase in arrested drivers who tested positive for 
benzodiazepines from the time period of 1996 to 2000 (39%) and in 2008 (85%). 
This study utilised a screening method only and the positive results were not 
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confirmed. (Officer, 2009) Screening tests are further described in Chapter 2, 
screening tests are non-specific tests and therefore the use of a screening method 
alone means that there is a chance of false positives and the results of the study 
may not be accurate. The study does not mention any change in the screening 
method over time and therefore the false positive rate could be consistent leading 
to comparable results and a valid conclusion of an increase in benzodiazepine use 
in drivers in Scotland from 2000 to 2008.  
1.5. Structure 
Understanding of molecular structure of drugs is essential in forensic toxicology in 
order to make decisions on how best they can be analysed, the similarity or 
differences between drugs can be utilised for the identification of the compound. 
  
Figure 6: The structure of a 1, 4-benzodiazepine 
 
The general structure of a 1,4 benzodiazepine is made up of a seven-member 
diazepine ring with a fused benzene ring and a phenyl ring, see Figure 6. Table 3 
shows the differences in the structural positions of common benzodiazepines. 
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Table 3: The structural positions of common benzodiazepines 
Drug R1 R2 R3 R2’ R7 
Diazepam  CH3 O H2 H Cl 
Desmethyldiazepam H O H2 H Cl 
Temazepam CH3 O OH H Cl 
Oxazepam H O OH H Cl 
Lorazepam H O OH Cl Cl 
 
1.5.1. Designer benzodiazepines structure 
Designer benzodiazepines have a similar structure to the commonly prescribed 
benzodiazepines, for example an additional chlorine atom is the only difference 
between diclazepam and diazepam. The addition of the chlorine makes 
diclazepam a more potent drug than diazepam. The addition of a halogen such as 
fluorine or chlorine at the R2‘ position results in significantly enhanced activity at 
the receptor level. (Moosmann and Auwärter, 2018) Table 4 and Figure 7 show 
the differences in the structural positions of designer benzodiazepines.  
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Figure 7: The structure of a 1,4 benzodiazepine (a), thienotriazolodiazepine (b) 
and triazolodiazepine (c) 
Table 4: The structural positions of designer benzodiazepines 
Drug R1 R2 R2‘ R7 
1, 4 benzodiazepines     
Diclazepam CH3 O Cl Cl 
Flubromazepam H O F Br 
Meclonazepam H O Cl NO2 
Nifoxipam H O F NO2 
Phenazepam H O Cl Br 
Thienotriazolodiazepines     
Deschloroetizolam 
Etizolam 
Metizolam 
Triazolodiazepine 
CH3 
CH3 
H 
H 
Cl 
Cl 
- 
- 
- 
- 
- 
- 
Clonazolam 
Flubromazolam 
Pyrazolam 
NO2 
Br 
Br 
Cl 
F 
H 
- 
- 
- 
- 
- 
- 
 
There does not appear to be a relationship between structure and half-life 
therefore it is not possible to predict the half-life based on another benzodiazepine, 
for example diclazepam and flubromazepam share the 1,4 benzodiazepine 
structure and have only slight differences at positions R1, R2 and R5 however 
diclazepam has a much shorter half-life of 46 hours compared to flubromazepam 
estimated half-life of 106 hours. This increases the potential hazard for 
recreational users consuming benzodiazepines that there is little information 
about. Inadvertent re-dosing with a compound that has a very long half-life could 
result in toxicity due to unintended drug accumulation. (Greenblatt and Greenblatt, 
2019) A study from 2018 developed a model to predict the receptor binding affinity 
of the new benzodiazepines, the model known as quantitative structure-activity 
 
 
13 
relationship (QSAR) postulated the benzodiazepines classified under the 
Psychoactive Substances Act (PSA) did have a greater binding affinity than the 
medically prescribed benzodiazepines, the analysis concluded the 
triazolobenzodiazepines were the most potent group. (Waters et al., 2018) 
However, there are no in vivo studies to test this theory. Benzodiazepines can be 
classified by their structure, their duration of action or their half-life. Designer 
benzodiazepines are best classified by their structure as this information is fully 
known. Etizolam, phenazepam and alprazolam are not technically designer 
benzodiazepines as they are prescribed in other countries; etizolam is used 
medicinally in Japan, phenazepam in Russia and alprazolam in the USA. However 
they are not prescribed in the UK and their use in Scottish samples indicates illicit 
benzodiazepine use, therefore for simplicity they will be considered designer 
benzodiazepines in this study.  
Figure 8 shows the full structure of the diclazepam, pyrazolam and 
flubromazepam, the three drugs of particular interest in this research, 
predominantly in post-mortem blood. 
 
Figure 8: Diclazepam, pyrazolam and flubromazepam structures 
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1.6. Mechanism of action 
The mechanism of action explains on a cellular level how the drug has an effect on 
the body. In order to understand how benzodiazepines work on the human body 
knowledge of their mechanism of action is required, therefore it is quite 
astonishing that the benzodiazepine receptor was not detailed in literature until 
1977, 17 years after diazepam was first prescribed. (Möhler and Okada, 1977) It is 
now understood that benzodiazepines bind allosterically to the gamma-
aminobutyric acid A (GABAA) receptors in the central nervous system (CNS). 
GABA is the major inhibitory neurotransmitter in the CNS. The GABAA receptor is 
a protein complex, which is made up of five subunits forming a chlorine ion 
channel. There are 16 subunits within the seven subunit families (α 1-6, β 1-3 γ 1-
3, δ, ε, π, θ) that make up various combinations; the most common combination in 
the brain is α2β2γ. (Olsen and Sieghart, 2009) Benzodiazepines bind allosterically 
between the α1 and γ2 subunits. Allosteric binding describes the binding of a 
molecule to the receptor at a site other than the neurotransmitter site; therefore the 
molecule has an indirect effect. Figure 9 shows a schematic diagram of the 
receptor; the A denotes the benzodiazepine binding site and the B denotes the 
GABA binding site. Benzodiazepine binding increases the frequency of the 
opening of the chlorine channel when neurotransmitter gamma-aminobutyric acid 
(GABA) is bound to its own site on the receptor. An increased concentration of 
chlorine ions in the postsynaptic neurons results in a hyperpolarised membrane, 
this gives a sedative effect, as the membrane is less excitable. (Sieghart, 1995) 
Ethanol and barbiturates are examples of other drugs which also bind allosterically 
to the GABAA receptor. Barbiturates work in a slightly different way at the receptor 
level than benzodiazepines, they do not need GABA to also be bound to the 
receptor and they increase the length of time the ion channel is open rather than 
the frequency. As a result, barbiturates are capable of greater CNS depression 
and toxicity than benzodiazepines. (Tan, Rudolph and Lüscher, 2011) 
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Figure 9: The GABAA receptor protein complex 
 
The potential for benzodiazepine dependence is still not fully understood, there are 
studies that have suggested dependence is purely psychological and is associated 
with the ritual of daily benzodiazepine use. (de las Cuevas, Sanz and de la 
Fuente, 2003) However other studies have suggested there is potential for 
addiction as withdrawal symptoms such as tremors are often noted after the 
cessation of use. These symptoms are likely from neuroadaptions attempting to 
maintain the body‘s homeostasis by overcoming the increased depression of the 
CNS. When the use of benzodiazepines is halted these neuroadaptions cause the 
sudden hyper-excitability of the nervous system and this is the appearance of 
withdrawal symptoms. (Allison and Pratt, 2003) 
1.7. Metabolism 
Drug metabolism is extremely valuable for toxicologists as the metabolites provide 
markers for drug detection. Benzodiazepine metabolism in particular can be 
complex as many parent drugs can produce the same metabolites in the body and 
some will metabolise to drugs that are also prescribed e.g temazepam is a parent 
drug and a metabolite of diazepam making interpretation complex. Blood 
concentrations are required to assess the ratio of the drugs to determine what may 
have been ingested.  
Metabolism is the chemical alteration of a drug by the body for the purpose of 
excretion. It consists of two stages known as phase I and phase II metabolism. 
Phase I is responsible for the transformation or addition of a functional group by 
oxidation, reduction or hydrolysis. Phase II is responsible for conjugation, this 
transforms the molecule by conjugating the drug or metabolite to an endogenous 
molecule such as glucuronic acid. (J.-P. Tillement, 2007) Oxidation and 
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glucuronidation are the two main pathways in benzodiazepine metabolism. 
(Mandrioli, Mercolini and Raggi, 2008) 
The phase I oxidation step is carried out by cytochrome P450 which is a 
superfamily of enzymes. The main cytochrome P450 enzymes involved in 
diazepam metabolism are CYP3A4 and CYP2C19. CYP3A4 is the most common 
isoform found in the human liver and is responsible for catalysing the metabolism 
of over 50% of clinical drugs. (Mizuno et al., 2009) Genetic polymorphisms 
(individual differences determined by genetics) in the cytochrome P450 enzymes 
cause variation in how individuals metabolise a drug (e.g. fast and slow 
metabolisers). (Gibson and Skett, 2013; J.-P. Tillement, 2007) The oxidation of 
benzodiazepines by the cytochrome P450 system produces active metabolites, 
which in turn have to be glucuronidated to be excreted. The duration of this 
process and the production of active metabolites mean the duration of action can 
be very long. Drugs such as oxazepam and lorazepam that are metabolised by 
direct glucuronidation have short durations of action as the glucuronidation 
produces inactive metabolites that are rapidly excreted. (Mandrioli, Mercolini and 
Raggi, 2008) Figure 10 shows how diazepam is metabolised to 
desmethyldiazepam and temazepam, which are then both metabolised to 
oxazepam, which is then conjugated into a glucuronide metabolite for excretion. 
Temazepam is also excreted by glucuronidation. Diazepam and 
desmethyldiazepam are the main analytes detected in the blood as oxazepam and 
temazepam undergo glucuronidation and are excreted at almost the same rate as 
they are produced. (Mandrioli, Mercolini and Raggi, 2008) 
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Figure 10: Diazepam metabolism 
 
1.7.1. Designer benzodiazepines metabolism 
As designer benzodiazepines have not been subjected to clinical trials the way 
pharmaceutical benzodiazepines have, there is limited information on their 
metabolism and pharmacokinetic properties. However recent studies have shown 
they undergo the same pathways of oxidation and glucuronidation as 
pharmaceutical benzodiazepines. (Moosmann, Bisel and Auwärter, 2014; 
Moosmann and Auwärter, 2018) Figure 11 shows how diclazepam is metabolised 
to delorazepam and lormetazepam, which are then both metabolised to 
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lorazepam, which is turned into a glucuronide for excretion. Lormetazepam and 
delorazapam are also excreted by glucuronidation. 
 
Figure 11: Diclazepam metabolism 
 
A study by Moosmann et al identified two hydroxyl metabolites for flubromazepam, 
(Moosmann et al., 2013a) one of these metabolites was debrominated which is 
thought to be the result of bacterial degradation of flubromazepam in the gut. 
(Moosmann and Auwärter, 2018) The main metabolite is 3-
hydroxyflubromazepam. (Moosmann and Auwärter, 2018) Both hydroxyl 
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metabolites are glucuronidated and only a low concentration of the parent drug 
was detected in urine. Figure 12 shows the metabolism of flubromazepam. 
(Moosmann et al., 2013a) 
 
Figure 12: Flubromazepam metabolism 
 
Initial studies suggested that pyrazolam was not extensively metabolised, as the 
unchanged parent drug can be easily detected in urine. (Moosmann et al., 2013b) 
However a subsequent study has shown a parent glucuronide as well as a 
hydroxyl glucuronide. (Pettersson Bergstrand et al., 2018)  
The elimination half-life of some designer benzodiazepines has been estimated 
using volunteer studies. (Moosmann, Bisel and Auwärter, 2014; Moosmann et al., 
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2013b; Moosmann and Auwärter, 2018; Moosmann et al., 2013a; Huppertz et al., 
2015) Self-administration of a low dose of some designer benzodiazepines in 
serum by healthy volunteers was described in articles by Moosmann et al and 
Huppertz et al, Table 5 gives a summary of the dose and half-life. (Moosmann et 
al., 2013b; Moosmann et al., 2013a; Moosmann, Bisel and Auwärter, 2014; 
Huppertz et al., 2015) As these studies are one instance of the drug being 
ingested once by one person it is very preliminary data.  
Table 5: Results from four designer benzodiazepine self-administration studies 
Drug Dose ingested 
(mg) 
Maximum 
concentration 
reached (mg/L) 
Elimination half-life 
(h) 
Pyrazolam 1 0.051 17 
Flubromazepam 4 0.078 106 
Diclazepam 1 0.003 42 
Flubromazolam 0.5 0.009 10-20 
  
The metabolism of phenazepam is not well documented in literature and this 
poses an issue as 3-hydroxyphenazepam was reported to the EMCDDA in 2016 
as a designer benzodiazepine however it is also a phenazepam metabolite. One 
study demonstrated how 3-hydroxyphenazepam only fortified samples contained 
phenazepam; this is thought to be due to thermal instability. This makes 
interpretation complex, as it is not clear what has been consumed. (Crichton et al., 
2015) 
1.8. Legislation 
All benzodiazepines are Schedule IV controlled drugs, with the exception of 
flunitrazepam, which is a Schedule III controlled drug under the UN Convention on 
Psychotropic Substances. This is an international treaty designed to control 
psychoactive drugs. (United Nations Office Drugs and Crime, 1968) 
Benzodiazepines are controlled under the Misuse of Drugs Act 1971 in the UK, as 
Class C drugs. (Misuse of Drugs Act 1971, 2019) Class C drugs are considered to 
be the drugs, which have the least capacity for harm of all controlled drugs, 
however it has been suggested that the classification does not accurately reflect 
potential for harm. (Nutt, King and Phillips, 2010) The benzodiazepines that are 
medicines in the UK, such as diazepam and lorazepam are listed under schedule 
4 part 1 of the Misuse of Drugs Regulations 2001. The Misuse of Drugs 
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Regulations 2001 determines the legitimate use for controlled drugs. Schedule 4 
part 1 prohibits the production of the drugs listed but allows for medicinal 
consumption. (The Misuse of Drug Regulations 2001, 2001) 
An amendment to The Misuse of Drugs Act 1971 in May 2017 classified most 
designer benzodiazepines as a Class C drug in the UK. (Misuse of Drugs Act 
1971, 2019) The designer benzodiazepines are listed under schedule 1 the 
Misuse of Drugs Regulations 2001. Schedule 1 lists the drugs that have no 
medicinal use in the UK. (The Misuse of Drug Regulations 2001, 2001) The 
Advisory Council on the Misuse of Drugs  (ACMD) recently released a report 
recommending the classification of a 13 further designer benzodiazepines such as 
flualprazolam as Class C drugs under the Misuse of Drugs Act 1971 and as 
Schedule 1 under the Misuse of Drugs Regulations in line with the other designer 
benzodiazepines. (Advisory Council on the Misuse of Drugs, 2020) 
1.9. Benzodiazepines in drug related deaths 
Collating the data for drugs which are present in deaths and in particular drug 
related deaths (DRD) allows trends to be identified in drug use and more 
importantly can inform which drugs are most dangerous or which concentrations of 
drugs are dangerous. Benzodiazepines are not known to be fatal drugs however 
their presence amongst drug deaths is common. This is due to them being used in 
combination with of other drugs particularly opiates as discussed in section 1. 4. 
The Office for National Statistics report on ‗Deaths related to drug poisoning in 
England and Wales: 2018 registrations‘ showed around 10% of drug poisoning 
deaths included the name of a benzodiazepine in the cause of death. In the report 
the definition of a drug related death is given as ―a …death …where either the 
underlying cause is drug abuse or drug dependence, or the underlying cause is 
drug poisoning and any of the substances controlled under the Misuse of Drugs 
Act 1971 are involved.‖ (Office for National Statistics, 2019) 
Figure 13 shows how many cases mentioned a benzodiazepine in the cause of 
death in England and Wales from 1993 to 2018. In recent years there has been an 
upward trend however there has been an increase in drug-related deaths since 
2012. Previously these deaths had mostly been linked to heroin/morphine however 
the 2018 dataset included a wider variety of drugs including cocaine and more 
―novel‖ drugs. (Office for National Statistics, 2019) 
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Figure 13: Number of cases with a benzodiazepine mentioned in the cause of 
death in England and Wales over a 25 year period 
(Office for National Statistics, 2019) 
The National Records for Scotland ―Drug-related deaths in Scotland in 2018‖ 
report found that 2018 had the highest ever number of drug deaths at 1,187; a 
27% increase from the 2017 figures. The report states they use the same 
definition as the Office of National Statistics for a drug related death. The report 
also determined that 72% of people dying of a drug related death were male and 
the two age groups spanning 25-44 years old had the largest number of drug 
related deaths. Benzodiazepines were implicated or potentially contributed to 792 
drug related deaths, which is 67% overall. The report states that ‗street‘ 
benzodiazepines such as etizolam were implicated or potentially contributed to 
765 drug related deaths, which is 57% overall. ‗Prescribable‘ benzodiazepines 
such as diazepam are noted to be implicated much less; 228 deaths or 20% 
overall. There were 11 deaths that were attributed to one benzodiazepine only with 
no other drugs detected other than alcohol in some cases; 7 of these 11 were due 
to etizolam. Figure 14 shows the implication of benzodiazepines in drug related 
deaths in Scotland from 2000 to 2018 and the increase in recent years. Figure 14 
also displays the percentage of drug related death cases where a benzodiazepine 
has been included; this shows the increasing trend since 2014. 
 The percentage of benzodiazepines included in the cause of death in Scotland 
has been under 40% from 2004 to 2014, it has been relatively stable for these 10 
years. Perhaps this is partly due to pathologists recognising the traditional 
benzodiazepines such as diazepam, when new drugs appear however this leads 
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to more uncertainty and they are hesitant to exclude them from the cause of death. 
The increase may also be simply due to the rise in popularity of benzodiazepine 
use in drug users. Interestingly, a study published in 2004 compared the 
concentrations of free morphine in the post-mortem blood with co-existant drugs 
and concluded that benzodiazepines result in a higher free morphine 
concentration compared to morphine and alcohol alone. This suggests that 
benzodiazepines are playing an important role in drug-related drugs in particular 
however the cause of the high concentration is not clear and may be a result of 
pharmacokinetics, user tolerance or user error due to intoxication. (Stenhouse, 
Stephen and Grieve, 2004)  
Comparison of Figure 13 and 14 demonstrates how Scotland has a much bigger 
relationship with benzodiazepine use compared to England and Wales. Scotland‘s 
drug deaths (per head of population) are almost three times larger than that of the 
UK as a whole. (National Records of Scotland, 2019) However it is not clear if all 
areas are comparable, it may be that some regions test for a reduced 
benzodiazepine panel in drug related deaths and may not test for the likes of 
etizolam and other designer benzodiazepines. Scotland may detect more 
benzodiazepines in drug related deaths due consistent testing, as these drugs 
have been popular in the country for decades.  
 
Figure 14: Number of cases with benzodiazepine reported in a drug-related death 
in Scotland over a 19 year period.  
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1.9.1. Designer benzodiazepines role in drug related deaths 
There were 575 deaths in which NPS were implicated in 2018 in Scotland; 
designer benzodiazepines were the only NPS present in 571 of those. (National 
Records of Scotland, 2019) Etizolam was the most implicated designer 
benzodiazepine in drug-related deaths and NPS-related deaths although the 
report does not specify the exact etizolam figure for the NPS deaths. Other 
designer benzodiazepines mentioned were alprazolam (alprazolam is a prescribed 
drug in other countries such as the USA, however it is used illicitly in the UK), 
which was included in 137 drug-related deaths then diclazepam in 31 and 
phenazepam in 27. It is worth noting that the report states if a death has a medical 
condition selected first as the cause of death then a drug will not be counted in the 
statistics, despite being named. An example given to explain this would be a 
cause of death given as ‗Coronary artery thrombosis and morphine, etizolam and 
diclazepam intoxication‘ - this would not be counted as a drug related death. 
(National Records of Scotland, 2019) Therefore the drug-related death statistics 
only gives limited information in post-mortem findings of a particular drug as some 
cases will be omitted and this will underestimate the impact of drug abuse.   
With etizolam well documented in drug related deaths from just examining one 
year of data, questions still remain over designer benzodiazepines that came 
immediately after. Pyrazolam, diclazepam and flubromazepam emerged closely 
after etizolam, see Figure 1. It is not clear from the yearly report on drug-related 
deaths what trends these drugs followed and if they are present in the Scottish 
drug users dying from drug related deaths or any death for that matter. The lack of 
data in this area leads to uncertain toxicological interpretation, as there is a lack 
case data to consult. From the high number of etizolam positives in post-mortem 
samples, inferences can be drawn that one or more of the drugs which followed on 
from etizolam would be popular amongst drug users in Scotland and therefore 
present in post-mortem blood samples especially as these drugs were not 
controlled by any legislation initially and were sold in shops and online.  
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1.9.2. Designer benzodiazepine prevalence 
In general, drug prevalence is very difficult to quantify and ascertain. Self-reporting 
studies and defined sub-populations such as individuals requiring treatment from 
emergency departments can be a way to estimate this. 
The National Poison Data System (NPDS) in the USA collated the data from 
reported intentional exposures of single-agent designer benzodiazepines. The 
NPDS had been tracking etizolam exposures from 2007 but not the other designer 
benzodiazepines; these were added in 2016. The study results show that from 
2014 to 2017 there have been 162 instances of etizolam exposure, 4 instances of 
diclazepam and 3 of flubromazepam (Carpenter et al., 2019)  
An article published in 2018 detected 15 designer benzodiazepines, from 2012 to 
2016, in individuals presenting as intoxicated to Swedish emergency departments. 
The study found that there was an increase in positive designer benzodiazepines 
from 4% in 2012 to 19% to 2015. Amongst other designer benzodiazepines, the 
study noted that flubromazolam had been detected in urine samples in 92 
instances, pyrazolam in 33 instances, flubromazepam was also detected in 33 
instances, etizolam in 20 instances and phenazepam in 1 instance. (Bäckberg et 
al., 2019) There is no data to suggest the designer benzodiazepines were all 
individual cases but it was noted that 89% of cases tested had other drugs 
present. No metabolites appeared to be tested for, with the exception of 3-
hydroxyphenazepam for phenazepam. The study concluded that the absence of a 
parent compound counted as a negative result, so the presence of 3-
hydroxyphenazepam was not a positive for phenazepam. The article did not 
consider 3-hydroxyphenazepam is also a drug, not just a metabolite and its 
presence may indicate 3-hydroxyphenazepam use not phenazepam use. There 
are likely positive instances that have been missed in this sample population due 
to a lack of metabolites tested. No concentration data was included in the article.  
Another article described an unresponsive 30-year old male who was admitted to 
an emergency department in Florida. (Runnstrom et al., 2019) The urine screen 
(not further described) was positive for lorazepam and cannabis. After ten days in 
hospital the patient had recovered and reported he had ingested 240 mg of 
diclazepam in liquid form. There were no concentrations in tissue samples 
reported for this case, presumably as the emergency department were not aware 
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of what the patient had taken however the lorazepam, a metabolite of diclazepam 
in urine indicates diclazepam exposure. (Runnstrom et al., 2019) 
A study in China carried out retrospective analysis on the records of forensic 
cases from 2017. The study found six positive benzodiazepine cases in the 
biological samples of drug-facilitated sexual assault (DFSA) victims. There were 
also six diclazepam-positive liquor samples from DFSA cases. (Xiang et al., 2018) 
However it was not clear if the liquor was from the same cases as the biological 
samples. Another Chinese study describes detecting diclazepam in a milky fluid 
from a DFSA case. (Xiang et al., 2018) 
Table 6 displays the studies that have reported a designer benzodiazepine 
concentration in a human tissue sample. The median concentration is shown when 
the study had multiple positive results. The concentration without a median is from 
one positive case or self-administration studies.  
A recent Norwegian study collated the blood concentrations from designer 
benzodiazepines from both living offenders such as apprehended drivers and 
post-mortem samples. (Heide et al., 2020) These cases were from June 2016 and 
September 2019. The median concentrations from the drugs in this study are 
shown in Table 6. An interesting aspect of this study is that in 25 of the living 
offender cases there was no other drugs detected or the concentration of these 
drugs were not considered to be the cause of impairment, this makes an 
assessment of impairment possible and can be related to the concentration of the 
drug found in the blood. The clinical impairment conclusion ranged from not 
impaired to considerably impaired with mildly and moderately impaired in between. 
Diclazepam was the most commonly detected drug in 16 out of the 25 cases 
discussed. The concentrations for the not impaired individuals were 0.0054, 
0.0077, 0.0089 and 0.032 mg/L. The concentrations for the mildly impaired 
individuals were 0.0051, 0.0077 and 0.035 mg/L. The concentrations for the 
moderately impaired individuals were 0.011, 0.016, 0.019, 0.032, 0.045, 
0.061mg/L. The concentrations for the considerably impaired individuals were 
0.014, 0.035 and 0.048 mg/L. The median concentration of not impaired was 
determined to be 0.0083 mg/L and 0.025 mg/L for impaired.(Heide et al., 2020) 
The study acknowledges different physicians carried out the clinical impairment 
assessment and therefore the consistency in this assessment is unknown. The 
authors were not privy to information regarding time of consumption, dosing or 
 
 
27 
past drug use history. Diclazepam was detected in 13 out of the 21 post-mortem 
cases in this study, the concentrations ranged from 0.0018 to 0.032 with a median 
of 0.0032 mg/L. The other designer benzodiazepines detected in post-mortem 
blood were phenazepam (n=5), etizolam (n=2) and flubromazolam (n=1). The low 
number of etizolam positives in post-mortem blood, 2 out of 6,500 cases, is very 
interesting as it is so low compared to the findings in Scotland where etizolam was 
the most implicated designer benzodiazepine in drug-related deaths, see section 
1.9.1. The authors in the study did not know the cause of death so it was not 
possible to consider the drugs role in this way.  
A 2019 American study found after re-analysing 33 PM samples for designer 
benzodiazepines, they identified analytes previously missed in 5 samples, 
including diclazepam, delorazepam, flubromazolam and clonazolam. (Mei et al., 
2019) This demonstrates how novel drugs are often missed in routine analysis.  
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Table 6: Reported designer benzodiazepine concentrations in human samples 
Author(s) Year 
Designer 
benzodiazepine 
Matrix 
Concentration 
(mg/L) 
AM/PM* 
Number 
of cases 
Moosmann et al 
(Moosmann, 
Bisel and Auwärter, 2014)
 
2014 Diclazepam Serum 0.003 AM 1 
Høiseth et al 
(Høiseth, Tuv and 
Karinen, 2016)
 
2016 Diclazepam Blood 0.013 -median AM 15 
Lehmann et al 
(Lehmann et al., 
2019)
 
2019 Diclazepam Blood 0.001 PM 1 
Lehmann et al 
(Lehmann et al., 
2019)
 
2019 Diclazepam Urine 0.001 PM 1 
Heide et al 
(Heide et al., 2020)
 2020 Diclazepam Blood 0.0094-median AM 334 
Heide et al 
(Heide et al., 2020)
 2020 Diclazepam Blood 0.0032-median PM 13 
Mei et al 
(Mei et al., 2019)
 2019 Delorazepam Blood 0.037-median PM 4 
Høiseth et al 
(Høiseth, Tuv and 
Karinen, 2016)
 
2016 Etizolam Blood 0.0053-median AM 14 
Heide et al 
(Heide et al., 2020)
 2020 Etizolam Blood 0.054-median AM 40 
Heide et al 
(Heide et al., 2020)
 2020 Etizolam Blood 0.026-median PM 2 
Moosmann et al 
(Moosmann et 
al., 2013a)
 
2013 Flubromazepam Serum 0.078 AM 1 
Høiseth et al 
(Høiseth, Tuv and 
Karinen, 2016)
 
2016 Flubromazepam Blood 0.055-median AM 24 
Koch et al 
(Koch et al., 2018)
 2018 Flubromazepam Blood 0.83  AM 1 
Heide et al 
(Heide et al., 2020)
 2020 Flubromazepam Blood 0.037-median AM 5 
Høiseth et al 
(Høiseth, Tuv and 
Karinen, 2016)
 
2016 Flubromazolam Blood 0.012 -median AM 25 
Łukasik-Głębocka et al 
(Łukasik-Głębocka et al., 2016)
 
2018 Flubromazolam Serum 0.059 AM 1 
Heide et al 
(Heide et al., 2020)
 2020 Flubromazolam Blood 0.0056-median AM 20 
Heide et al 
(Heide et al., 2020)
 2020 Flubromazolam Blood 0.052 PM 1 
Shearer et al 
(Shearer et al., 2015)
 2015 Phenazepam Blood 
0.10 –median in 
DRDs 
0.09 median in non 
DRDs 
PM 
54 
89 
Heide et al 
(Heide et al., 2020)
 2020 Phenazepam Blood 0.022-median AM 138 
Heide et al 
(Heide et al., 2020)
 2020 Phenazepam Blood 0.0059-median PM 5 
Crichton et al 
(Crichton et al., 
2015)
 
2015 Phenazepam Blood 0.097 - median PM 29 
Moosmann et al 
(Moosmann et 
al., 2013b)
 
2013 Pyrazolam Serum 0.051 AM 1 
Høiseth et al 
(Høiseth, Tuv and 
Karinen, 2016)
 
2016 Pyrazolam Blood 0.074 AM 1 
Lehmann et al 
(Lehmann et al., 
2019)
 
2019 Pyrazolam Blood 0.028 PM 1 
*AM = Ante-mortem, PM =Post-mortem 
With the exception of Shearer et al, Crichton et al and Heide et al there is a lack of 
information in the scientific literature of the post-mortem blood concentrations of 
designer benzodiazepines in multiple cases. Diclazepam and pyrazolam post-
mortem blood concentrations are discussed by Lehmann et al but in a single case 
and Mei et al discusses PM findings but again only in five case therefore the 
primary goal of this study is to provide typical blood concentrations found at post-
mortem in order to aid toxicologists and pathologists in the interpretation. Firstly, it 
must be determined if an ELISA screening method is able to detect these drugs in 
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order to flag the positive samples for confirmation. The secondary goal is to 
ascertain the use of benzodiazepines in sub-populations who are at high risk of 
using these drugs but are under conditions where they should not use them. 
These are living participants who have given a urine sample, which is non-invasive 
unlike blood.  
1.10. Analytical testing of benzodiazepines 
As benzodiazepines are commonly prescribed throughout the world a large 
number of analytical methods in human tissue have been described in published 
literature. Table 7 shows an overview of the methods for the designer 
benzodiazepines, including the instrumentation and extraction method used.  
 Systematic toxicological analysis follows a methodical approach of detection, 
identification and quantification. (Negrusz and Cooper, 2013) It is important to 
understand if the methods currently used in toxicology laboratories are able to 
detect newly emerged benzodiazepines. Laboratories commonly carry out the first 
step of detection by a screening method such immunoassay before any 
confirmatory tests are commenced. The number of confirmatory tests can be 
reduced in this way, as the negative samples will not require further analysis. As 
immunoassay techniques utilise antibodies targeting the general structure of a 
drug, there is a lack of selectivity, and therefore they typically can detect a drug 
group and not a specific compound. This concept is promising as structural 
analogs similar to the target drug will not give a negative response and therefore 
new designer drugs may give a positive immunoassay result. This is further 
discussed in chapter 2.  
After presumptive detection, the specific analyte(s) must be confirmed and 
quantified typically by either liquid chromatography tandem mass spectrometry 
(LC-MS/MS) or Gas Chromatography Mass Spectrometry (GC-MS) but before 
this, a suitable sample preparation method must be determined. Sample 
preparation techniques depend on factors such as sample matrix, the aim of the 
analysis and the type of instrumentation used. Two common sample preparation 
techniques for extracting benzodiazepines are Solid Phase Extraction (SPE) and 
Liquid Liquid extraction (LLE). SPE works by exploiting the differences in polarity 
between the analyte of interest and the other components in a complex sample. 
The solid phase is a sorbent within the cartridge, which retains the analyte of 
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interest. The other interferent components such as proteins can be washed 
through the sorbent to waste; the target analyte is then eluted from the sorbent 
and collected to be evaporated and reconstituted into a solvent mixture suitable for 
injection onto the analytical instrument. The use of SPE is more expensive than 
using LLE, as the SPE cartridges must be purchased, however SPE is more 
selective, gives cleaner extracts, increased extraction recovery and avoids 
emulsion formation. LLE works by using two different immiscible liquids, a polar 
solution usually an aqueous buffer containing sample is mixed with a non-polar 
solvent in which the analyte is soluble in. The pH of the buffer is controlling the 
ionisation of the analyte of interest and this helps to facilitate the transition from 
one liquid to the other. After mixing and centrifugation the solvent portion now 
containing the analyte of interest can be removed for injection or evaporation then 
reconstitution in a solvent mixture suitable for injection onto the analytical 
instrument. The aqueous portion containing the interferant components is 
discarded. LLE is a broad extraction technique with much less selectivity than 
SPE. This can be an advantage in the detection of new structurally related 
compounds as they are likely to also be extracted, whereas they may not elute 
from a specific SPE cartridge. LLE as an extraction method has been chosen by 
most for the designer benzodiazepines likely because it is a broad extraction, see 
Table 7.  
Urine analysis of benzodiazepines may require enzymatic hydrolysis steps before 
the extraction takes place if the conjugated metabolites are not included in the 
analytical method. As shown the section 1.7, the compounds will undergo 
glucuronidation in order to excrete them from the body. Enzymatic hydrolysis 
cleaves the glucuronide freeing the analyte and therefore making it more 
detectable. Including a hydrolysis step adds to the assay turnaround time, as an 
incubation period is required. There is also the issue of different metabolites 
having a variable hydrolysis rate; incomplete hydrolysis will lead to a false 
decreased concentration or a potential false positive for an analyte. (Johnson-
Davis, 2018) Beta-glucuronidase from Helix Pomatia is commonly used in 
benzodiazepine urinalysis as it gives a high yield for a number of benzodiazepines 
(Fu et al., 2010) which is crucial as a urine sample often contains multiple 
analytes.  
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Table 7: Overview of designer benzodiazepine analysis methods published 
Author(s) Analyte(s) Matrix 
Sample 
Preparation 
Instrumentation Internal standard 
LOD 
(mg/L) 
Crichton et al 
(Crichton et al., 2015)
 
3-
hydroxyphenazepam 
Phenazepam 
Blood 
Plasma 
Urine 
Vitreous 
Muscle 
Liver 
Brain 
LLE LC-MS/MS Diazepam-D5 
 
0.0003 
0.007 
(in 
plasma) 
Meyer et al 
(Meyer et al., 2016)
 
Clonazolam 
Meclonazolam 
Nifoxipam 
Urine LLE LC-MS 
Methamphetamine-D5 
Pethidine-D4 
n/a 
Høiseth et al 
(Høiseth, Tuv and 
Karinen, 2016) 
 
Clonazolam 
Diclazepam 
Etizolam 
Flubromazepam 
Flubromazolam 
Pyrazolam 
Blood LLE UPLC-MS/MS Diazepam-D5 
0.0014 
0.0016 
0.0014 
0.0033 
0.00037 
0.0035 
Heide et al 
(Heide et al., 2020) 
Clonazolam 
Diclazepam 
Etizolam 
Flubromazepam 
Flubromazolam 
Phenazepam 
Blood LLE UHPLC-MS/MS 
Diazepam-D5 
Nitrazepam-D5 
Flunitrazepam-D7 
Diclazepam-D4 
Etizolam-D3 
0.0014 
0.0016 
0.0014 
0.0033 
0.00037 
0.0017 
Mei et al 
(Mei et al., 2019) 
Clonazolam 
Diclazepam 
Delorazepam 
Flubromazepam 
Flubromazolam 
Meclonazepam 
Phenazepam 
Nifoxipam 
Pyrazolam 
3-hydroxyphenazepam 
 
Blood SPE LC-MS/MS 
Diazepam-D5 
Chlordiazepoxide-D5 
DMD-D5 
Temazepam-D5 
0.0005 
0.0005 
0.0005 
0.0005 
0.0005 
0.0005 
0.0005 
0.0005 
0.0005 
0.0005 
Moosmann et al 
(Moosmann, Bisel and 
Auwärter, 2014)
 
Diclazepam 
Plasma 
Urine 
Hyrolysis by 
beta-
glucuronide 
LLE 
LC-MS/MS 
Diazepam-D5 
Lorazepam-D4 
DMD-D5 
Temazepam-D5 
0.00025 
Bergstrand et al  
(Bergstrand, Helander 
and Beck, 2016)
 
Diclazepam 
Pyrazolam 
Flubromazepam 
Meclonazepam 
Phenazepam 
Etizolam 
Nifioxipam 
Deschloroetizolam 
Clonazolam 
Flubromazolam 
Urine 
Hyrolysis by 
beta-
glucuronide 
Direct injection 
LC-MS/MS 
Estrazolam-D5 
Temazepam-D5 
0.0020 
0.0040 
0.0025 
0.0010 
0.0050 
0.0020 
0.0100 
0.0020 
0.0050 
0.0020 
 
Fracasso et al 
(Fracasso et al., 1991)
 
Etizolam 
Plamsa 
Urine 
LLE HPLC Alprazolam 0.001 
Nakamae et al 
(Nakamae et al., 2008)
 
Etizolam 
Plamsa 
Urine 
SPE GC-MS/MS Fludiazepam n/a 
Moosmann  et al 
(Moosmann et al., 2013a)
 
Flubromazepam 
Plasma 
Urine 
LLE LC-MS/MS DMD 0.001 
Kintz et al 
(Kintz et al., 2017)
 
Metizolam Urine LLE LC-MS/MS 
Methyl-clonazepam 
OH-ethylthoephyllin 
0.00025 
Stephenson et al  
(Stephenson, Golz and 
Brasher, 2013)
 
Phenazepam Plasma LLE LC-MS/MS Diazepam 0.012 
Moosmann et al 
(Moosmann et al., 2013b)
 
Pyrazolam 
Plasma 
Urine 
LLE LC-MS/MS Alprazolam 0.001 
 
The use of GC-MS requires a derivatisation step post-extraction. Derivatisation is 
the modification of a compound to make it more suitable for analysis. 
Derivatisation is essential to form a stable benzodiazepine complex, which can be 
analysed by GC-MS without decomposing on the GC column due to the high 
temperature required for elution. The lack of a suitable universal derivatisation 
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agent for benzodiazepines is an issue and using a LC technique avoids any 
derivatisation problems. (Segura et al., 2001) 
LC-MS/MS is now often the preferred analytical instrument for forensic toxicology 
laboratories. LC-MS/MS is able to analyse larger, polar compounds than GC-
MS(/MS) as there is no need to impart high temperatures, the sample preparation 
can also be faster and cheaper, for example there is no need to chemically modify 
compounds as is required with the derivatisation. However the initial cost of 
purchasing an LC-MS(/MS) instrument is much more costly than a GC-MS(/MS). 
(Drummer and Gerostamoulos, 2014) The weekly maintenance of a GC-MS is 
very quick and easy as it usual just requires a change of liner and septum with 
frequent auto-sampler wash bottle changes, in contrast a heavily used LC-MS 
needs mobile phases prepared every few days and a weekly clean as there is a 
fast drop in sensitivity when regions around the source entry become dirty. In 
addition, ion suppression or enhancement is an issue specific to the technique 
(Furey and Moriarty, 2011) (see section 3.4.6 in chapter 3), if either of these occur 
then changes in the protocol such as sample dilution, reagent changes, using 
different ionisation (APCI rather than ESI) and chromatographic changes may 
have to be investigated. The use of multiple reaction monitoring in LC-MS(/MS) 
has led to the ability to target large numbers of drugs in a sample simultaneous in 
a relative short period of time however problems have been encountered where a 
metabolite of a drug has the same mass/charge ratio as one of the target analytes 
within the analytical method, particularly if they also have the same retention time. 
This was observed when a single MRM transition was used for the identification of 
tramadol leading to false positives in patients who had been treated with 
venlafaxine. This false positive has due to metabolite, O-desmethylvenlafaxine 
and tramadol being isobaric and as the method had a short run time (6.5 minutes) 
they were co-eluting. (Allen, 2006) This issue is solved with using more than one 
transition, using a complementary technique in addition to LC-MS(/MS) (i.e a UV 
spectrum will tell them apart) (Furey and Moriarty, 2011) and baseline resolution 
can be attempted once an issue like this one is known. (Allen, 2006) LC-MS does 
not have established spectral libraries in the way that GC-MS does which is a 
huge advantage to using GC-MS. (Drummer and Gerostamoulos, 2014) Overall, 
both instruments are extremely valuable to the field of forensic toxicology and 
access to both is preferable and complementary. 
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It is accepted that LC-MS(/MS) is more appropriate than GC-MS(/MS) to analyse 
benzodiazepines due to their non-volatile and polar nature (Nakamura, 2011; 
Drummer and Gerostamoulos, 2014) and the requirement to determine low 
concentrations of benzodiazepines in cases such as a drug-facilitated sexual 
assault (DFSA) has also seen methods move from GC-MS to LC-MS(/MS). 
(Persona et al., 2015)   
This work used LC-MS/MS to analyse benzodiazepines in urine and post-mortem 
blood samples.  
The LC-MS/MS instrument is a High Pressure Liquid Chromatography (HPLC) 
system combined with a mass spectrometer (MS). There are two main 
components which make up the mass spectrometer; the ion source, which causes 
the ionisation of the molecules and the mass analyser, which is responsible for 
filtering the ions by their mass to charge ratios (m/z). (Agilent Technologies, 2001) 
The discovery of Atmospheric Pressure Ionisation (API) improved the interface 
between the HPLC and mass spectrometer leading to ions being obtained in a 
more reliable manner. There are two main types of API. 
1.10.1. Electrospray ionisation 
In electrospray ionisation (ESI) gas phase ions are converted from solution phase 
analytes. Following elution from the LC system, the mobile phase carries the 
analytes into the ESI to the capillary tip where a high voltage is applied. Nebuliser 
gas, often nitrogen, flows outside the capillary and sprays the sample; this turns 
the sample and mobile phase into a fine aerosol. The droplets within the aerosol 
are charged with the same polarity as the voltage applied. The solvent continues 
to evaporate under temperature control and as these charged particles move 
around, causing an increasing electric field on the droplet surface until fission 
occurs and the droplets become smaller more stable droplets. This cycle of fission 
is repeated until they are small enough that the sample ions are liberated into the 
gas phase. (Agilent Technologies, 2001; McMaster, 2005) Figure 15 shows a 
schematic diagram of an ESI source. 
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Figure 15: ESI diagram  
(reproduced with permission from Agilent) 
 
1.10.2. (Atmospheric Pressure) Chemical ionisation 
In (Atmospheric Pressure) chemical ionisation (APCI), the sample and solvent are 
vaporised by spraying the LC eluent under temperature, which can be heated up 
to 400°C, using an inert gas, usually nitrogen. Stable reaction ions are then 
generated by discharge from the corona ionising the solvent ions. Sample 
molecules are then ionised by the transfer of protons between the reaction ions 
and the sample molecules.(Agilent Technologies, 2001) Figure 16 shows a 
schematic diagram of an APCI source.  
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Figure 16: API-CI diagram  
(reproduced with permission from Agilent) 
 
1.10.3. Mass analysers 
Two common mass analysers used are a triple quadrupole and ion trap. The 
quadrupole analyser uses four parallel rods arranged in a square formation, the 
sample ions travel down the tunnel created by the rods. Voltages applied to the 
rods create the electromagnetic fields and changing radio frequency signals 
sweep the ions along with each frequency selecting a different mass to charge 
ratio. This gives the ions a stable path to the detector, the ions strike the detector 
surface generating a signal, which is amplified and sent to the computer to 
compose the Total Ion Count (TIC). This kind of analyser can be operated in a 
variety of modes; there are four main scans for multiple applications of the LC-
MS/MS system. The product ion scan uses a selected precursor ion in quadrapole 
1 (Q1) and focuses it into the collision cell (Q2) where a process known as 
collision induced dissociation occurs, this is when inert gas such as nitrogen 
collides with ions causing fragmentation, the fragments are then filtered by their 
m/z in quadrapole 3 (Q3) producing a spectrum of product ions. The precursor ion 
scan is used to identify an ion with a chosen m/z in Q3, Q1 scans over the desired 
m\z range then into Q2 for fragmentation then Q3 is held static on the desired m/z 
resulting in the precursor ion spectrum. The third scan type is constant neutral 
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scanning. This is utilised to monitor particular compounds by setting a mass offset 
between Q1 and Q3, which will both scan across the whole m/z range. Q2 will 
allow only the ions that differ by the pre-set mass units into Q3, this is the neutral 
fragment, for example alcohols could be monitored in this way by setting a loss of 
18 Da (water) between Q1 and Q3. The forth type of scan mode is multiple 
reaction monitoring (MRM). In MRM mode, the MS/MS is set to detect the 
precursor and product ions of a known compound. The targeted approach of MRM 
makes it a highly sensitive and specific application.  
A ion trap systems works on a similar principle to the quadrupole but instead of 
filtering streaming ions, the ion trap holds them in a three dimensional space. The 
ions sit between two electrodes and are ejected to the detector or are stored there 
based on the radio frequency applied. (McMaster, 2005; Agilent Technologies, 
2001) 
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1.11. Aims and objectives 
The primary aim of this project was to determine the typical concentrations of 
diclazepam (and two of its metabolites, delorazepam and lormetazepam), 
flubromazepam and pyrazolam in post-mortem blood in order to aid toxicological 
interpretation. In order to assess the use of these drugs in this cohort the following 
objectives were set.  
1. Ascertain if designer benzodiazepines in the post-mortem confirmation 
methods will trigger a positive response in an ELISA screening method. 
2. Validate the analytical quantitative SPE - LC-MS/MS method to detect 
diclazepam (and two of its metabolites, delorazepam and lormetazepam), 
flubromazepam and pyrazolam in post-mortem blood. 
3. To apply the validated method to post-mortem blood samples to determine 
typical concentrations in this sample set, collect demographic data relating 
to these cases to determine the prevalent populations and how their 
presence is implicated in the cause of death.  
The secondary aim of this study was to determine the use of benzodiazepines in 
urine samples from different Scottish high-risk sub-populations. In order to achieve 
this the following objectives were set. 
1. To develop and partial validate a benzodiazepine LLE - LC-MS/MS 
qualitative method for urine samples. 
2. To apply this analytical method to prison samples, drug court samples and 
psychiatric urine samples in order to assess if these drugs are used. 
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2. ELISA cross-reactivity determination of phenazepam, etizolam, 
diclazepam, delorazepam, pyrazolam and flubromazepam 
2.1. Introduction 
2.1.1. Immunoassay 
An immunoassay is a biochemical test that utilises an antibody to detect the 
presence of a compound (an antigen). Antibodies‘ role in nature is to detect 
disease, and this has been manipulated in order to use their discriminatory powers 
to detect other molecules such as drugs, hormones or marker proteins. Since the 
1970s, pregnancy tests have used immunoassay as a fast and convenient method 
to detect the human chorionic gonadotropin (hCG) hormone in urine. (Horwitz and 
Lee, 1978) 
 
Figure 17: The antibody – antigen reaction  
(reproduced with permission from Jiménez-Martínez - Scientific Figure on ResearchGate. Available 
from: https://www.researchgate.net/figure/Antigen-antibody-reaction-Each-antibody-is-able-to-bind-
its-specific-antigen-forming_fig1_320265684) 
When an antibody and its specific antigen meet, an immune complex forms, see 
Figure 17. Normally this process is undetectable therefore a label is required. A 
label is a sensor that has some kind of activity that produces an output and can 
then be read in a laboratory (e.g. radiation, fluorescence or an enzyme reaction 
with a substrate producing a colour change).  
2.1.2. Immunoassays in forensic toxicology 
Prior to immunoassay, drug detection in biological samples was carried out using 
techniques such as microcrystalline testing and Thin Layer Chromatography 
(TLC). Microcrystalline tests work by introducing the sample to a specific reagent, 
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which will form unique crystals if the suspected drug is present; these are then 
compared to the crystals formed by reference material under a microscope. (Elie 
et al., 2009) TLC is a simple chromatography technique in which compounds will 
separate out onto a stationary phase depending on their affinity for the mobile 
phase. Immunoassay is useful in toxicology as it indicates which drug group is 
present, but it is not a complete tool as it cannot detect the specific drug, therefore 
further investigation is required. Immunoassay can sometimes give false positives, 
when another substance gives a similar response to the target substance, 
therefore all positive results must be confirmed by a second test. There can also 
be instances of false negative results therefore it is imperative to manufacture a 
device which has the required sensitivity, whilst not returning too many false 
positive results. The introduction of immunoassays to forensic toxicology had a 
direct impact on the speed at which samples could be screened. (Chung and 
Choe, 2017; Moody, 2006) 
Due to the possibility of false-positive results, immunoassays are considered 
presumptive only tests; the results cannot be used in legal proceedings and must 
be confirmed by a more sophisticated technique. Immunoassay use is appropriate 
in situations such as workplace drug testing where a high percentage of samples 
are expected to give negative results. There have been examples of the use of 
immunoassay with no confirmation testing in legal proceedings in recent years. 
The Motherisk Drug Testing Laboratory in Canada tested hair samples from 
parents for Child Protection Services in Ontario. All hair samples were tested using 
ELISA from January 2005 to August 2010 by the laboratory; the tests most 
frequently carried out were cocaine, benzoylecgonine and delta-9-
tetrahydrocannabinol (THC). In this time period ELISA results were reported 
without any further confirmation tests. The laboratory was responsible for testing 
around 2,000 hair samples per year. This finding along with the lack of standard 
operating procedures, documentation and general lab management led to an 
independent review on the behalf of the Attorney General which found the 
laboratory ―inadequate and unreliable for use in child protection and criminal 
proceedings and that the Laboratory did not meet internationally recognised 
forensic standards.‖ (Lang, 2015) 
A recent article described how a newly developed immunoassay, based on a 
biochip rather than the lateral flow technique, could be used as part of the post-
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mortem procedure in order to make decisions on whether confirmation tests are 
required. The device used in this study showed a high degree of agreement with 
confirmatory techniques, >98% agreement when used on femoral blood. 
(McLaughlin et al., 2019) There has been a move away from immunoassay in 
forensic toxicology in recent years aided by the evolution of other screening 
techniques using advanced instrumentation such as Time of Flight (TOF). The 
high cost of consumables also makes immunoassay a less attractive option.  
Calibrators are used to produce a calibration curve, which can be compared to the 
unknown samples. These concentrations are not reported, but can be used to 
determine if dilutions are required for positive samples. The lowest calibrator or 
control is used as the cut-off to give a decision point between negative and 
presumptively positive samples. (Moody, 2006) In line with other quality 
procedures in forensic toxicology, a drug-free sample in the same matrix (a blank) 
should be included in every immunoassay screen. At least one positive control 
should also be analysed to demonstrate that the assay is working correctly. 
Biological samples that screen presumptively positive are typically confirmed by a 
hyphenated mass spectrometric technique (e.g. LC-MS/MS or GC/MS), which will 
identify the specific drug and/or metabolite present. When isobaric compounds are 
a concern, high performance liquid chromatography with a diode array detector 
(HPLC-DAD) may be employed, as the UV spectra will distinguish between them. 
(Furey and Moriarty, 2011) 
Samples that are negative do not usually require any further testing for that drug 
group. This can be potentially risky strategy for the groups of drugs that are 
expanding due to the rise in NPS such as fentanyls and benzodiazepines. Due to 
the way drug antibodies are raised, they may partially bind to drugs that are 
chemically similar to their specific target. This is known as cross-reactivity. An 
article by Guerrieri et al, explored the cross-reactivity of the fentanyl analogs with 
an existing fentanyl targeted kit, they were found to give good cross reactivity with 
the exception of carfentanil due to an additional carbomethoxy group present in its 
structure. (Guerrieri et al., 2019) Therefore when reporting results care must be 
taken to understand what drugs the kit is able to screen for. The ELISA kit used in 
this study is specific to oxazepam but is used for the detection of other 
benzodiazepines. Oxazepam is a metabolite of diazepam, desmethyldiazepam, 
temazepam, chlordiazepoxide and a range of other lesser-encountered 
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benzodiazepines as well as a parent drug itself. The benzene ring and its 
positional groups are the area of the molecule responsible for binding. It is 
important to know the level of cross-reactivity of new drugs to existing 
immunoassay kits due to the possibility that not all designer benzodiazepines will 
bind. This could result in the laboratory failing to identify the drug if immunoassay 
alone is relied upon. A study carried out in 2017 assessed the cross-reactivity of 
13 designer benzodiazepines (clonazolam, deschloroetizolam, diclazepam, 
estazolam, etizolam, flubromazepam, flubromazolam, flutazolam, 3-
hydroxyphenazepam, meclonazepam, nifoxipam, phenazepam, and pyrazolam) in 
urine in four different immunoassay kits. The authors evaluated the CEDIA, EMIT 
II Plus, HEIA, and KIMS II immunoassays. They found that all 13 drugs tested in 
spiked urine had high cross-reactivity to the benzodiazepines antibody and this 
was confirmed when authentic positive urine samples were tested. They found that 
flutazolam gave the lowest cross-reactivity, (3, 4, 13 and 41% over the four kits 
tested, most other analytes tested were over 50% for at least three out of the four 
kits), which may be explained by its structure; as it is the most divergent from the 
other benzodiazepines, see Figure 18. They found the CEDIA and KIMS II 
immunoassays to be the most cross-reactive, and EMIT II Plus to be the least 
cross-reactive. (Pettersson Bergstrand et al., 2017)  
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Figure 18: Oxazepam (a) and flutazolam (b) structure 
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2.2. Aim 
The aim of this study was to determine if phenazepam, etizolam, diclazepam, 
delorazepam, pyrazolam and flubromazepam would cross react with the 
Immunalysis® Benzodiazepine ELISA kit. These drugs were chosen, as there was 
increasing evidence from various agencies such as the police and online searches 
that these drugs may be abused in Scotland. It is crucial for a toxicology laboratory 
to be aware if their screening techniques are adequate and do not fail to identify 
positive samples which need further confirmatory testing.  
2.3. Materials and Methods 
2.3.1. Materials 
Phenazepam, etizolam and oxazepam were purchased from Sigma Aldrich, UK. 
Pyrazolam and diclazepam were purchased from Chiron AS, Trondheim, Norway. 
Flubromazepam and delorazepam were purchased from LGC Standards, 
Teddington, UK. Blank blood used was purchased from the Scottish National 
Blood Transfusion Service, Gartnavel Hospital, Glasgow, UK. The Immunalysis® 
Benzodiazepine ELISA kit and the pH 7.0 phosphate buffered saline (PBS) were 
purchased from Alere Toxicology, Abingdon, UK (now Abbot). HPLC grade 
methanol was purchased from VWR, Leicestershire, UK. 
Immunalysis® Benzodiazepine ELISA kit contains ready to use reagents. Table 8 
explains what is included in the kit and what they do. 
Table 8: Immunalysis® Benzodiazepine ELISA kit reagents 
Item Purpose 
Plate/well The plates are composed of 96 wells, which are small round 
containers coated with the antibody. Each well holds a 
volume of 350 µL. 
 
Conjugate The conjugate is an enzyme specific compound which is 
added to compete with the drug of interest for the antibody 
binding site. 
 
TMB substrate 3,3‘,5,5‘-tetramethylbenzidine and peroxide in a buffer. The 
TMB substrate attaches to the conjugate and provides the 
label, this gives the colour change reaction. 
 
Stop solution 1 N hydrochloric acid, the stop solution, halts and stabilises 
the reaction caused by the TMB substrate. The reaction must 
be stopped and stabilised to be read by the 
spectrophotometer. 
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2.4. Solution preparation 
2.4.1. Stock solutions 
Individual stock solutions in methanol containing 10 µg/mL of each individual drug 
was prepared, see Table 9. Oxazepam was used for the cross-reactivity 
comparison, as this is the manufacturers target molecule.  
Class A volumetric flasks were used to prepare the stock solutions; they were 
inverted several times to mix then transferred to labelled containers. The stock 
solutions were stored in the freezer (≤-20 °C). 
Table 9: Cross-reactivity calibrator and spiked sample stock solutions preparation 
Stock Solutions 
@ 10 µg/mL 
Drug @ 1 mg/mL 
100 µl added 
Drug @ 100 µg/mL 
1 mL added 
Solvent 
Up to 10 mL 
Calibrator  Oxazepam - Methanol 
Phenazepam  Phenazepam - Methanol 
Etizolam  Etizolam - Methanol 
Diclazepam Diclazepam - Methanol 
Delorazepam  - Delorazepam Methanol 
Pyrazolam  Pyrazolam - Methanol 
Flubromazepam  Flubromazepam - Methanol 
 
2.4.2. Working solutions 
Individual working solutions (1 µg/mL) were prepared by a 1 in 10 dilution of the 
stock solutions detailed in Table 9. These were prepared in Class A volumetric 
flasks, they were inverted several times to mix then transferred to labelled 
containers. 
2.4.3. Calibrator and spiked sample preparation  
Blank blood (drug-free) and PBS were both spiked with oxazepam at 
concentrations of 0, 5, 10, 100 and 300 ng/mL. These were used as calibrators. 
Blank blood was spiked with phenazepam, etizolam pyrazolam, flubromazepam, 
diclazepam and delorazepam at the same concentrations (see Table 10 for the 
preparation details). These concentrations were chosen, as they were in-line with 
the concentrations used in the FMS in-house method. 
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Table 10: Cross-reactivity calibrator and spiked sample working solutions 
preparation 
Calibrator/spike sample 
Concentration 
(ng/mL) 
Volume of Working 
Calibrator/Spike 
Solution (1 µg/mL)  
 (μL) 
Volume of  
PBS /blank blood 
(μL) 
Calibrator 0 0 0 1000 
Calibrator 5 5 5 995 
Calibrator 10 10 10 990 
Calibrator 100 100 100 900 
Calibrator 300 300 300 700 
Individual drug spike 0 0 0 1000 
Individual drug spike 5 5 5 995 
Individual drug spike 10 10 10 990 
Individual drug spike 100 100 100 900 
Individual drug spike 300 300 300 700 
 
A 250 μL aliquot of each calibrator and spiked blood was pipetted into a fresh tube 
and diluted with 1:4 (1 mL added) with PBS and vortex mixed for five seconds.  
2.4.4. Instrumentation 
The Miniprep 75 was used to automatically pipette the samples into the wells of 
the ELISA plate. A Columbus plate washer was used to wash the plates and a 
Sunrise plate reader was used to read the absorbance of the TMB at a wavelength 
of 450 nm. The Miniprep 75, plate washer and plate reader are all manufactured 
by Tecan Group Ltd, Switzerland. 
2.4.5. Immunoassay procedure 
The calibrators and spiked samples detailed in section 2.4.3 were prepared fresh 
before the immunoassay procedure, each calibrator and spiked sample was 
pipetted onto the plate in duplicate. The whole procedure was carried out twice on 
separate days giving four replicates for each drug. 
Figure 19 describes the procedure used for this experiment. 
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Figure 19: ELISA procedure used  
(reproduced with permission from Immunalysis) (www.immunalysis.com., February 2016  ) 
2.4.6. Cross-reactivity determination 
The absorbance at 5, 10, 100 and 300 ng/mL for each drug was compared to the 
absorbance of oxazepam (OXZ) calibrators prepared at the same concentrations, 
using equation 1. 
Equation 1: %Cross-reactivity 
 
%Cross reactivity (
mean absorbance of OX 
mean absorbance of drug
) 100 
The higher the %cross-reactivity, the more affinity the drug has for binding to the 
target. The value can be above 100% as it is a comparison of the drugs binding to 
the binding of oxazepam; it is possible that some compounds may bind better than 
oxazepam. 
2.4.7. Data handling and statistical analysis 
Once results had been generated from the plate reader, they were transferred 
onto a Microsoft® Excel® (version 14.7.3) spreadsheet and a second toxicologist 
checked transcription and validity of the results before any calculations were 
performed. Microsoft® Excel® was then used to calculate the %cross-reactivity, 
standard deviation and %CV.  The Statsplus (AnalystSoft™, version 7.7.31) add 
on for Microsoft® Excel® was used to conduct a paired two sample t-test to 
determine if there was a statistical difference between the blood results and PBS 
results. The spreadsheet was saved on a secure drive to protect the data. 
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2.5. Results and discussion 
The study shows that cross-reactivity of some designer benzodiazepines such as 
diclazepam and flubromazepam is better in PBS than in blood, see Table 11, 
matrix effects may explain this. However the blood results show less variation in 
cross-reactivity across the concentration range for etizolam and pyrazolam. Blood 
has additional proteins and possibly other drugs present in real sample blood so 
this presents a more complex challenge for the ELISA kit. However, some blood 
and PBS results are comparable; etizolam at 10 ng/mL for example shows no 
issues in the blood matrix. There is no statistical difference between the blood 
results and the PBS results shown in this study at the 5, 10, and 100 ng/mL 
concentrations (p-values = 0.07, 0.33 and 0.24). The 300 ng/mL concentration 
gave a higher cross-reactivity for all drugs in PBS compared to blood and this was 
significant (p-values = <0.05). However the cross-reactivity at 300 ng/mL was 
above 70% for all drugs tested.  
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Table 11: Cross-reactivity with PBS buffer and blank blood calibrators 
Drug Concentration 
(ng/mL) 
Calibrators in PBS buffer 
%Cross-reactivity 
SD 
(n = 4) 
Calibrators in blood 
%Cross-reactivity 
SD 
(n = 4) 
Phenazepam 5 107 0.01 96 0.01 
 10 110 0.02 109 0.03 
 100 143 0.01 84 0.01 
 300 93 0.02 69 0.02 
Mean  113  90  
SD  18  15  
%CV  16  17  
      
Etizolam 5 111 0.03 100 0.03 
 10 96 0.05 96 0.06 
 100 84 0.01 126 0.01 
 300 143 0.01 107 0.01 
Mean  109  107  
SD  22  12  
%CV  20  11  
      
Pyrazolam 5 90 0.06 94 0.10 
 10 75 0.04 88 0.13 
 100 139 0.03 82 0.03 
 300 111 0.02 81 0.01 
Mean 
 
104  86  
SD  24  5  
%CV  23  6  
      
Flubromazepam 5 98 0.08 91 0.01 
 10 103 0.11 98 0.03 
 100 82 0.02 75 0.02 
 300 105 0.01 73 0.01 
Mean 
 
97  84  
SD  9  11  
%CV  9  13  
      
Diclazepam 5 106 0.08 85 0.04 
 10 91 0.07 98 0.03 
 100 122 0.04 72 0.04 
 300 95 0.00 62 0.01 
Mean 
 
104  79  
SD  12  14  
%CV  12  17  
      
Delorazepam 5 89 0.09 87 0.08 
 10 90 0.07 93 0.05 
 100 72 0.03 70 0.03 
 300 93 0.01 69 0.01 
Mean  86  80  
SD  8  10  
%CV  10  13  
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The cross-reactivity demonstrated by the results of this study is not unsurprising 
considering the molecular structure of the target analyte oxazepam compared to 
the six drugs tested. Figure 20 shows the structure of oxazepam with the six drugs 
tested in this experiment. Etizolam and pyrazolam have more divergent structures 
from oxazepam but both still gave high %cross-reactivity, particularly etizolam, 
which gave very high mean %cross-reactivity results when calibrators were 
prepared in blood. 
 
Figure 20: Molecular structure of oxazepam and the drugs tested for cross-
reactivity 
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The cross-reactivity of diclazepam‘s other metabolites, lorazepam and 
lormetazepam are included in the manufacture‘s kit insert. The cross-reactivity of 
lorazepam is stated as 90% at a concentration of 50 pg/well and 85% at a 
concentration of 100 pg/well. The cross-reactivity of lormetazepam is stated as 
120% at a concentration of 500 pg/well. (Immunalysis and Corporation, 2011) 
Each well holds 350 µL so: 500 pg/well = 500 pg/350 µL or 1,429 pg/1000 µL 
which is 1.43 ng/mL. The conversion of the insert data is shown in Table 12. The 
results from the kit insert demonstrates cross-reactivity at very low concentrations, 
likely to be much lower than the limit of detection of the confirmation techniques 
therefore the immunoassay may give a positive response that is negative on 
confirmation.  
Table 12: Immunalysis® Benzodiazepine ELISA kit insert results and conversion 
for lorazepam and lormetazepam 
Drug Concentration on 
insert 
% Cross-reactivity Converted 
concentration 
Lorazepam 50 pg/well 90 0.143 ng/mL 
Lorazepam 100 pg/well 85 0.29 ng/mL 
Lormetazepam 500 pg/well 120 1.43 ng/mL 
 
2.5.1. Limitations 
The limitations of immunoassay must be considered when interpreting these 
results. The cross-reactivity of a non-targeted antibody can be both a helpful 
characteristic as well as a problematic one. Immunoassay offers information on 
the drug group only; benzodiazepines could contain both licit in the form of 
prescribed medication and illicit compounds in the same sample. Other 
compounds in the sample may react and cause a false-positive response (e.g. 
compounds present due to HIV treatment or antidepressant use e.g sertraline). 
(Saitman, Park and Fitzgerald, 2014) Sample condition especially decomposed 
post-mortem blood may also have an effect on how well the kit detects any 
benzodiazepines. Additional biochemical compounds such as enzymes, other 
proteins and lipids in the decomposed blood can result in false positives or false 
negatives.  
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Benzodiazepines are a large class of drugs and a more specific technique such as 
LC-MS/MS will always be needed in order to identify what specific 
benzodiazepines and metabolites are in a sample and at what concentrations.  
2.5.2. Case study 
The following case study demonstrates how designer benzodiazepines were 
positively detected by ELISA in a real post-mortem case.  
This case study describes the death of a 20-year-old male who according to his 
medical history had a psychotic disorder. He was prescribed lymecycline, 
fluoxetine, pregabalin and zuclopenthixol. Items found at the scene indicated he 
had purchased ―legal highs‖ online. The deceased's blood was screened using the 
Immunalysis® Benzodiazepine ELISA kit and gave a presumptive positive result. 
The in-house LC-MS/MS confirmation test used includes 10 benzodiazepines 
drugs/metabolites: diazepam, desmethyldiazepam, oxazepam, temazepam, 
lorazepam, 7-aminoflunitrazepam, nitrazepam, chlordiazepoxide, phenazepam 
and etizolam. Etizolam was confirmed at a concentration of 0.011 mg/L (11 
ng/mL). A specific LC-MS/MS confirmation test for pyrazolam was also carried out 
due to suspected pyrazolam tablets found at the scene. Pyrazolam was also found 
in the blood at a concentration of 0.070 mg/L (70 ng/mL). All of the other 
benzodiazepines tested were negative. This suggests that the Immunalysis® 
Benzodiazepine ELISA kit can identify etizolam and/or pyrazolam in post-mortem 
blood. 
2.6. Conclusion 
This study determined that the designer benzodiazepines, phenazepam, etizolam, 
pyrazolam, flubromazepam, diclazepam and delorazepam cross-react with the 
Immunalysis® Benzodiazepine ELISA kit. When the calibrators were made up in 
PBS the mean cross-reactivity was 113, 109, 104, 97, 104 and 86% for 
phenazepam, etizolam, pyrazolam, flubromazepam, diclazepam and delorazepam, 
respectively. When the calibrators were prepared in blood, the average cross-
reactivity was 90, 107, 86, 84, 79 and 80% for phenazepam, etizolam, pyrazolam, 
flubromazepam, diclazepam and delorazepam, respectively. (O'Connor, Torrance 
and McKeown, 2016) This study demonstrates that the Immunalysis® 
Benzodiazepine ELISA kit can be used as a screening technique for the designer 
benzodiazepines tested. (O'Connor, Torrance and McKeown, 2016) A positive 
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blood sample at the concentration of 5 ng/mL and above should be detectable 
however as the application of this study would be in post-mortem blood, sample 
condition must be considered. As post-mortem blood samples are often 
decomposed, clotted, fatty or oily the same results may not be achieved and blood 
in these conditions could not be tested in the same way as in this study.   
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3. Validation of a LC-MS/MS method for the quantitation of diclazepam, 
delorazepam, lormetazepam, flubromazepam and pyrazolam in blood 
3.1. Introduction 
Forensic and clinical toxicologists need reliable analytical methods to ensure the 
correct interpretation of toxicological results. As discussed in chapter 1, section 
1.10, LC-MS(/MS) rather than GC-MS(/MS) is the preferred instrumental technique 
for benzodiazepine detection. There are many published LC-MS(/MS) methods 
published for the well-established, prescribed benzodiazepines (Nakamura, 2011; 
Persona et al., 2015; Dunlop et al., 2017; Montenarh et al., 2014; Edinboro and 
Poklis, 1994; Marin and McMillin, 2010; Glover and Allen, 2010; Marin et al., 2008; 
Marin et al., 2012; Ngwa et al., 2007) and these can be adapted to accommodate 
the new designer benzodiazepines. The challenge for a well-equipped laboratory 
is the lack of literature pertaining to the new compounds and the lack of available 
certified reference materials. Without certified reference materials a laboratory 
cannot be fully confident in the presence of an analyte. The pace of the newly 
emerging drugs has been rapid compared to the production of reference materials 
and the requirement for both the parent drug and the metabolites is a further 
challenge. (Archer, Treble and Williams, 2011) The appearance of a novel drug 
may be sudden and have a very brief lifetime that presents a commercial 
challenge to the reference material suppliers; in turn it can be very expensive for 
laboratories to purchase the required materials if they are available.  
Analytical methods must be validated to ensure they are fit for purpose in 
providing accurate, robust and reproducible data. (International Organization for 
Standardization, 2017) Unreliable methods could be challenged in court and have 
legal implications or result in a patient receiving the wrong treatment therefore 
validation is very important. An interesting example of misleading forensic 
evidence is the Patricia Stallings case in the USA, she was convicted and 
sentenced to life in prison for murdering her son by causing him to ingest anti-
freeze. Tests appeared to show a high concentration of ethylene glycol in the 
blood that supported the anti-freeze theory. Patricia‘s other son then began to 
demonstrate the same symptoms whilst Patricia had no access to him. He was 
diagnosed with Methylamalonic Acidemia (MMA), a rare genetic condition that 
causes the body to produce propionic acid. Ethylene glycol and propionic acid 
have a very similar chemical formula, which only differ by one carbon atom. Re-
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analysis of the deceased‘s tissue samples showed he also suffered from MMA. 
Patricia Stallings was exonerated and received several million dollars in 
compensation from her lawsuits against the hospital and testing laboratory. A 
professor who became involved with the case sent samples containing 
methylamalonic acid to several commercial laboratories and around half of them 
reported the wrong result. (The National Registry of Exonerations, 2012) Instances 
like the Patricia Stallings case show the gravity of incorrect forensic evidence. The 
scientific community has produced various articles to guide scientists on validation 
in an attempt to come to an international consensus. (Scientific Working Group for 
Forensic Toxicology, 2013; Wille et al., 2011; Booth et al., 2015; Wille et al., 2017) 
3.2. Aim 
The aim of this work was to validate a quantitative LC-MS/MS method for 
diclazepam, delorazepam, lormetazepam, pyrazolam and flubromazepam in blood 
according to the guidelines published in the ―Standard Practices for Method 
Validation in Forensic Toxicology‖ published by The Scientific Working Group for 
Forensic Toxicology (SWGTOX) (Scientific Working Group for Forensic 
Toxicology, 2013) which have subsequently been replaced by the ANSI/ASB 
Standard 036 for Method Validation in Forensic Toxicology. (LeBeau, 2020) These 
guidelines were used, as they are specific to the validation of methods used for 
forensic toxicology and are the product of expert consensus on method validation.  
 
3.3. Materials and Methods 
3.3.1. Materials 
Diclazepam (1mg/mL in MeOH, >99%), pyrazolam (1mg/mL in ACN, >99%), and 
flubromazepam (1mg/mL in MeOH, >99%), were purchased from Chiron 
(Trondheim, Norway). Delorazepam (0.1mg/mL in MeOH, >99%), lormetazepam 
(1mg/mL in MeOH, >99%), lorazepam-D4 (0.1mg/mL in MeOH, >99%), and 
diazepam-D5 (0.1mg/mL in MeOH, >99%), were purchased from Sigma Aldrich 
(Gillingham, UK). DiH2O was prepared in-house using the Purite (Thame, UK) 
diH2O system. Disodium hydrogen orthophosphate anhydrous (AR Grade) and 
sodium dihydrogen orthophosphate dihydrate (AR Grade) were purchased from 
Fisher Scientific (Loughborough, UK). Ammonium acetate (AR grade) was 
purchased from Sigma Aldrich (Gillingham, UK). Methanol (HPLC grade), 
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acetonitrile (LC/MS grade), cyclohexane (CP grade), ethyl acetate (Tech grade), 
ammonia (AR grade, 28%) and formic acid (AR grade, >99%) were all purchased 
from VWR (Lutterworth, Leicestershire, UK). Expired red blood cells were 
purchased from the Scottish National Blood Transfusion Service (SNBTS) at 
Gartnavel Hospital (Glasgow, UK). Human whole blood was purchased from 
Biological Specialty Corporation (Pennsylvania, USA). The solid phase extraction 
United Chemical Technologies CleanScreen® DAU (200 mg, 10 mL) (SPE) 
cartridges used were purchased from Chromatography Direct (Runcorn, UK). 
3.3.2. Reagent preparation 
The reagents used in the extraction and their preparation is detailed in Table 13. 
Class A graduated measuring cylinders and volumetric flasks were used to make 
up the reagents and the contents mixed prior to transferring to glass reagent 
bottles.  
Table 13: Blood method validation reagent preparation 
Reagent 
Substance  
1 
Substance  
2 
Substance 
3 
Substance  
4 
Storage  
Phosphate 
buffer (pH 6, 
0.1M) 
Disodium 
hydrogen 
orthophosphate 
anhydrous 
1.7 g 
Sodium 
dihydrogen 
orthophosphate 
dihydrate 
12.14 g 
DiH2O 
Up to 1000 
mL 
0.1M 
monobasic/dibasic 
sodium phosphate 
(for pH adjustment) 
Room 
temp. 
 
Phosphate 
buffer (pH 6, 
0.1M): DiH2O 
(1:2, v:v) 
Phosphate buffer 
(pH 6, 0.1M) 
500 mL 
DiH2O 
1000 mL 
- - 
Room 
temp. 
 
Phosphate 
buffer: 
Acetonitrile 
(80:20, v:v) 
Phosphate buffer 
(pH 6, 0.1M) 
160 mL 
Acetonitrile 
40 mL 
- - 
Room 
temp. 
 
Ethyl acetate 
with 2% 
ammonium 
Ethyl acetate 
980 mL 
Ammonia 
20 mL 
- - 
Room 
temp. 
 
Blank blood 
Red blood cells 
500 mL 
DiH2O 
500 mL 
- - 
Fridge 
(2-8°C) 
 
Reconstitution 
solution 
(50:50, v:v) 
Methanol 
500 mL 
DiH2O 
500 mL 
- - 
Room 
temp. 
 
Reconstitution 
ACN solution 
(25:75, v:v) 
Acetonitrile 
50 mL 
DiH2O 
150 mL 
- - 
Room 
temp. 
 
2M ammonium 
acetate 
Ammonium 
acetate 
15.4 g 
DiH2O 
100 mL 
- - 
Room 
temp. 
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Mobile Phase A 
DiH2O 
2000 mL 
2M ammonium 
acetate 
2 mL 
Formic acid 
2 mL 
- 
Room 
temp. 
 
Mobile Phase B 
Methanol 
2000 mL 
2M ammonium 
acetate 
2 mL 
Formic acid 
2 mL 
- 
Room 
temp. 
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3.3.3. Calibrator, QC and Internal Standard Preparation 
The preparation details for the calibrator stock and working solutions are detailed 
in Tables 14 and 15. Class A volumetric flasks were used to make up the solutions 
and vigorously inverted several times to mix. Both stock and working solutions 
were stored in the freezer (≤-20 °C). 
 
Table 14: Blood method validation calibrator stock preparation 
Calibrator stock 
solution 
@ 10 µg/mL 
Drug @ 1 mg/mL 
100 µl added 
Drug @ 100 µg/mL 
1 mL added 
Solvent 
Up to 10 mL 
Diclazepam Delorazepam Methanol 
Lormetazepam   
Pyrazolam   
Flubromazepam   
 
Table 15: Blood method validation calibrator working solution preparation 
Calibrator working 
solution  
@ 1 µg/mL 
Substance 1 Substance 2 
Calibrator stock 
solution 
@ 10 µg/mL 
 1 mL 
Methanol 
Up to 10 mL 
The quality control (QC) stock and working solutions were prepared in the same 
way as the calibrator solutions at the same concentration, see Tables 14 and 15. 
The QCs were prepared using reference standards with different lot numbers from 
the calibrators and were prepared independently to the calibrators by a different 
analyst in order to avoid preparation errors. The internal standard preparation is 
shown in Tables 16 and 17. Diazepam-D5 is used as the internal standard for all 
analytes except lormetazepam which uses lorazepam-D4. When the validation 
tests were carried out the only internal standard used for all analytes was 
diazepam-D5. Lorazepam-D4 is used for lormetazepam more recently as it has a 
closer retention time and is closer structural to lormetazepam. Table 18 displays 
the preparation of the calibrators and QCs using the working solutions prepared in 
table 15. 
Table 16: Blood method validation internal standard stock preparation 
Internal 
standard stock 
solution 
@ 10 µg/mL 
Drug @ 100 µg/mL 
1 mL added 
Solvent 
Up to 10 mL 
Diazepam-D5 Methanol 
Lorazepam-D4  
  
  
Table 17: Blood method validation internal standard working solution preparation 
Solution Substance 1 Substance 2 
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Internal standard 
working solution  
@ 1 µg/mL 
Internal standard 
stock solution 
@ 10 µg/mL 
 1 mL 
Methanol 
Up to 10 mL 
 
Table 18: Blood method validation calibrators and QC preparation 
Calibrator/QC 
Final 
Concentration 
(mg/L) 
Volume of Working Calibrator/ 
Spike/QC Solution (1 μg/mL) 
(μL) 
Calibrator 1 0.005 5 
Calibrator 2 0.010 10 
Calibrator 3 0.020 20 
Calibrator 4 0.050 50 
Calibrator 5 0.100 100 
Calibrator 6 0.200 200 
Spike 0.042 42 
QC 1 0.015 15 
QC 2 0.042 42 
QC 3 0.150 150 
LOD 3 0.0030 3 
LOD 2.5 0.0025 2.5 
LOD 2 0.0020 2 
ME Low 0.010 10 
ME High 0.170 170 
Carry-over 0.500 500 
 
3.3.4. LC-MS/MS Instrumentation and parameters 
The analysis was carried out using an Agilent 1200 LC system coupled to an AB 
Sciex 3200 QTRAP MS. The software utilised was Analyst® 1.7. The column oven 
was set at 40 °C and was fitted with a Phenomenex Gemini C18 column (150 mm 
x 2.0 mm, 5 µm) which had a pre column SecurityGuard™ cartridge (4.0 mm x 2.0 
mm) in place. A reversed phase isocratic system consisting of two mobile phases; 
2 mM ammonium acetate and 0.1% formic acid in diH2O water (mobile phase A) 
and 2 mM ammonium acetate and 0.1% formic acid in methanol (mobile phase B) 
was used. The isocratic system was maintained at 40/60% A/B with a total runtime 
of 7 mins. The injection volume was 10 µL. 
Positive electrospray ionisation was utilised and the ion source temperature was 
maintained at 350°C. Nitrogen was used as the source and collision gas. The 
collision gas (CAD) was set at 4 and the ion source gas 1 and 2 were set at 30 psi. 
Multiple reaction monitoring (MRM) mode was used to detect the analytes see 
Table 19. 
 The MRM transitions in Table 19 were chosen as they displayed the greatest 
abundance when subjected to post-column infusion. Diazepam-D5 was the 
internal standard for all analytes except lorametazepam, which used lorazepam-
D4. 
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Table 19: Blood method analytes and MS parameters 
Name Q1 Q3 DP EP CEP CE CXP 
Diclazepam QT 319.1 227.2 71 10.5 16 43 6 
Diclazepam QL 319.1 154.1 71 10.5 16 39 6 
Delorazepam QT 305.1 140.0 66 10.5 12 41 6 
Delorazepam_QL 305.1 206.1 66 10.5 12 49 6 
Lormetazepam QT 335.1 289.1 46 10.5 16 31 6 
Lormetazepam QL 335.1 177.0 46 10.5 16 55 6 
Flubromazepam QT 333.0 226.2 71 10.5 14 41 6 
Flubromazepam QL 333.0 184.0 71 10.5 14 43 6 
Pyrazolam QT 354.1 206.2 61 11.0 16 43 6 
Pyrazolam QL 354.1 167.0 61 11.0 16 45 6 
Diazepam-D5 290.1 198.1 66 10.5 14 45 4 
Lorazepam-D4 325.1 279.2 51 10.0 14 33 6 
 
3.3.5.  Sample extraction.  
The extraction was carried out by SPE, Figure 21 shows a flowchart outlining the 
SPE method used. SPE was chosen as the extraction technique for this method 
as the samples tested were post-mortem blood, which is often decomposed or 
fatty, SPE provides a clean extract. LLE would produce a less clean extract, which 
in turn would result in an increased need for instrument maintenance.  
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Figure 21: Blood method - SPE procedure 
 
3.3.6. Data handling and statistical analysis 
Once results had been generated in the Analyst software, they were copied onto a 
Microsoft® Excel® (version 14.7.3) spreadsheet and batch checked by a second 
toxicologist before any calculations were performed. The results copied include the 
peak areas of the analyte and the internal standard, the calculated values of the 
calibration standards and QCs in mg/L and the datapath information. Microsoft® 
Excel® was then used to calculate the mean, standard deviation, %CV, %ME, 
Into 10 mL glass test tubes 
• 3.5 mL pH 6 buffer deionised water (1:2) mix 
• 200 µL of internal standard diazepam-D5 and lorazepam-D4 (1 µg/mL) 
• Blank tube: 1 mL of blank blood  
• QC tube: Relevant volume  of working solution µL of the QC solution (1 µg/mL) (see table 18) and 
1 mL of blank blood 
• Calibrator tubes: Relevant volume  of working solution (1 µg/mL) (see table 18) and 1 mL of blank blood 
• Vortex mix then centrifuge @ 3000 RPM for 10 mins 
Into labelled CleanScreen® SPE cartridges   
• Condition: 3 mL of methanol, 3 mL  of diH2O, 2 mL of pH 6, 0.1 M phosphate buffer  
• Load: loaded on and allowed to completely pass thorough the cartridges 
• Wash: 2 mL phosphate buffer/ACN (80:20%) then dried under full vacuum for 1 min 
• Wash: 2 mL cyclohexane then dried under full vacuum for 1 min 
• Wash: 3 mL diH2O  then dried under full vacuum for 5 mins 
Into 3 mL labelled glass vials 
• Elution: 3 mL ethyl acetate with 2% NH3 
• Evaporation: 40 °C under a stream of nitrogen 
• Reconstitution: 1.5 mL of 50% methanol:50% diH2O 
Transfer to labelled auto sampler vials and cap 
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%PE and %RE where necessary. A second toxicologist, as part of the batch 
checking, also checked the formula used in the spreadsheets for each calculation. 
Line graphs were generated in the spreadsheet to track autosampler stabilty. The 
Statsplus (AnalystSoft™, version 7.7.31) add on for Microsoft® Excel® was used 
to generate residual plots to investigate linearity. The spreadsheets were saved on 
a secure drive to protect the data. 
 
3.4. Method validation experimental 
3.4.1. Selectivity 
Selectivity has been described, as ―the ability to unambiguously assess the 
analyte of interest while in the presence of all expected components, which may 
consist of degradants, excipients/sample matrix, and sample blank peaks.‖ 
(Scientific Working Group for Forensic Toxicology, 2013; Tiwari and Tiwari, 2010) 
Endogenous substances such as proteins, salts, lipids and small molecules can be 
a common source of interference. There should be no interfering signals at the 
retention times of interest for the drugs/metabolites. 
A selectivity experiment was carried out using 10 different sources of drug free 
whole blood extracted in singlicate within a single batch to determine if 
endogenous interference is an issue. 
3.4.2. Specificity 
Exogenous interference from other drugs and metabolites was evaluated by 
injecting 31 analytes, in triplicate, unextracted in reconstitution solution at a 
concentration of 0.5 mg/L. The 31 drugs and metabolites are detailed in Table 20. 
These drugs were selected, as they are common drugs encountered in forensic 
toxicology. They are not all benzodiazepines or structurally similar to 
benzodiazepines and were chosen for their commonality in case samples not their 
structure. These drugs were in 3 individual solutions, solution 1 contained all the 
drugs from chlorpromazine to amitriptyline, solution 2 contained the 
benzodiazepines from oxazepam to nitrazepam and solution 3 was a drugs of 
abuse mix containing all the drugs from cocaine to 6-MAM in Table 20. 
Table 20: Blood method validation - Drugs used to evaluate specificity 
Chlorpromazine Phenazepam 
 
 
62 
Tramadol Etizolam 
Diphenhydramine Lorazepam 
Lignocaine Nitrazepam 
Methadone Cocaine 
Citalopram Benzoylecognine 
Chlorpheniramine Amphetamine 
Mirtazapine Methamphetamine 
Diltiazem MDMA 
Zolpidem MDA 
Amitriptyline MDEA 
Oxazepam Morphine 
Chlordiazepoxide Codeine 
Diazepam Dihydrocodeine 
Desmethyldiazepam 6-MAM 
Temazepam  
 
3.4.3. Linearity  
Linearity is crucial as it ―assesses the ability of the method to obtain test results 
that are directly proportional to the concentration of the analyte in the sample.‖ 
(Tiwari and Tiwari, 2010)  
For the calibrators, blank blood was spiked with each analyte at six concentrations 
from 0.005 to 0.20 mg/L, in singlicate, within ten batches over ten months; these 
were used to evaluate linearity. A blank (with internal standard) was extracted with 
each calibration curve. The concentration range was from 0.005 – 0.2 mg/L; six 
calibrators at the concentrations of 0.005, 0.010, 0.020, 0.050, 0.10 and 0.20 mg/L 
make up the calibration curves, see Table 18 for preparation details. Calibration 
curves were generated using the Analyst 1.7 software. All calibrators within each 
curve must have an accuracy within ±20% of the target value and the curves must 
have a correlation coefficient (r) greater than 0.99 (r>0.99).  
The standard deviation (SD) and coefficient of variation (%CV) were calculated for 
the ten calibration curves using equations 2 and 3.  
Equation 2: Standard deviation 
SD =√
∑(   ) 
(   )
 
Where x is the value,   is the mean and   is the sample size.  
Equation 3: %Coefficient of variation 
%CV = SD/         
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Where   is the mean. 
The precision of the lower limit of quantitation (LLOQ) and the upper limit of 
quantitation (ULOQ) will be evaluated. The inter-day precision of the LLOQ 
and ULOQ was calculated using %CV, see equation 3, for the ten calibration 
curves. 
3.4.4. Limit of detection 
The limit of detection (LOD) is the ―lowest concentration of an analyte in a sample 
which can be detected but not necessarily quantified as an exact value.‖ (Tiwari 
and Tiwari, 2010)  
LOD can be determined by measuring the signal-to-noise ratio of the peak. As 
there is instrumental noise present even in a drug free injection, the s/n ratio was 
used to determine the LOD in this study as this approach takes that noise into 
consideration, calculating LOD by equation does not account for background 
noise. The Analyst ® software is able to assist with this as it allows the operator to 
highlight the peak (signal) and a suitable area of noise close to the peak of interest 
in the baseline. It then calculates the signal-to-noise ratio and displays this on the 
peak. 
LOD for each analyte was evaluated. Extracted concentrations of 0.003, 0.0025 
and 0.002 mg/L (see Table 18 for preparation details) were tested in duplicate. 
The signal-to-noise ratio should be ≥3 for the analyte to be considered detectable. 
Retention time for each analyte should be consistent.  
3.4.5. Precision and bias 
Precision is the degree of scatter or closeness of agreement in a series of 
measurements. The %CV (equation 3) is used to demonstrate precision. For the 
%CV to be considered acceptable it should be less than 20%. Bias is expressed 
as the percentage accuracy, which shows deviation from the target value. Bias 
demonstrates the difference between the test results and the target value. The 
acceptable range is ±20%). 
Three different QC concentrations (0.015, 0.042 and 0.150 mg/L), see Table 18 for 
preparation details, were each extracted five times and run within one batch on the 
same day for intra-day bias and precision. Three different QC concentrations 
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(0.015, 0.042 and 0.150 mg/L) were each extracted five times and run over five 
different batches run on five different days for inter-day bias and precision. 
3.4.6. Matrix effects, recovery and process efficiency  
Interfering compounds within the sample matrix or reagents such as buffers can 
cause matrix effects (ME). Sample nature can dictate the occurrence of matrix 
effects, which makes them very unpredictable. Using an LC-MS method requires 
assessment of the matrix effects phenomenon, due to the techniques susceptibility 
to ion enhancement or suppression, which can lead to inaccurate quantitative 
results.  
Ion suppression occurs when less volatile compounds change the efficiency of the 
droplet formation, which leads to less of the charged ion in the gas phase that 
reaches the detector. (Annesley, 2003) The mechanism responsible for ion 
enhancement is still not fully understood but it leads to an increase in the 
formation of ions. The ME can be expressed as %accuracy. The %ME range 
should fall within ±25% to be considered acceptable. Ion suppression will be 
shown as <100% and ion enhancement as >100%. The precision (%CV) should 
not exceed 15% according to SWGTOX. (Scientific Working Group for Forensic 
Toxicology, 2013) 
Recovery (RE) can also be assessed with the same set of experiments used to 
evaluate ME. Recovery is defined as the percentage of analyte extracted from the 
sample matrix at the end of the analysis. The importance of recovery is argued; 
with some authors stating that providing other parameters such LOD is acceptable 
there is no requirement for a high percentage of recovery. (Tiwari and Tiwari, 
2010; Peters, Drummer and Musshoff, 2007) It is recommended that recovery 
should be at least 50%. 
Process efficiency (PE) represents the combination of ME and RE to give an 
overall assessment of the difference the matrix has induced on each analyte 
during the complete extraction process, compared to the analyte in reconstitution 
solution.  
For two concentrations investigated, ME, RE and PE were calculated using the 
post-extraction addition approach detailed by Matuszewski et al. (Matuszewski, 
Constanzer and Chavez-Eng, 2003) 
Drug-free (blank) whole blood from 10 different sources was used for the ME, RE 
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and PE experiments. The analytes, diclazepam, delorazepam, lormetazepam, 
pyrazolam and flubromazepam, at two different concentrations (ME Low 0.010 and 
ME High 0.17 mg/L, see Table 18), were evaluated. The ME, RE and PE 
experiments were performed as follows:  
 Set A: neat unextracted analyte mix and internal standard in reconstitution 
solution was prepared six times. 
 Set B: blank blood from 10 different sources were spiked with the analyte 
mix and internal standard in reconstitution solution after SPE. Set B was 
prepared in duplicate. 
 Set C: blank blood from 10 different sources were spiked with analyte mix 
and internal standard prior to SPE. Set C was prepared in singlicate. 
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The percentage matrix effects (%ME) were calculated using equation 4. 
Equation 4: %Matrix effects 
%ME = (
 
 
)        
Where 
A = Mean peak area of neat unextracted analyte 
B = Mean peak area of post-extraction spiked analyte 
The percentage recovery (%RE) was calculated using equation 5. 
 
Equation 5: %Recovery 
%RE = (
 
 
)        
Where 
B = Mean peak area of post extraction spiked analyte 
C = Mean peak area of extracted analyte 
The percentage process efficiency (%PE) was calculated using equation 6. 
Equation 6: %Process efficiency 
%PE = (
 
 
)        
Where 
A = Mean peak area of neat unextracted analytes 
C = Mean peak area of extracted analyte 
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3.4.7. Carryover  
Examining injections of drug-free reconstitution solution, which are injected directly 
following a high concentration for analyte peaks, provides an assessment of 
carryover. There should be no signal at or near the retention time of the analytes 
of interest. An extracted concentration of 0.5 mg/L of diclazepam, delorazepam, 
lormetazepam, pyrazolam and flubromazepam, was injected in triplicate followed, 
by three injections of drug-free reconstitution solution (50:50% methanol:diH2O). 
The concentration 0.5 mg/L was chosen, as this is more than double the ULOQ. 
3.4.8. Autosampler stability 
Stability can be defined as ―the chemical stability of an analyte in a given matrix 
under specific conditions for given time intervals.‖ (Tiwari and Tiwari, 2010) It is 
important to evaluate stability to address the circumstances encountered in normal 
laboratory situations. In a busy laboratory environment vials may sit on the 
autosampler for several hours before the run is complete. 
Blank blood was spiked at the high QC (0.15 mg/L) and the low QC (0.015 mg/L) 
concentration in triplicate and extracted using the SPE procedure detailed in 
Figure 21. These extracts were then run on the method detailed in section 3.3.4 to 
determine a time zero response (t0), the same extracts were then injected at three 
hour intervals up to 48 hours. The autosampler was not temperature controlled. 
The laboratory was temperature controlled between 16°C and 24°C during the 
experiment. This reflects the normal temperature range of the laboratory in which 
real life samples are analysed. 
3.5. Method Validation Results and Discussion 
3.5.1. Selectivity 
An absence of interfering signals at or near the retention times of the analytes of 
interest, diclazepam, delorazepam, lormetazepam, flubromazepam and 
pyrazolam, was demonstrated by this experiment, there were no viable peaks 
detected for the ten sources of blank blood tested. Figures 22 and 23 display 
example chromatograms with and without internal standard respectively, from one 
of the sources of blank blood tested; the analyte retention times have been added 
to show each analytes position and the lack of interference in the area of interest. 
The green and blue peaks are lorazepam-D4 and diazepam-D5 respectively. 
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Figure 22: Example chromatogram of method selectivity, with internal standard, 
lack of interfering signal at the retention time of the analytes of interest. 
 
Figure 23: Example of method selectivity, without internal standard, lack of 
interfering signal at the retention time of the analytes of interest. 
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3.5.2. Specificity 
No interfering peaks were detected from any of the 31 drugs/metabolites at the 
retention times of interest of any of the analytes tested for in this method. Figure 
24 shows the blank signal, which was obtained after the injection of solution 3 (see 
3.4.2) which included cocaine, benzoylecognine, amphetamine, 
methamphetamine, MDMA, MDA, MDEA, morphine, codeine, dihydrocodeine and 
6-MAM. All drugs within Table 20 gave no signal, similar to the example shown in 
Figure 24.  
 
 
Figure 24: Example chromatogram of method specificity, from other 
drugs/metabolites, shown by the lack of signal at the analytes of interest retention 
time. 
3.5.3. Linearity 
Linearity was tested with ten calibration curves which where ran over a ten-month 
period. The linearity data for all 5 analytes is displayed in Table 21. All analytes 
displayed good linearity with 1/x weighted linear regression over the calibration 
range 0.005 to 0.20 mg/L, with all curves r>0.99. All calibrators were within the 
±20% accuracy criterion. 1/x weighting was chosen to minimise the distribution of 
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variance across the calibration range, larger deviations present in the higher 
concentrations will influence the curve more leading to impaired accuracy on the at 
the lower concentrations. To balance this out weighting is applied, when 1/x 
weighting is applied the slope more closely approximates the majority of calibrator 
points. Figure 25 gives example calibration curves for diclazepam, delorazepam, 
lormetazepam, flubromazepam and pyrazolam. The residuals from five calibration 
curves were plotted for each analyte (as per SWGTOX recommendation), see 
Figure 26. The residuals represent the difference in observed value from the 
predicted value. These values can be positive or negative depending on if the 
observed value is more or less than the predicted value. A residual plot with 
randomly distributed positive and negative values around the 0 axis with no 
defined trend demonstrates a linear model is appropriate. (Polettini, 2006) There is 
no convincing pattern in the residual plots for diclazepam, delorazepam, 
lormetazepam, and pyrazolam, demonstrating linearity is achieved. The range of 
variances increases with the concentration confirming a weighted calibration is 
required which was applied. (Polettini, 2006) Flubromazepam appears to be more 
positively distributed and therefore a quadratic fit may be more appropriate 
however the calibration curves produced have all been linear with a r>0.99. It is 
recognised that when calibration points are displaying accuracy within the 
acceptable limits then an alternative fit is not required and deviations can be 
overlooked. (Peters and Maurer, 2002) 
Table 21: Blood method validation linearity data 
Analyte Mean r 
(n=10) 
SD %CV Calibrator 
% 
accuracy  
range 
Diclazepam 0.9994 0.0005 0.0539 93-108 
Delorazepam 0.9992 0.0011 0.1130 84-114 
Lormetazepam 0.9981 0.0029 0.2874 90-114 
Pyrazolam 0.9963 0.0024 0.2362 81-112 
Flubromazepam 0.9990 0.0007 0.0686 82-116 
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Figure 25: Example calibration curves for diclazepam, delorazepam, 
lormetazepam, flubromazepam and pyrazolam. 
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Figure 26: Residual plots for diclazepam, delorazepam, lormetazepam, 
flubromazepam and pyrazolam 
 
The inter-day precision of the LLOQ and ULOQ was calculated in order to 
evaluate the low and high point of the calibration curve for all analytes. The inter-
day %CV met the acceptance criterion of <20% for diclazepam (<1.5), 
delorazepam (<9.5), lormetazepam (11.2), flubromazepam (<11.6%) and 
pyrazolam (<17.2%) for both the LLOQ and ULOQ showing that both high and low 
points are precise for this method. Diclazepam LLOQ data demonstrates good 
precision giving a SD and %CV of 0 to 3 decimal places. The %bias was also 
calculated and demonstrated good accuracy for the LLOQ. Table 22 shows the 
LLOQ mean concentration, SD and inter-day precision and bias. 
Table 22: Blood method validation LLOQ (0.005 mg/L) inter-day precision and bias 
data 
 
Diclazepam Delorazepam Lormetazepam Flubromazepam Pyrazolam 
Mean 
concentration 0.005 0.005 0.005 0.005 0.005 
SD 0.000 0.000 0.001 0.001 0.001 
%CV 0.0 9.4 11 12 17 
%Bias 0 0 -2 -4 0 
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Table 23 shows the data used to calculate the ULOQ precision and bias. The 
precision and bias for the ULOQ for all analytes is particularly good at <5% and 
<2%, respectively. 
Table 23: Blood method validation ULOQ (0.20 mg/L) inter-day precision and bias 
data 
 
Diclazepam Delorazepam Lormetazepam Flubromazepam Pyrazolam 
Mean 
concentration 0.197 0.198 0.199 0.199 0.200 
SD 0.003 0.004 0.006 0.004 0.010 
%CV 1.4 2.1 3.2 2.1 5.0 
%Bias 3 1 1 1 2 
 
3.5.4. Limit of detection 
The limit of detection (LOD) was determined by evaluating the signal-to-noise 
ratios for the analytes of interest. LOD is an approximation of the lowest 
concentration detectable by the method and can change depending on the set of 
experimental data used, laboratory conditions and how clean the instrument is. 
Since this is just an approximation of detectability the S/N ratio is not used to 
determine LOQ. S/N uses the baseline as a blank in which to compare to the 
signal generated by the analyte, a blank without the analyte cannot be used 
accurately as the noise is dependent on the signal magnitude. (Desimoni and 
Brunetti, 2015) A signal-to-noise ratio ≥3 at the correct retention is considered to 
be a detectable peak. Using the baseline means instrumental noise is considered 
but also can widely vary between injections. The S/N ratio alone is not the only 
aspect considered when using this technique for LOD determination; the peaks 
must also be visually inspected to ensure good Gaussian peak shapes. 
Diclazepam, delorazepam, lormetazepam, flubromazepam and pyrazolam all had 
signal-to-noise ratios >3 for all the concentrations tested therefore the LOD for all 
five drugs was determined as 0.002 mg/L (2 ng/mL). Flubromazepam gave the 
lowest signal-to-noise ratio across the three concentrations. Table 24 displays the 
signal-to-noise ratio results for all analytes at the three concentrations tested. 
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Table 24: Blood method - Limit of detection (LOD) data 
Analyte Signal-to-noise ratio 
 LOD 3 LOD 2.5 LOD 2 
 QT QL QT QL QT QL 
Diclazepam 15.2 26.5 15.2 71.5 13.5 44.5 
Delorazepam 53.5 33.5 53.5 4.5 17.5 8.5 
Lormetazepam 26.2 7.0 26.2 9.8 12.8 6.5 
Pyrazolam 12.0 15.0 12.0 11.0 6.5 12.5 
Flubromazepam 6.0 16.0 6.0 24.5 4.5 14.5 
 
3.5.5. Precision and bias 
The results for the intra- and inter-day precision and bias data are shown in Tables 
25 and 26. The precision evaluated by the %CV was within the acceptance 
criterion of <20% for diclazepam, delorazepam, lormetazepam, pyrazolam and 
flubromazepam for all three QC concentrations for both intra- and inter-day 
batches. The bias evaluated by %bias was within the acceptance criterion of ±20% 
(accuracy of 80-120%) for diclazepam, delorazepam, lormetazepam, pyrazolam 
and flubromazepam for all three concentrations for both intra- and inter-day 
batches.  
Table 25: Blood method validation intra-day precision and bias  
 
Analyte 
 
Diclazepam Delorazepam Lormetazepam Flubromazepam Pyrazolam 
QC 1 0.015 mg/L 
Mean (n = 5) 0.016 0.016 0.015 0.016 0.014 (n = 4) 
SD 0.001 0.001 0.002 0.000 0.002 
%CV 3.1 9.3 11 2.5 13 
%Bias 10 4 -1 5 -4 
QC 2 0.042 mg/L 
Mean (n = 5) 0.043 0.041 0.043 0.043 0.050 
SD 0.002 0.002 0.002 0.002 0.001 
%CV 3.7 4.7 4.3 4.4 3.1 
%Bias 2 -3 3 3 18 
QC 3 0.150 mg/L 
Mean (n = 5) 0.152 0.146 0.151 0.160 0.179 (n = 4) 
SD 0.005 0.002 0.007 0.003 0.022 
%CV 3.0 1.7 4.7 2.1 12 
%Bias 2 --3 0 7 19 
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Table 26: Blood Validation Method Inter-day precision and bias 
 
Analyte 
 
Diclazepam Delorazepam Lormetazepam Flubromazepam Pyrazolam 
QC 1 0.015 mg/L 
Mean (n = 5) 0.015 0.014 0.014 0.016 0.014 
Low 0.012 0.008 0.010 0.013 0.007 
High 0.017 0.017 0.017 0.019 0.020 
SD 0.001 0.002 0.002 0.001 0.003 
%CV 7.9 17 13 8.4 20 
%Bias 2 -6 -5 8 -6 
QC 2 0.042 mg/L 
Mean (n = 5) 0.044 0.041 0.041 0.048 0.046 
Low 0.038 0.030 0.031 0.037 0.039 
High 0.052 0.047 0.047 0.057 0.056 
SD 0.004 0.005 0.005 0.005 0.007 
%CV 8.8 12 11 11 14 
%Bias 5 -2 -2 13 9 
QC 3 0.150 mg/L 
Mean (n = 5) 0.159 0.152 0.159 0.177 0.179 
Low 0.135 0.114 0.113 0.139 0.115 
High 0.180 0.173 0.191 0.216 0.221 
SD 0.011 0.016 0.022 0.021 0.034 
%CV 7.1 11 14 12 19 
%Bias 6 1 6 18 19 
 
3.5.6. Matrix effects, recovery and process efficiency 
The matrix effects for diclazepam, delorazepam, lormetazepam, pyrazolam and 
flubromazepam are shown for the low concentration (0.010 mg/L) in Table 27 and 
the high concentration (0.17 mg/L) in Table 28.  
Table 27: Blood method validation - ME results at 0.010 mg/L 
 
%ME (n=2) 0.010 mg/L 
 
Diclazepam Delorazepam Lormetazepam Pyrazolam Flubromazepam 
 
QT QT QT QT QT 
Overall 
Mean %ME 
(n=10) 
-14 -19 -21 -10 -14 
Overall ME 
%CV 
7.5 7.6 7.4 8.5 8.8 
 
The mean %ME for diclazepam, delorazepam, lormetazepam, pyrazolam and 
flubromazepam were -14, -19, -21, -10 and -14% respectively at the low 
concentration tested. All mean results were within the ±25% criterion for %ME and 
<15% for precision.  
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Table 28: Blood method validation - ME results at 0.170 mg/L 
 
%ME (n=2) 0.170 mg/L 
 
Diclazepam Delorazepam Lormetazepam Pyrazolam Flubromazepam 
 
QT QT QT QT QT 
Overall 
Mean %ME 
(n=10) 
16 14 12 9 21 
Overall ME 
%CV 
1.2 2.0 2.0 2.6 1.8 
 
The mean %ME for diclazepam, delorazepam, lormetazepam, flubromazepam and 
pyrazolam were 16, 14, 12, 21 and 9% respectively at the high concentration 
tested. All mean results were within the ±25% criterion and the precision well 
under the <15% criteria.  
Table 29: Blood method validation - ME internal standard results  
  Diazepam-D5 %ME (n=2)  
 
(0.010 mg/L) (0.170 mg/L) 
Overall Mean 
%ME (n=10) 
-6 6 
Overall ME 
%CV 
3.5 2.4 
 
The %ME for the internal standard is shown in Table 29; there is no significant ME 
evident for the internal standard. 
The %RE and %PE for diclazepam, delorazepam, lormetazepam, pyrazolam and 
flubromazepam are shown for the low concentration (0.010 mg/L) in Table 30 and 
the high concentration (0.17 mg/L) in Table 31.  
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Table 30: Blood method validation - RE and PE results at 0.010 mg/L 
Drug QT 
(0.010 mg/L) 
%RE mean  
(%CV) 
(n=10) 
%PE mean  
(%CV) 
(n=10) 
Diclazepam 
57  
(10) 
49  
(7.7) 
Delorazepam 
64  
(9.0) 
52  
(9.2) 
Lormetazepam 
42  
(9.9) 
33  
(10) 
Flubromazepam 
31  
(18) 
26 
(16) 
Pyrazolam 
28  
(18) 
25 
(17) 
 
Table 31: Blood method validation - RE and PE results 0.17 mg/L 
Drug QT 
(0.017 mg/L) 
%RE mean  
(%CV) 
(n=10) 
%PE mean  
(%CV) 
(n=10) 
Diclazepam 
64  
(6.7) 
75  
(7.4) 
Delorazepam 
63  
(6.8) 
73  
(7.9) 
Lormetazepam 
45  
(7.6) 
50  
(9.0) 
Flubromazepam 
43  
(12) 
52 
(13) 
Pyrazolam 
27  
(7.6) 
30 
 (9.5) 
 
Table 32 Blood method validation- RE and PE internal standard data 
Drug 
 
%RE mean  
(%CV) 
(n=10) 
%PE mean  
(%CV) 
(n=10) 
Diazepam-D5 
17  
(3.1) 
16  
(2.8) 
 
The RE and PE results for diclazepam and delorazepam are acceptable and 
around 50% or above for both concentrations tested. Lormetazepam was below 
50% for RE and PE but over 40% for RE for both concentrations, this is 
considered suboptimal but should not have a deleterious effect. Flubromazepam 
has sufficient PE and above 40% RE at the high concentration tested but under 
40% for RE and PE at the low concentration tested, therefore the accuracy at the 
lower end of the calibration curve may not be as good as at the high end; however 
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the LLOQ shows good precision and bias (see Table 22) and the analyte is 
detectable down to 0.002 mg/L. The RE and PE for pyrazolam at both 
concentrations is poor at 30% and under however the LLOQ shows good precision 
and bias (see Table 22) and the analyte is detectable down to 0.002 mg/L. This 
suggests an issue with this extraction for pyrazolam. One possibility is that 
pyrazolam is less soluble in methanol than it is in acetonitrile (pyrazolam is 
purchased in acetonitrile) and therefore does not fully dissolve at the reconstitution 
step or there is a stability issue with pyrazolam in the combined methanolic 
working solution. The ME for all analytes was acceptable and although there was 
low RE and PE for pyrazolam and flubromazepam the precision and bias were 
acceptable and an acceptable LOD down to 0.002 mg/L was achieved for both.  
The mean PE and RE for the internal standard was suboptimal as it is low at 16% 
and 17%, see Table 32 however it is consistent across all ten sources and the 
peak areas are sufficiently strong at 1,000,000 cps or above.  
3.5.7. Carryover  
Carryover is assessed by the absence or presence of peaks in the injections of 
drug-free reconstitution solution directly following injections of a high concentration 
of the analytes of interest. There were no peaks in the drug-free reconstitution 
solution injection that followed three injections of 0.50 mg/L of diclazepam, 
delorazepam, lormetazepam, pyrazolam and flubromazepam, see Figure 27. 
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Figure 27: Example chromatogram of the absence of peaks after injections of 0.50 
mg/L, demonstrating the lack of carryover 
 
3.5.8. Autosampler stability 
The results from this experiment were plotted on graphs to evaluate autosampler 
stability. Figures 28 and 29 shows all analytes for the low (0.015 mg/L) and the 
high (0.15 mg/L) concentration, respectively. The response did not fall below 20% 
of the time zero response (t0) within 48 hours in a temperature controlled room 
(16°C - 24°C) and all analytes were considered stable under these conditions. 
Lormetazepam appeared to be the least stable and showed a downward trend for 
both concentrations compared to the other analytes however the responses for all 
time points were within 20% of t0. 
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Figure 28: Autosampler stability for all blood method analytes at a concentration of 
0.015 mg/L over 48 hours at 16-24 °C 
 
 
Figure 29: Autosampler stability for all blood method analytes at a concentration of 
0.15 mg/L over 48 hours at 16-24 °C. 
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3.6. Conclusion 
This method is suitable for the quantitative analysis of blood samples for 
diclazepam and its metabolites (delorazepam and lormetazepam), flubromazepam 
and pyrazolam. The method spans a concentration range (0.005-0.20 mg/L) for 
these drugs in blood with acceptable linearity. The method is specific and 
selective, and demonstrated no carryover at the concentration tested. Bias and 
precision were acceptable for all analytes. Matrix effects were found to be 
acceptable for all analytes and within the ±25% criterion for %ME and <15% for 
precision. Recovery and process efficiency was suitable for diclazepam and 
delorazepam, it was suboptimal for lormetazepam and flubromazepam however 
the bias, precision and sensitivity were good. Pyrazolams recovery and process 
efficiency was particularly low and this should be considered when analysing real 
samples in particular decomposed samples as they may give a lower 
concentration and samples which are positive at the lower end of the 
concentration range may give a negative result. All analytes were stable in the 
autosampler stability up to 48 hours in a laboratory with the temperature range 16-
24 °C. A temperature-controlled autosampler would allow more control over the 
analyte stabilty however it has been demonstrated that analysis within 48 hours 
should not be an issue. As further work, freeze and thaw stability should be 
investigated for these analytes, as the long-term stabilty in blood is still unknown.  
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4. Development and validation of a qualitative LC-MS/MS method for the 
detection of designer benzodiazepines in urine  
4.1. Introduction 
The first step in method development is to establish the purpose of the method, as 
this should dictate the subsequent decisions such as what sample preparation, 
chromatographic and detection system to use. It is important to choose relevant 
drugs/metabolites, internal standards and an appropriate sample matrix. In order 
to detect designer benzodiazepines in urine it was important that a robust method 
was developed and validated in order to acquire the qualitative results for the 
projects detailed in chapters 5 and 6 of this thesis. 
4.2. Aim 
The aim of this work was to develop and validate a qualitative LLE, LC-MS/MS 
method for the detection of benzodiazepines including designer benzodiazepines 
in urine. 
4.3. Materials and Methods 
4.3.1. Materials 
Diclazepam (1mg/mL in MeOH, >99%), flubromazepam (1mg/mL in MeOH, 
>99%), pyrazolam (1mg/mL in ACN, >99%), nifoxipam (1mg/mL in MeOH, >98%), 
clonazolam (1mg/mL in MeOH, >99%), flubromazolam (1mg/mL in MeOH, >99%), 
deschloroetizolam (1mg/mL in MeOH, >99%), meclonazepam (1mg/mL in MeOH, 
>99%), 3-hydroxyphenazepam (1mg/mL in MeOH, >99%) and metizolam 
(0.1mg/mL in MeOH, >99%) were purchased from Chiron (Trondheim, Norway). 
Chlordiazepoxide (1mg/mL in MeOH, >99%), nitrazepam, (1mg/mL in ACN, >99%) 
alprazolam (1mg/mL in MeOH, >99%), lorazepam (1mg/mL in ACN, >99%), 
oxazepam, (1mg/mL in MeOH, >99%) temazepam (1mg/mL in MeOH, >99%), 
lormetazepam, (1mg/mL in MeOH, >99%), delorazepam (0.1mg/mL in MeOH, 
>99%), etizolam (1mg/mL in MeOH, >99%), phenazepam (1mg/mL in ACN, 
>99%), desmethyldiazepam (1mg/mL in MeOH, >99%) and diazepam (1mg/mL in 
MeOH, >99%) were purchased from Sigma Aldrich (Gillingham, UK). Deionised 
water was prepared in-house using the Purite (Thame, UK) deionised water 
system. Disodium hydrogen orthophosphate anhydrous (AR Grade) and sodium 
dihydrogen orthophosphate dihydrate (AR grade), sodium acetate trihydrate (AR 
grade) and glacial acetate acid (AR grade, >99.7%) were purchased from Fisher 
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Scientific (Loughborough, UK). Tertiary methyl butyl ether (tBME) (anhydrous 
grade, >99%), β-glucuronidase from Helix Pomatia (≥100,000 units/mL) and 
ammonium acetate (AR grade) were purchased from Sigma Aldrich (Gillingham, 
UK). Methanol (HPLC grade), acetonitrile (LC/MS grade), formic acid (AR grade, 
>99%) and ammonia (AR grade, 28%) were purchased from VWR (Lutterworth, 
Leicestershire, UK). Blank (drug-free) urine was provided anonymously by in-
house donors. The blank urine collection process was approved by the University 
of Glasgow Medical, Veterinary and Life Sciences ethics committee under 
reference No. 200160020. (See appendix 1.1). 
4.3.2. Reagent preparation  
Table 33 details how the reagents used for the urine method were prepared.  
Table 33: Urine method reagent preparation 
Reagents Substance 1 Substance 2 Substance 3 Substance 4 Storage 
Sodium 
acetate buffer 
(pH 5.0, 0.1M) 
Sodium acetate 
trihydrate 
5.86g 
DiH2O 
Up to 1000 mL 
Glacial acetic acid 
(for pH adjustment) 
- 
Room 
Temp. 
Phosphate 
buffer (pH 6, 
0.1M) 
Disodium 
hydrogen 
orthophosphate 
anhydrous 
1.7 g 
Sodium 
dihydrogen 
orthophosphate 
dihydrate 
12.14 g 
DiH2O 
Up to 1000 
mL 
0.1M monobasic/dibasic 
sodium phosphate 
(for pH adjustment) 
Room 
Temp. 
 
0.1M 
monobasic 
sodium 
phosphate 
 
Sodium 
dihydrogen 
orthophosphate 
dihydrate 
2.76 g 
DiH2O 
Up to 150 mL 
- - 
Fridge 
(2-8°C) 
0.1M dibasic 
sodium 
phosphate 
 
Disodium 
hydrogen 
orthophosphate 
anhydrous 
2.84 g 
DiH2O 
Up to 150 mL 
- - 
Fridge 
(2-8°C) 
Reconstitution 
solution 
(25:75, v:v) 
Methanol 
50 mL 
DiH2O 
150 mL 
2M 
ammonium 
acetate 
200 µL 
Formic acid 
200 µL 
Room 
Temp. 
 
2M 
ammonium 
acetate 
Ammonium 
acetate 
15.4 g 
DiH2O 
100 mL 
- - 
Room 
Temp. 
Infusion 
solution 
Methanol 
500 mL 
DiH2O 
500 mL 
Formic acid 
1 mL 
2M ammonium 
acetate 
1 mL 
Room 
Temp. 
Mobile Phase 
A 
DiH2O 
1000 mL 
2M ammonium 
acetate 
1 ml 
Formic acid 
1 mL 
 
Room 
Temp. 
Mobile Phase 
B 
Methanol 
1000 mL 
2 M ammonium 
acetate 
1 ml 
Formic acid 
1 mL 
 
Room 
Temp. 
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All solutions were inverted to mix then transferred to appropriate containers. 
4.3.3. Drug and internal standard preparation 
Table 34 shows how the benzodiazepine drug stock solutions were prepared. 
Table 35 details how working drug solutions (high and low QCs, LOD and 
autosampler stability) were prepared using the benzodiazepine drug stock 
solution. 
Table 34: Urine method benzodiazepine drug stock solution preparation 
Stock Solution 
@ 10 µg/mL 
Drug 
@ 1 mg/mL 
100 µL added 
Drug 
@ 100 µg/mL 
1 mL added 
Solvent 
Up to 10 mL 
 Storage 
Pyrazolam Metizolam Methanol  Freezer 
Nifoxipam Delorazepam   (≤-20 °C) 
Chlordiazepoxide     
Clonazolam     
Nitrazepam     
Alprazolam     
Flubromazolam     
Lorazepam     
Deschloroetizolam     
Etizolam     
Oxazepam     
Meclonazepam     
Temazepam     
Lormetazepam     
Flubromazepam     
Desmethyldiazepam     
Phenazepam     
Diclazepam     
Diazepam     
3-hydroxyphenazepam     
 
Table 35: Urine method drug working solution preparation 
Solution Substance 1 Substance 2 Storage 
Low QC 
(0.075 µg/mL) 
 
Stock solution  
(10 µg/mL) 
75 µL 
 
Methanol 
Up to 10 mL 
 
Freezer 
(≤-20 °C) 
High QC 
(0.40 µg/mL) 
Stock solution  
(10 µg/mL) 
0.4 mL 
Methanol 
Up to 10 mL 
Freezer 
(≤-20 °C) 
LOD and 
autosampler 
stability  
(1 µg/mL) 
Stock solution  
(10 µg/mL) 
1 mL 
Methanol 
Up to 10 mL 
Freezer 
(≤-20 °C) 
 
Tables 36 and 37 detail the preparation of the internal standard stock and working 
solutions. 
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Table 36: Urine method internal standard stock preparation 
Internal 
standard 
stock 
solution 
@ 10 µg/mL 
Drug @ 100 µg/mL 
1 mL added 
Solvent 
Up to 10 mL 
Diazepam-D5 Methanol 
Lorazepam-D4 
7-aminoflunitrazepam-D7 
 
  
Table 37: Urine method internal standard working solution preparation 
Solution Substance 1 Substance 2 
Internal standard 
working solution 
@ 1 µg/mL 
Internal standard 
stock solution 
@ 10 µg/mL 
 1 mL 
Methanol 
Up to 10 mL 
 
4.3.4. LC-MS/MS instrumentation and parameters 
The analysis was carried out using an Agilent 1200 LC system coupled to an AB 
Sciex 3200 QTRAP MS. The software utilised was Analyst® 1.7. The column oven 
was set at 40 °C and was fitted with a Phenomenex Gemini C18 column (150 mm 
x 2.0 mm, 5 µm) which had a pre-column SecurityGuard™ cartridge (4.0 mm x 2.0 
mm) in place. A gradient system consisting of two mobile phases; 2mM 
ammonium acetate and 0.1% formic acid in diH2O water (mobile phase A) and 
2mM ammonium acetate and 0.1% formic acid in methanol (mobile phase B) was 
used.  
Positive electrospray ionisation (turbo ion spray is the term used on the analyst 
software) was utilised and the ion source temperature was maintained at 350°C. 
Nitrogen was used as the source and collision gas. The collision gas (CAD) was 
set at 4 and the ion source gas 1 and 2 were set at 30 psi. The mass spectrometer 
was operated in multiple reaction monitoring (MRM) mode. 
  
 
 
86 
4.4. Qualitative method experimental 
4.4.1. Method development experimental  
4.4.1.1. MS/MS optimisation  
In order to identify and optimise the ion transitions and instrument settings for all 
analytes, each drug and internal standard were directly infused into the mass 
spectrometer at the rate 10 μL/min at a concentration of 1 μg/mL in infusion 
solution using the instruments inbuilt infusion pump. The instrument operating in 
triple quadrapole mode was set a range to scan to identify the precursor ion using 
the molecular weight of the drug, e.g diclazepam molecular weight is 319.18 so 
the scan range can be set to 270 – 370 Da initially to find the ion, then the range 
was narrowed as required. The product ion scan is then performed again using a 
suitable range; all the drugs in this method were scanned for fragments greater 
than 125 Da. The compound optimisation wizard was then set to determine the 
optimum settings for the four most abundant fragments within the mass range 
selected. The optimal product ion can then be selected from these four to form the 
method with the settings associated with that analyte. (AB Sciex, 2011) This 
selection is a compromise between sensitivity and specificity; the most abundant 
ion is not always the most optimal choice. For each MRM transition, the following 
parameters were optimised: declustering potential (DP), entrance potential (EP), 
collision entrance potential (CEP), collision energy (CE) and collision exit potential 
(CXP). The DP is the voltage which is applied at the source orifice to prevent all 
the ions clustering together. The EP is the next voltage applied after the ions have 
entered the orifice and helps to focus the ion‘s pathway. CE is the rate of 
acceleration in Q2, if the CE is too low fragmentation will be inefficient however 
extensive fragmentation can occur if it is too high. CEP and CXP are the collision 
entrance and exit potential respectively; these are responsible for accelerating and 
focussing the ions into and out of Q2, into to Q3 in the case of CXP. (AB Sciex, 
2011)  
4.4.1.2. LC gradient 
As the method has multiple benzodiazepines, some of which have a very similar 
structure, an isocratic method was unlikely to give the chromatographic resolution 
required within an acceptable run-time. Therefore use of a gradient was 
investigated. The mobile phase compositions and column selection were fixed to 
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allow it to be integrated to the FMS routine laboratory; therefore these were not 
further investigated for development.  
An unextracted mix of all the analytes plus the internal standards was prepared at 
a concentration of 0.1 mg/L in reconstitution solution. For each gradient 
programme tested this mix was injected at least four times to assess if the gradient 
was been sufficient to elute all analytes. A total of 22 gradients and 2 isocratic 
programmes were investigated. The two isocratic programmes were at 60 and 
30% mobile phase (MP) B. Of the 22 gradients, 18 were started at 30 or 40% MP 
B and contained ramps ranging from 40 to 90% MP B with run times ranging from 
36 to 55 minutes, these are further described in section 4.5.1.2. The other four 
gradients were started at 10 or 20% MP B and contained ramps ranging from 40 to 
90% MP B with run times ranging from 40 to 60 minutes. The aim was to use a 
gradient system with good chromatographic resolution with suitable time between 
some peaks so time periods could be set up. Altering the MRM dwell time from 
125 msecs to 100 msecs was also investigated. 
4.4.1.3. Sample extraction  
The extraction for this method needed to be fast, simple and cost effective as a 
large number of samples had to be analysed using this method (all samples 
received from the SPS, SDC and NHS GGC FD, see chapters 5 and 6) therefore 
an in-house LLE procedure was utilised. The volume of extraction solvent tBME 
was assessed but otherwise there was no further extraction development. In order 
to assess the volume of solvent a %RE and %ME experiment was carried out. The 
equations for %RE and %ME are given in section 3.4.6 in chapter 3. The two 
volumes that were investigated were 0.75 mL and 1.75 mL of tBME. The volume 
1.75 mL was selected as this was just below 2 mL but allows some room in the 4 
mL tubes used for efficient mixing without overflowing. The lower volume 0.75 mL 
was then selected, as it is a 1 mL difference. 
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 Set A: neat unextracted with low QC and high QC separately and internal 
standard in reconstitution solution was prepared in duplicate. 
 Set B: blank (drug free) urine was spiked with low QC and high QC 
separately and internal standard in reconstitution solution after LLE. Set B 
was prepared in duplicate for each of the two volumes of tBME being 
evaluated. 
 Set C: blank (drug free) urine was spiked with low QC and high QC 
separately and internal standard prior to LLE. Set C was prepared in 
duplicate for each of the two volumes of tBME being evaluated. 
4.4.1.4. Hydrolysis step optimisation 
The use of beta-glucuronidase is well established in benzodiazepine urinalysis (De 
Jager and Bailey, 2011; Marin and McMillin, 2010; Bergstrand, Helander and 
Beck, 2016), the object of this experiment is determine if a lower volume of beta-
glucuronidase can be used for this study compared to the usual FMS procedure. 
The current FMS benzodiazepine urine extraction uses 40 µL of beta-
glucuronidase from Helix Pometia but also utilises 1 mL of urine sample and is 
extracted using SPE. As the method developed for this study would use 0.5 mL of 
urine sample and use a LLE, a reduced volume of beta-glucuronidase would be 
advantageous; it would be less expensive and give a cleaner extract. In order to 
test if the volume of beta-glucuronidase used could be decreased, three real 
positive urine samples were extracted, once using 20 µL beta-glucuronidase in 
duplicate and once using 40 µL beta-glucuronidase in duplicate giving a total of 12 
sample tubes. The real urine samples were from the SDC cohort; results of the 
drug court study are detailed in chapter 5. The samples were chosen as the 
individual had admitted to taking diazepam on their questionnaire so were 
anticipated to give positive results. Figure 30 shows the process used to carry out 
this experiment.  
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Figure 30: Hydrolysis step optimisation LLE process 
 
To the 12 sample tubes add 0.5 mL of sodium 
acetate buffer (pH 5)  
Pipette 20 or 40 µL  β-glucuronidase solution 
into each sample in duplicate 
Incubate at 60°C for 3 hours 
Add 1 mL pH 6 phosphate buffer to all tubes  
Vortex mix all tubes  
Add 1.75 mL tBME to each tube, mix tubes on 
mixer for ≥ 5 min 
Centrifuge at 3000 rpm for 10 min 
Transfer the top layer to clean, labelled 3.5 mL 
vials 
Evaporate to dryness under nitrogen at ≤40°C  
Reconstitute in 1000 µL 25:75 MeOH:dH2O 
Transfer to labelled autosampler vials 
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4.4.2. Method validation experimental 
The validation parameters were evaluated for the final LLE method detailed in 
section 4.5.2 and the final LC-MS/MS method detailed in section 4.3.4. The 
parameters evaluated were limit of detection, specificity, matrix effects, recovery 
and process efficiency, carryover and autosampler stability. 
4.4.2.1. Limit of detection 
The LOD study was carried out in the same way as described in section 3.4.4 of 
chapter 3. LOD for each analyte was evaluated. Extracted concentrations of 0.002, 
0.004, 0.006 and 0.008 mg/L were tested in duplicate. The signal-to-noise ratio 
should be ≥3 for the analyte to be considered detectable. Retention time for each 
analyte should be consistent.  
4.4.2.2. Specificity 
In order to understand if the benzodiazepine drugs would create interference 
issues within the detection window of each drug within the urine method, a 
selection of benzodiazepines including all drugs contained in the method plus 
flunitrazepam, flurazepam, clozapine, midazolam, clobazam, prazepam, 7-
aminoflunitrazepam and clonazepam were individually injected, as an unextracted 
0.10 mg/L solution. Each drug was injected in triplicate. 
4.4.2.3. Matrix effects, recovery and process efficiency 
Matrix effects, recovery and process efficiency are described in section 3.4.6 of 
chapter 3.  
For two concentrations investigated, ME, RE and PE were calculated using the 
post-extraction addition approach detailed by Matuszewski et al. (Matuszewski, 
Constanzer and Chavez-Eng, 2003) 
Blank (drug free) urine from 10 different sources was used for the experiments. 
The analytes at two different concentrations (ME Low QC 0.015 and ME High QC 
0.40 mg/L) were evaluated. The ME, RE and PE experiments were performed as 
follows:  
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 Set A: neat unextracted analyte mix and internal standard in reconstitution 
solution was prepared ten times. 
 Set B: blank urine from 10 different sources were spiked with the analyte 
mix and internal standard in reconstitution solution after LLE. Set B was 
prepared in duplicate. 
 Set C: blank urine from 10 different sources were spiked with analyte mix 
and internal standard prior to LLE. Set C was prepared in duplicate. 
4.4.2.4. Carryover 
Carryover is described in section 3.4.7 of chapter 3.  
A solution was prepared to give a concentration of 4 mg/L for all 22 analytes, this 
was extracted using the LLE method and injected in triplicate followed, by three 
injections of drug-free reconstitution solution. The concentration 4 mg/L was 
chosen, as this is ten times the high QC concentration and double the 
concentration of benzodiazepines used in the FMS in-house method. 
4.4.2.5. Autosampler stability 
Blank (drug free) urine was spiked using the AS stability solution at a high (0.150 
mg/L) and the low (0.015 mg/L) concentration in triplicate and extracted using the 
LLE procedure detailed in section 4.5.1.3 These extracts were then run on the 
method detailed in section 4.3.4 to determine a time zero response (t0); the same 
extracts were then injected at four-hour intervals up to 36 hours. The laboratory 
was temperature controlled between 16°C and 24°C during the experiment. 
4.4.3. Data handling and statistical analysis 
Once results had been generated in the Analyst software, they were copied onto a 
Microsoft® Excel® (version 14.7.3) spreadsheet and batch checked by a second 
toxicologist before any calculations were performed. The results copied include the 
peak areas of the analyte and the internal standard, the calculated values of the 
calibration standards and QCs in mg/L and the datapath information. Microsoft® 
Excel® was then used to calculate the mean, standard deviation, %CV, %ME, 
%PE and %RE where necessary. A second toxicologist, as part of the batch 
checking, also checked the formula used in the spreadsheets for each calculation. 
Line graphs were generated in the spreadsheet to track autosampler stability. The 
Statsplus (AnalystSoft™, version 7.7.31) add on for Microsoft® Excel® was used 
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to conduct a paired two sample t-test to determine if there was a statistical 
difference between the volumes of tBME used. The spreadsheets were saved on a 
secure drive to protect the data. 
4.5. Results and discussion 
4.5.1. Method development 
4.5.1.1. MS/MS Optimisation 
The identified MRM transitions and optimised MS parameters for all analytes in the 
method are displayed in Table 38. 
The method contains 22 benzodiazepine drugs/metabolites with 2 MRM transitions 
for each as well as 3 internal standards for which one MRM was monitored. The 
MS parameters in Table 38 gave the optimal response for all analyte MRMs and 
the precursor ion identified for all analytes was [M+H]+. Two product ions, which 
gave appropriate sensitivity and specificity, were selected to form the quantifier 
(QT) and qualifier (QL) MRMs. The MS resolution used in Q1 for all analytes was 
unit and low for Q3.  
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Table 38: Urine method MRM transitions and optimised MS parameters 
Analyte Q1 Q3 DP EP CEP CE CXP 
Pyrazolam-QT 354.2 206.2 61 11.0 16 43 6 
Pyrazolam-QL 354.1 167.0 61 11.0 16 45 6 
Nifoxipam-QT 316.1 270.2 51 5.0 16 25 4 
Nifoxipam-QL 316.1 298.2 51 5.0 16 21 4 
Chlordiazepoxide-QT 300.1 227.2 41 8.0 14 35 4 
Chlordiazepoxide-QL 300.1 241.2 41 8.0 14 23 6 
Clonazolam-QT 354.0 308.2 61 5 30 27 6 
Clonazolam-QL 354.0 280.1 61 5 30 47 4 
Nitrazepam-QT 282.1 236.3 66 10.5 14 35 4 
Nitrazepam-QL 282.1 180.3 66 10.5 14 51 4 
Alprazolam-QT 309.1 281.3 61 10.5 14 37 6 
Alprazolam-QL 309.1 205.2 61 10.5 14 55 6 
Flubromazolam-QT 370.9 223.1 81 5.0 26 55 4 
Flubromazolam-QL 370.9 343.1 81 5.0 26 55 6 
Lorazepam-QT 321.0 229.2 46 10.5 14 31 4 
Lorazepam-QL 321.0 275.2 46 10.5 14 39 4 
Deschloroetizolam-QT 309.2 280.1 66 8.5 14 33 4 
Deschloroetizolam-QL 309.2 255.2 66 8.5 14 33 4 
Etizolam-QT 343.1 314.3 66 10.5 14 33 6 
Etizolam-QL 343.1 259.1 66 10.5 14 45 6 
Oxazepam-QT 287.0 241.2 46 9.0 12 33 4 
Oxazepam-QL 287.0 269.2 46 9.0 12 19 4 
Meclonazepam-QT 330.1 284.1 66 8 22 35 4 
Meclonazepam-QL 330.1 214.2 66 8 22 51 4 
Temazepam-QT 301.1 255.1 46 8.0 14 33 4 
Temazepam-QL 301.1 283.2 46 8.0 14 17 4 
Lormetazepam-QT 335.1 289.1 46 10.5 16 31 6 
Lormetazepam-QL 335.1 177.0 46 10.5 16 55 6 
Flubromazepam-QT 333.0 226.2 71 10.5 14 43 6 
Flubromazepam-QL 333.0 184.0 71 10.5 14 41 6 
Delorazepam-QT 305.1 140.0 66 10.5 12 41 6 
Delorazepam-QL 305.1 206.1 66 10.5 12 49 6 
DMD-QT 271.1 140.0 66 10.0 12 39 4 
DMD-QL 271.1 165.1 66 10.0 12 39 4 
Phenazepam-QT 348.9 206.2 71 10.5 14 49 6 
Phenazepam-QL 348.9 184.1 71 10.5 14 43 6 
Diclazepam-QT 319.1 227.2 71 10.5 16 39 6 
Diclazepam-QL 319.1 154.1 71 10.5 16 43 6 
Diazepam-QT 285.1 193.1 61 10.5 14 43 4 
Diazepam-QL 285.1 154.1 61 10.5 14 37 4 
3-hydroxyphenazepam-QT 364.9 319.1 51 5 22 27 6 
3-hydroxyphenazepam-QL 364.9 273.0 51 5 22 43 6 
Metizolam-QT 329.0 275.3 66 8 18 41 4 
Metizolam-QL 329.0 300.0 66 8 18 41 6 
Lorazepam-D4 325.1 279.2 51 10.0 14 33 6 
Diazepam-D5 290.1 198.1 66 10.5 14 45 4 
7-aminoflunitrazepam-D7 291.2 138.3 56 11.0 12 39 4 
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Benzodiazepines have naturally occurring isotopes present within their structure, 
which can be observed when using MS. Two of which are chlorine present as 35Cl 
and 37Cl and bromine present as 79Br and 81Br. Since 35Cl is 76% abundant versus 
37Cl 24% abundance the 35Cl precursor ion was used in the final method. Bromine 
isotopes are almost even in abundance with 79Br making up 51%. Br79 was used in 
the final method. Table 39 displays if chlorine or bromine is present in the structure 
of the designer benzodiazepines contained within this urine method. 
Table 39: Urine method – chlorine and bromine in the designer benzodiazepines 
Analyte Cl Br 
Pyrazolam No Yes 
Nifoxipam No No 
Clonazolam Yes No 
Flubromazolam No Yes 
Deschloroetizolam No No 
Etizolam Yes No 
Meclonazepam Yes No 
Flubromazepam No Yes 
Phenazepam Yes Yes 
Diclazepam 
Delorazepam 
Yes 
Yes 
No 
No 
3-hydroxyphenazepam Yes Yes 
Metizolam Yes No 
 
Figure 31 shows the initial product ion MS spectra for pyrazolam (MW 354.2) for 
both the 79Br (354.2) and 81Br (356.2). Figure 32 shows the final product ion MS 
spectra for both bromine isotopes for pyrazolam, the m/z 285 for the 79Br and the 
m/z 287 for the 81Br shows the bromine is still retained on the fragment at this point 
but are no longer retained for the product ions used in the final method as both 
m/z 206 and m/z 167 are present in both the 79Br and 81Br final product ion 
spectra.  
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Figure 31: Initial product ion spectra of pyrazolam for both bromine isotopes 
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Figure 32: Final product ion spectra of pyrazolam for both bromine isotopes 
 
The fragmentation pathway of each analyte was considered to reinforce the 
correct selection of transitions and understanding of how the analyte behaved 
when subjected to the mass spectrometer. Figure 33 shows an example of 
diclazepam fragmentation. Figure 34 shows the initial and final product ion spectra 
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for 35Cl diclazepam, the ions m/z 227 and 154 can be seen on the final product 
scan spectra. 
 
 Figure 33: Diclazepam fragmentation pathway 
 
 
-CH3N = mz 227
-Cl = mz 193 
mz = 154
-CO = mz 291
-Cl = mz 256
Diclazepam. Mol. Mass. 319.18
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Figure 34: Diclazepam initial and final product ion spectra  
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4.5.1.2. LC Gradients 
The LC was run isocratic at 60% MP B however as expected the analytes co-
eluted from the column fairly fast in less than 6 minutes. While this fast run time 
would have been an advantage it was necessary to slow co-elution down in order 
to gain better chromatographic resolution. The LC was also run isocratic at 30% 
MP B and as expected the analytes co-eluted from the column far too slowly with 
most analytes not eluting at all after 40 minutes, this percentage of organic solvent 
in an isocratic system is too low for the benzodiazepines. Figure 35 shows an 
example chromatogram of an injection at 30% MP B.  
 
Figure 35: Example chromatogram of a run at 30% mobile phase B.  
 
In total 22 gradients were tested in a variety of combinations, 16 of the 
combinations are shown in Table 40 with comments on how the analytes behaved, 
these combinations were all discarded but gives the chronological order to the final 
gradient decision. The aim was to achieve good chromatographic resolution but 
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also two gaps in which no peaks eluted in order to divide the analytes in to MS 
time periods. Analytes clustered together may also increase ion suppression which 
should be avoided. The different combinations were investigated in order to 
ascertain the best gradient to meet this goal. Four other gradients tested were 
started at 10 or 20% MP B and contained ramps ranging from 40 to 95% MP B 
with run times ranging from 40 to 60 minutes. Figure 36 displays an example 
chromatogram of a gradient programme starting at 10% MP B. Starting at low 
percent solvents such as 10 or 20% had no advantage for a benzodiazepine 
method as the analyte will retain on the column and then will all co-elute quickly 
once more solvent is introduced.  
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Table 40: Urine method –LC gradient programme combinations investigated. 
Gradient 
programme 
% MP 
B at 
start 
Description of % MP B 
Total 
run 
time 
(mins) 
Comments 
1 40 
Ramped from 40 to 60 steadily over 
30 mins - dropped to 40 over 5 mins 
40 
Fairly good chromatographic 
separation, a lot of co-elution at 
16 mins 
2 40 
Held at 40 for 14 mins - ramped to 90 
steadily over 16 mins - dropped to 40 
over 10 mins 
40 
Most analytes co-elute at 20 to 
26 mins 
3 30 
Held at 30 for 10 mins - ramped to 70 
steadily over 12 mins - held at 70 for 6 
mins- dropped to 30 over 10 mins 
40 
Most analytes co-elute at 24 to 
28 mins 
4 30 
Held at 30 for 10 mins - ramped to 60 
steadily over 18 mins - dropped to 30 
over 10 mins 
40 
Most analytes co-elute at 26 to 
32 mins 
5 30 
Held at 30 for 10 mins - ramped to 40 
steadily over 20 mins - dropped to 30 
over 10 mins 
40 
Only some analytes eluted, not 
enough organic solvent 
6 30 
Ramped from 30 to 60 steadily over 
45 mins -dropped to 30 over 5 mins - 
held at 30 for 5 mins 
55 
Long run time, most analytes 
not eluting until after 20 mins 
7 30 
Held at 30 for 4 mins - ramped to 40 
steadily over 8 mins - dropped to 30 
over 28 mins 
40 
Only some analytes elute, not 
enough organic solvent 
8 30 
Held at 30 for 4 mins - ramped to 40 
steadily over 8 mins - ramped to 90 
over 2 mins- dropped to 40 over 2 
mins- dropped to 30 over 11 mins – 
held at 40 for 13 mins 
40 
Most analytes co-elute at 17 to 
19 mins 
9 30 
Held at 30 for 4 mins - ramped to 40 
steadily over 8 mins - ramped to 90 - 
held for 8 mins- dropped to 30 - held 
at 30 for 20 mins 
40 
Most analytes co-elute at 17 
mins 
10 30 
Ramped from 30 to 45 steadily over 
12 mins – held to 45 for 15 mins – 
dropped to 30-held at 30 for 13 mins 
40 
Not every analyte eluted, not 
enough organic solvent. 
11 35 
Ramped from 35 to 50 steadily over 
30 mins - dropped to 35 over 10 mins 
40 
Peaks from last injection are 
present at the start of the run, 
not enough time to equilibrate 
back to 35% MP B 
12 30 
Ramped from 30 to 50 steadily over 
40 mins - dropped to 30 over 10 mins 
50 
Good chromatographic 
resolution, very long method 
and not every analyte had 
eluted by the end 
13 40 
Ramped from 40 to 60 steadily over 
10 mins – held at 60 for 2 mins - 
dropped to 40 over 8 mins - held at 40 
for 18 mins 
40 
Most analytes co-eluted at 12 to 
15 mins 
14 40 
Ramped from 40 to 60 steadily over 
10 mins – held at 60 for 2 mins - 
dropped to 40 over 2 mins-held at 40 
for 25 mins 
40 
Most analytes co-eluted at 12 to 
15 mins 
15 40 
Ramped from 40 to 60 steadily over 5 
mins – held at 60 for 2 mins - dropped 
to 40 over 5 mins-held at 40 for 30 
mins 
40 
An improvement on gradient 13 
and 14 in terms of 
chromatographic resolution as 
most analytes co-elute at 8 to 
15 mins 
16 40 
Held at 40 for 2 mins - ramped to 50 
steadily over 2 mins - ramped to 55 
over 11 mins - held for 3 mins- 
dropped to 40 over 2 mins - held at 40 
for 16 mins 
36 
Chromatographic resolution is 
better than other gradients tried 
considering shorter run time, 
this is a slight variation of the 
final gradient used. 
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Figure 36: Graphical representation of LC gradient programme starting at 10% MP 
B and an example chromatogram 
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Figure 37: Graphical representation for LC gradient programme 3 and an example 
chromatogram  
 
Figure 37 shows gradient programme 3 (see Table 40) and an example 
chromatogram, this gradient is retaining the analytes due to the low organic 
solvent content at the beginning then they are co-eluting very quickly at the 70% 
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MP B step of the programme. The analyte peaks have no chromatographic 
resolution and the run time is not being used efficiently. 
 
 
Figure 38: Graphical representation of LC gradient programme 11 and an example 
chromatogram 
 
Figure 38 shows the gradient programme 11 and an example chromatogram, this 
gradient gives a good chromatographic resolution of most analytes between 17 
 
 
105 
mins and 37 mins however the peaks at the start of the chromatograph are from 
the previous injection. The more retentive analytes at the end of the run are not 
being eluted in time before the programme switches to decrease the solvent MP B 
and return to the starting solvent of 35%. This demonstrates the requirement to 
provide time within the gradient programme for the system to equilibrate back to 
the starting MP composition.   
Gradient 18 was the gradient programme used in the final method and is detailed 
in Table 41 and Figure 39. This gradient was chosen due to the ability to insert 
three time periods due to the absence of peaks at particular time points. 
The final chosen gradient details are detailed in Table 41. Figure 39 gives a 
graphical representation and example chromatogram zoomed in show 3 to 23 
minutes of the final gradient used in this method.  
Table 41: Urine method final LC gradient programme 
Time 
(mins) 
Flow rate 
(µL/min) 
A (%) B (%) 
0 300 60 40 
0.1 300 60 40 
4 300 60 40 
8 300 50 50 
8.1 300 50 50 
22 300 45 55 
25 300 45 55 
25.1 300 60 40 
35 300 60 40 
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Figure 39: Graphical Representation of the urine method final LC gradient 
programme and an example chromatogram 
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Following development of the gradient, the further improvement of creating time 
periods was made in order to ensure each analyte had a good Gaussian peak 
shape. As the elution time of each compound was known, the analytes were split 
up into three defined time periods. Each time period only scans for the expected 
analytes in that period and therefore disregards the other analytes until it gets to 
their time period. This allows the instrument to work smarter in multi-analyte 
methods and improves cycle numbers in each time period. The number of cycles 
is the number of times it cycles through all the MRMs so the higher number of 
cycles the better quality of data. As a minimum, 10 data points should be used to 
generate a peak with 15 to 30 being more preferable and reproducible. Dwell time 
is the amount of time the instrument is collecting data for each specific MRM. 
There is a compromise between sensitivity, background instrument noise and 
enough data points across the peak. Increasing dwell time results in less noise 
and increased sensitivity but reduces the number of data points across the peak. 
Decreasing the dwell time results in more points across the peak, as more cycle 
times can occur as less time is spent on each analyte. A dwell time of 125 msecs 
was selected for the MRMs in period 1 and 3 as this gave a high number points 
across the peak and good sensitivity for all analytes. Period 2 was the area of the 
method where these considerations were most important. A dwell time of 100 
msecs was selected for all MRMs as all analytes gave sufficient data points across 
the peak. This period had the most analytes and a shorter dwell time allowed more 
cycles to occur. A dwell time of 125 msecs for these MRMs gave triangle shaped 
peaks for 3-hydroxyphenazepam, metizolam and meclonazepam with data points 
across the peak of 7, 10 and 9 respectively. The time period details for this method 
are shown in Table 42. 
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Table 42: Urine method mass spectrometer time periods 
Time period 
1 
(Starts at 0 Mins, 
Dwell time 125 msecs)  
 
2 
(Starts at 13.5 mins, 
Dwell time 100 msecs) 
 
3 
(Starts at 19.11 mins, 
Dwell time 125 msecs) 
 
 
Data 
points 
 
Data 
points 
 
Data 
points 
Pyrazolam 31 Alprazolam 15 Phenazepam 66 
Nifoxipam 42 Flubromazolam 15 Diazepam 55 
Chlordiazepoxide 36 Deschloroetizolam 15 Diclazepam 66 
Clonazolam 25 Metizolam 14 Diazepam-D5 54 
Nitrazepam 30 Oxazepam 18   
7-Aminoflunitrazepam-D7 35 Lorazepam 20   
  Meclonazepam 14   
  Temazepam 18   
  3OH-phenazepam 11   
  Etizolam 19   
  Lormetazepam 18   
  Flubromazepam 16   
  Desmethyldiazepam 17   
  Delorazepam 17   
  Lorazepam-D4 20   
 
4.5.1.3. Sample extraction 
A LLE was chosen for the urine samples as a high throughput method was 
required for analysing all the samples - a cost effective and fast method was 
required, especially as a hydrolysis step was required. LLE is also a broad 
extraction technique that will allow all the analytes to be extracted which may be 
an issue with a SPE that is too selective.  
The volume of extraction solvent tBME to be used was investigated and the results 
are detailed in Table 43. The results show that the %RE for QC1 at 0.75 mL tBME 
ranged from 9.5 to 62.8, %RE for QC2 at 0.75 mL tBME ranged from 11.7 to 69.0, 
%RE for QC1 at 1.75 mL tBME ranged from 6.7 to 58.6, %RE for QC2 at 1.75 mL 
tBME ranged from 12.5 to 86.4. From this experiment 1.75 mL tBME gives better 
recovery for QC2, the higher concentration (p-value =>0.05), 0.75 mL gives better 
recovery for QC1 (p-value=>0.05). The volume selected for the final extraction 
was 1.75 mL, the samples are urine and the benzodiazepine concentrations are 
typically higher in urine than in blood.  
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Table 43: Urine method – comparison of tBME used in the extraction process 
 
%RE %ME 
Vol. of tMTBE (mL) 
0.75 
QC 1 
0.75 
QC 2 
1.75 
QC 1 
1.75 
QC 2 
0.75 
QC 1 
0.75 
QC 2 
1.75 
QC 1 
1.75 
QC 2 
Drug 
        
Pyrazolam 9.5 11.7 6.7 12.5 93.5 94.6 92.1 99.6 
Nifoxipam 40.1 43.6 36.4 51.6 93.5 94.0 89.1 98.8 
Chlordiazepoxide 51.6 58.4 49.5 68.6 88.4 88.3 85.8 90.5 
Clonazolam 33.6 36.9 26.8 44.5 91.6 89.5 90.6 92.8 
Nitrazepam 60.5 67.8 52.5 76.1 85.2 84.6 77.5 87.7 
Alprazolam 40.7 49.8 33.8 61.5 90.0 94.8 88.3 99.9 
Flubromazolam 43.2 52.4 36.6 65.9 92.0 90.9 90.3 97.0 
Lorazepam 57.8 64.5 52.0 81.6 97.1 100.2 93.9 106.5 
Deschloroetizolam 46.6 55.3 39.8 64.1 88.6 90.1 88.9 94.2 
Etizolam 44.0 51.3 37.0 64.4 86.6 89.1 82.2 93.3 
Oxazepam 57.7 65.5 53.0 79.0 100.8 103.0 99.1 110.5 
Meclonazepam 56.2 63.1 52.9 78.5 89.2 94.0 89.2 99.1 
Temazepam 61.1 64.5 56.2 78.5 99.3 96.6 95.1 101.1 
3OH-phenazepam 55.4 62.5 49.4 79.8 100.7 96.2 95.4 102.8 
Metizolam 48.9 60.6 43.9 72.4 89.3 96.7 86.3 101.9 
Lormetazepam 59.7 69.0 54.1 86.4 97.2 100.6 95.4 108.8 
Flubromazepam 59.2 67.9 54.8 82.4 87.3 91.8 82.7 96.6 
Delorazepam 57.0 64.1 52.7 81.9 94.1 96.8 90.8 103.6 
DMD 62.8 68.5 58.6 75.9 91.2 92.9 89.2 94.4 
Phenazepam 56.6 62.3 53.4 81.8 96.9 96.2 92.4 100.2 
Diclazepam 51.8 58.7 48.2 73.9 85.2 89.3 84.1 93.8 
Diazepam 57.7 64.6 55.2 74.0 83.9 85.6 81.5 88.4 
 
The final urine LLE procedure utilised in this study is detailed in the flow diagram 
in Figure 40.  
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Figure 40: Urine method final LLE procedure 
 
To all tubes add 0.5 mL of sodium acetate buffer  
(pH 5)  
To all tubes add 100 µL of Internal Standard  
Add 100 µL of the relevant QC to labelled tubes 
Add 100 µL of methanol to sample tubes and blank 
tube 
Add 500 µL blank urine to blank and QC tubes  
Pipette 500 µL sample into sample tubes 
Pipette 20 µL β-glucuronidase solution into each  
tube 
Incubate at 60°C for 3 hours 
Add 1 mL pH 6 phosphate buffer to all tubes  
Vortex mix all tubes  
Add 1.75 mL tBME to each tube, mix tubes on mixer for 
≥ 5 min 
Centrifuge at 3000 rpm for 10 min 
Transfer the top layer to clean, labelled 3.5 mL vials 
Evaporate to dryness under nitrogen at ≤40°C  
Reconstitute in 1000 µL 25:75 MeOH:dH2O 
Transfer to labelled autosampler vials 
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4.5.1.4. Hydrolysis step optimisation  
Hydrolysis of the benzodiazepines is required when urine analysis is carried out 
due to the conjugation resulting from metabolism.  
The three real urine samples used in this beta-glucuronidase optimisation study 
were positive for oxazepam, temazepam, desmethyldiazepam and lorazepam. 
Sample 2 and 3 were also positive for diazepam. Sample 1 was negative for 
diazepam. Table 44 shows the results of the beta-glucuronidase volume 
comparison. In most instances reducing the volume of the beta-glucuronidase had 
little impact on the peak area and at times improved it. There was an improvement 
in the oxazepam peak areas when 20 µL was used however there was a decrease 
in desmethyldiazepam. Due to these results it was concluded that 20 µL was 
sufficient to use for this method. The beta-glucuronidase used for the hydrolysis 
was ≥100,000 Fishman units /mL. One Fishman unit is commonly defined as the 
amount of enzyme required to liberate 1 µg of phenolphthalein from its glucuronide 
in 1 mL of urine per hour at 37°C at pH5. As the beta-glucuronidase used was 
≥100,000 Fishman units /mL therefore there is ≥2,000 Fishman units in the 20 µL 
used in the urine extraction (≥4,000 in the 40 µL used in this comparison 
experiment). A study into the hydrolysis of benzodiazepines concluded that 5,000 
Fishman units per 1 mL of urine at pH4.5 at 56°C for 2 hours was optimal. (Meatherall, 
1994) 
Table 44: Urine method - volume of beta-glucuronidase comparison (20 µL vs 40 
µL) for the hydrolysis of benzodiazepines 
 Oxazepam 
peak area (cps) 
Temazepam 
peak area (cps) 
Desmethyldiazepam 
peak area (cps) 
Diazepam 
peak area (cps) 
Lorazepam 
peak area (cps) 
 
Vol. of beta-
glucuronidase 
(µL) 
20 40 20 40 20 40 20 40 20 40 
Sample 1 872174 674772 337311 278996 20030 21363 - - 239444 183033 
 
783971 877893 317175 364408 20342 27801 - - 213957 236641 
  
 
 
 
 
     
Sample 2 7769134 7426079 11094760 11082305 1558520 1710703 81116 88430 9416 10087 
 
7876801 6975532 11541697 9945216 1597442 1455443 79535 76063 10674 8334 
  
 
 
 
 
 
   
 
Sample 3 3020322 2828944 7968798 7994662 509057 669618 18994 20289 16895 15937 
 
3006728 2951060 7947879 8409910 544006 764595 18263 19150 16847 16332 
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4.5.2. Method validation 
4.5.2.1. Limit of detection  
Using the s/n ratio method all analytes had a LOD of 2 ng/mL (0.002 mg/L) with 
the exception of nifoxipam, lorazepam and 3-hydroxyphenazepam. Nifoxipam, 
lorazepam and 3-hydroxyphenazepam are all detected above the s/n noise 
criterion of 3 at 6 ng/mL (0.006 mg/L). The s/n ratio for lorazepam at 6 ng/mL is 
still low at 3.4 for the QT MRM, however the s/n ratio for the QL MRM is 80 at 6 
ng/mL, which confirms it is detectable. The s/n results for the LOD experiment are 
shown in Table 45. 
Table 45: Urine method LOD signal-to-noise ratio results 
 s/n 
Analyte 8 ng/mL 6 ng/mL 4 ng/mL 2 ng/mL 
Pyrazolam 73.5 25.5 33.5 25.5 
Nifoxipam 15.5 11.0 0.0 0.0 
Chlordiazepoxide 244.5 132.5 96.0 46.5 
Clonazolam 39.5 35.5 15.0 24.5 
Nitrazepam 204.5 129.5 44.5 26.2 
Alprazolam 135.8 54.0 49.8 56.0 
Flubromazolam 33.9 49.3 20.8 4.9 
Lorazepam 15.0 3.4 3.0 0.0 
Deschloroetizolam 118.8 25.8 31.4 84.0 
Etizolam 570.5 121.2 120.2 239.5 
Oxazepam 69.5 64.2 20.2 18.5 
Meclonazepam 57.5 72.5 47.5 14.5 
Temazepam 159.8 125.5 51.8 50.8 
3OH-Phenazepam 31.5 13.5 1.0 0.0 
Metizolam 723.5 295.5 32.5 137.5 
Lormetazepam 148.5 94.0 16.2 24.0 
Flubromazepam 68.5 37.5 6.5 5.5 
Phenazepam 49.0 38.5 28.5 6.2 
Diclazepam 63.0 45.9 22.5 19.8 
Diazepam 119.8 89.5 55.5 33.6 
Delorazepam 52.5 91.5 16.5 21.5 
Desmethyldiazepam 138.5 33.5 19.5 21.0 
 
4.5.2.2. Specificity 
Table 46 shows the drugs/metabolites and internal standards injected as 
unextracted solutions individually down the LC-MS/MS method and which MRM 
transition a peak was present in. The table also shows the analytes present in the 
method, their retention time and the peak area from extracted low QC to use as a 
comparison. The crosses in the ―Transitions with a response column‖ represent 
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the absence of a peak. Clonazepam is on the very edge of the nifoxipam 
transition, far from the retention time of interest. Deschloroetizolam and 
alprazolam interfere with each other with deschloroetizolam eluting first, the 
QT/QL ratio can be used to tell these analytes apart. Lorazepam-D4‘s presence in 
the alprazolam, deschloroetizolam and lormetazepam transition gave low peak 
areas less than 9000 for lormetazepam and less than 4000 for alprazolam and 
deschloroetizolam. It was expected the deuterated drug standards would be 
present near their drug counterpart with a slightly offset retention time. This 
experiment shows that while benzodiazepines may exhibit peaks in each others‘ 
transitions, this is not an issue as long as there is a reference standard for 
comparison and that the interferent peaks are resolved from the peak of interest.  
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Table 46: Urine method interference experiment results  
Analytes in method tR 
Peak 
Area 
low QC  
Individual drug injected 
Transitions with a 
response 
Peak 
Area 
tR 
7-Aminoflunitrazepam-D7 3.24 914578 
Lorazepam-D4 
Alprazolam QT 3789 15.59 
Pyrazolam 6.64 30216 
Deschloroetizolam 
QT+QL-jaggy peak 
1523 15.60 
Nifoxipam 8.60 32900 Diazepam-D5 x   
Chlordiazepoxide 6.70 239372  7-Aminoflunitrazepam-D7 x   
Clonazolam 12.10 69192 Metizolam x   
Nitrazepam 12.02 199726 Pyrazolam 
Clonazolam QT jaggy 
peak 
995 6.55 
Alprazolam 14.88 414059 Nifoxipam x   
Flubromazolam 14.81 250535 Chlordiazepoxide x   
Lorazepam 15.54 53922 Clonazolam x   
Deschloroetizolam 14.70 920502 Nitrazepam x   
Metizolam 14.65 642364 Flubromazepam x   
Lorazepam-D4 15.39 899387 Flubromazolam x   
Oxazepam 15.09 180929 Etizolam x   
Meclonazepam 15.79 165295 Oxazepam x   
Temazepam 16.44 787050 Temazepam x   
3OH-phenazepam 16.54 45325 
Lormetazepam 
Lorazepam QT+QL 18661 16.04 
Etizolam 17.22 713646 Lorazepam-D4 4780 16.00 
Lormetazepam 17.97 407545 Lorazepam Lorazepam-D4 881077 16.00 
Flubromazepam 17.70 13650 DMD x   
Desmethyldiazepam 17.77 298515 Phenazepam x   
Delorazepam 18.57 193883 Diclazepam x   
Phenazepam 19.88 59741 3OHPhenazepam x   
Diazepam-D5 20.04 789624 Alprazolam 
Deschloroetizolam 
QT+QL 
184133 15.20 
Diazepam 20.37 815308 Diazepam Diazepam-D5 728344 20.24 
Diclazepam 21.63 363439 Deschloroetizolam Alprazolam QT+QL 107445 14.01 
   
Meclonazepam x   
   
Delorazepam Diclazepam QT+QL 43071 22.2 
   
Flunitrazepam x   
   
Flurazepam x   
   
Clozapine x   
   
Midazolam x   
   
Clobazam x   
   
Prazepam x   
   
7Aminoflunitrazepam x   
   
Clonazepam Nifoxipam QT Cut off ≅ 13 
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4.5.2.3. Matrix effects, recovery and process efficiency 
The matrix effects (%ME) for the low QC (0.015 mg/L) are displayed in Table 47 
and the high QC  (0.40 mg/L) in Table 48. The mean matrix effects for the low QC 
were all within the ±25% (criterion for %ME and <15% for precision. The Mean 
%ME for lorazepam, oxazepam and 3-hydroxyphenazepam all showed some 
enhancement at the high QC with a mean of 31, 34 and 28% respectively. This is 
higher than the criteria of 25%. All 10 sources of urine for these three analytes 
gave a %ME greater than 25%. These three analytes also elute within 1.5 minute 
of each other at around 15.00 to 16.50 minutes, improving the chromatographic 
conditions may improve the results for these analytes.  
Table 47: Urine method validation - ME results at 0.015 mg/L 
Drug QT 
%ME 0.015 mg/L 
 
Overall 
Mean 
%ME 
(n=10) 
Overall  
%CV 
(n=10) 
Pyrazolam 2 4.4 
Nifoxipam 11 4.2 
Chlordiazepoxide -10 4.2 
Clonazolam 3 3.2 
Nitrazepam 9 3.6 
Alprazolam 0 5.1 
Flubromazolam -6 4.6 
Lorazepam 17 4.6 
Deschloroetizolam 0 3.1 
Etizolam 4 3.6 
Oxazepam 19 8.7 
Meclonazepam 16 9.8 
Temazepam 11 7.6 
3OH-Phenazepam 19 5.2 
Metizolam 5 3.3 
Lormetazepam 12 4.8 
Flubromazepam 14 8.6 
Phenazepam 11 5.8 
Diclazepam 1 2.0 
Diazepam 1 3.3 
Delorazepam -11 3.8 
Desmethyldiazepam 14 9.4 
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Table 48: Urine method validation-ME results at 0.40 mg/L 
Drug QT 
 
%ME 0.04 mg/L 
Overall 
Mean 
(n=10) 
Overall 
%CV 
(n=10) 
Pyrazolam 7 1.6 
Nifoxipam 12 3.3 
Chlordiazepoxide 3 1.7 
Clonazolam 9 2.3 
Nitrazepam 14 2.4 
Alprazolam 19 0.9 
Flubromazolam 2 1.9 
Lorazepam 31 2.9 
Deschloroetizolam 4 1.3 
Etizolam 20 1.4 
Oxazepam 34 5.0 
Meclonazepam 14 11 
Temazepam 15 4.0 
3OH-Phenazepam 28 4.3 
Metizolam 4 2.0 
Lormetazepam 16 3.6 
Flubromazepam 25 4.9 
Phenazepam 16 3.5 
Diclazepam 21 2.0 
Diazepam 8 2.0 
Delorazepam 22 5.7 
Desmethyldiazepam 13 7.2 
 
The %RE and %PE for both QCs are displayed in Table 49. Pyrazolam has 
considerably lower %RE and %PE compared to the other analytes. The %RE and 
%PE data for the internal standards in the urine method are shown in Table 50. 7-
aminoflunitrazepam-D7 had the lowest mean %RE and %PE at 30% for both. This 
is adequate as no issues with the sensitivity were observed throughout the use of 
this method. The deuterated lorazepam and diazepam gave comparable results to 
their non-deuterated counterparts as expected. 
  
 
 
117 
Table 49: Urine method validation - mean percentage recovery (%RE) and 
process efficiency (%PE) for both low and high QC 
 
Low QC 
0.015 mg/L 
High QC 
0.40 mg/L 
Drug QT 
%RE 
mean 
(n=10) 
(%CV) 
%PE 
mean 
(n=10) 
(%CV) 
%RE 
mean 
(n=10) 
(%CV) 
%PE 
mean 
(n=10) 
(%CV) 
Alprazolam 
34  
(26.1) 
34  
(27.2) 
43  
(18.0) 
52  
(18.4) 
Flubromazolam 
39 
(18.4) 
37  
(20.0) 
48 
(18.0) 
49  
(17.6) 
Lorazepam 
45 
(28.3) 
53  
(27.8) 
53 
(21.0) 
70 
(19.3) 
Deschloroetizolam 
28 
(20.9) 
38  
(22.1) 
49 
(17.9) 
51 
(18.2) 
Etizolam 
41 
(21.0) 
43 
(22.7) 
51 
(18.0) 
43 
(22.7) 
Oxazepam 
47  
(28.7) 
56 
(25.1) 
47  
(28.7) 
56 
(25.1) 
Meclonazepam 
47 
(35.6) 
53  
(33.3) 
60  
(27.4) 
68 
(22.7) 
Temazepam 
54 
(20.2) 
60  
(17.0) 
60 
(20.5) 
69 
(18.4) 
3OH-phenazepam 
48 
(23.0) 
57  
(21.7) 
52 
(22.2) 
67 
(20.5) 
Metizolam 
46 
(15.7) 
48 
(14.9) 
57 
(17.6) 
60 
(17.5) 
Lormetazepam 
54 
(19.8) 
61 
(17.8) 
58 
(20.1) 
67 
(19.5) 
Flubromazepam 
48 
(26.7) 
55  
(25.4) 
59  
(21.3) 
73 
(18.8) 
Delorazepam 
49 
(25.5) 
42  
(22.9) 
60  
(10.7) 
70 
(19.5) 
Pyrazolam 
8  
(17.5) 
4  
(18.5) 
8  
(20.6) 
9  
(21.1) 
Nifoxipam 
43 
(25.3) 
47  
(24.5) 
49 
(18.8) 
55  
(18.3) 
Chlordiazepoxide 
48 
(22.7) 
43  
(24.0) 
61 
(14.3) 
63  
(14.4) 
Clonazepam 
32 
(23.3) 
38  
(22.1) 
33 
(20.8) 
36  
(21.5) 
Nitrazepam 
48 
(25.3) 
43 
(22.7) 
60 
(17.9) 
69 
(18.2) 
Desmethyldiazepam 
50  
(29.0) 
56  
(25.0) 
61 
(21.8) 
68 
(18.1) 
Phenazepam 
48 
(26.7) 
53  
(23.8) 
57  
(19.9) 
65 
(18.6) 
Diclazepam 
50 
(22.2) 
50  
(22.2) 
59 
(17.2) 
72 
(16.9) 
Diazepam 
49 
(21.9) 
50  
(21.9) 
63 
(15.4) 
68  
(14.9) 
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Table 50: Urine method validation - mean percentage recovery (%RE) and 
process efficiency (%PE) for internal standards 
Drug QT %RE 
mean 
(n=10) 
(%CV) 
%PE 
mean 
(n=10) 
(%CV) 
 
7-aminoflunitrazepam-D7 
 
30 
(23.1) 
 
30 
(23.1) 
 
Lorazepam-D4 
 
48 
(25.3) 
 
52 
(24.2) 
 
Diazepam-D5 
 
53 
(22.0) 
 
51 
(21.6) 
 
 
4.5.2.4. Carryover 
Carryover is assessed by the absence or presence of peaks in the injections of 
drug-free reconstitution solution directly following injections of a high concentration 
of the analytes of interest. There were no peaks in the drug-free reconstitution 
solution injection that followed three injections of the extracted stock solution 
containing all analytes at a concentration of 4 mg/L, see Figure 41. The increase in 
the instrument noise in period 2 compared to period 1 and 3 is clearly 
demonstrated in Figure 41. This is due to period 2 having more analytes, a lower 
dwell time and less cycles for the MRMs contained in that period. This is 
discussed in section 4.5.1.2 of this chapter.  
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Figure 41: Example chromatogram of the absence of peaks after injections of 4 
mg/L, demonstrating the lack of carryover. 
 
4.5.2.5. Autosampler stability 
The autosampler stability test results are shown in Figures 42 to 44 for the low 
(0.015 mg/L) QC concentration and Figure 45 to 47 for the high (0.150 mg/L) QC 
concentration. Each concentration was injected in triplicate every 4 hours, the 
average peak area was plotted on the graphs displayed in Figures 42 to 47. All 
compounds were still above 20% (represented by red line in the charts) of t0 after 
36 hours within the autosampler at 16-24 °C, this demonstrates that up to 36 
hours queued waiting to be injected is not an issue but can be more detrimental to 
some analytes than others within the method. Most analytes stayed fairly 
unchanged, some such as nifoxipam, flubromazepam and desmethyldiazepam 
showed a downward trend suggesting the stability was in decline. Nifoxipam is a 
nitro-benzodiazepines, which are chemically unstable particularly in bacteria 
contaminated samples such as post-mortem samples, it is recommended that 
preservative is used for the collection of samples potentially positive for nitro-
benzodiazepines. (Robertson and Drummer, 1998; Levine, Blanke and Valentour, 
1983) One stability study has shown that clonazolam, also a nitro-benzodiazepine 
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and nifoxipam are not stable in urine at -20°C and had degraded up to 38 and 
40% respectively over the course of seven months. A low pH in urine can degrade 
nitro-benzodiazepines due to ring-opening. (Bergstrand, Helander and Beck, 
2016) Without the correct collection and storage it may be extremely challanging 
to detect nitro-benzodiazepines in post-mortem blood or urine due to these stabilty 
issues confounded by the lack of available certified reference materials for the 
designer nitro-benzodiazepine metabolites.  
Some analytes such as chlordiazepoxide and clonazolam have shown an upward 
trend. This may also occur if there is slight evaporation of the solvent leading to a 
more concentrated solution, the autosampler is not temperature controlled 
however the laboratory has a temperature monitoring system in place and is 
maintained.  
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Figure 42: Urine method validation - Autosampler stability for first time period 
analytes at a concentration of 0.015 mg/L over 36 hours. 
 
Figure 43: Urine method validation - Autosampler stability for second time period 
analytes at a concentration of 0.015 mg/L over 36 hours. 
  
 
Figure 44: Urine method validation - Autosampler stability for third time period 
analytes at a concentration of 0.015 mg/L over 36 hours 
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Figure 45: Urine method validation - Autosampler stability for first time period 
analytes at a concentration of 0.15 mg/L over 36 hours. 
 
Figure 46: Urine method validation - Autosampler stability for second time period 
analytes at a concentration of 0.15 mg/L over 36 hours. 
 
Figure 47: Urine method validation - Autosampler stability for third time period 
analytes at a concentration of 0.15 mg/L over 36 hours. 
  
 
 
123 
4.6. Conclusion 
This method was developed, validated and found to be suitable for the qualitative 
analysis of urine samples for 22 analytes including both traditional and designer 
benzodiazepines and metabolites. The method MS/MS parameters were 
optimised for the 22 analytes and 22 gradient programmes were tested to achieve 
good chromatographic resolution with set MS time periods created to achieve 
improved Gaussian peak shapes with sufficient counts across the peak (>10). The 
two different volumes of extraction solvent were assessed before the final volume 
of 1.75 mL was selected. The volume of beta-glucuronidase used in each tube 
was reduced by half, after an investigation showed there was adequate hydrolysis 
activity at 20 µL.  
The analytes were detectable down to 2 ng/mL with the exception of nifoxipam, 
lorazepam and 3-hydroxyphenazepam, which were detectable at 6 ng/mL. 
Benzodiazepine specificity for the method was tested and interferents were found 
to be minimal; alprazolam and deschloroetizolam gave the most interference with 
each other but can be identified by their QT/QL ratio. Matrix effects were found to 
be acceptable for all analytes at the low concentration and within the ±25% 
criterion for %ME and <15% for precision with slight enhancement for three 
analytes (lorazepam, oxazepam and 3-hydroxyphenazepam) at the higher 
concentration. Recovery was suitable with the exception of pyrazolam however it 
had a sufficient LOD of 2 ng/mL however, due to the sub-optimal recovery this 
method may not a be suitable to analyse pyrazolam in urine and caution should be 
given to any pyrazolam positive samples (or suspected pyrazolam positive 
samples) and subsequently these should be confirmed using an additional 
method. No carryover was observed in the drug free reconstitution solution after 4 
mg/L was injected. All analytes were stable in the autosampler stability up to 36 
hours at 16-24 °C.  
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5. Drug Court and Forensic Directorate samples 
5.1. Introduction 
The use of NPS is often undetected by conventional methods of testing for drugs 
of abuse such as immunoassay or a defined drug panel. Chapter 2 demonstrated 
how the Immunalysis® Benzodiazepine ELISA kit immunoassay is effective at 
detecting six of the benzodiazepines explored in this study however this may not 
apply to all commercially available immunoassay kits and may not be the case 
with dip stick tests. Chapter 2 evaluated blood samples and not urine where the 
glucuronides may cause detection issues. There is a concern for frontline drug 
treatment services that they may miss cases of drug misuse and therefore not 
provide the most effective advice or treatment. As has always been the case with 
illicitly made drugs, the user cannot be sure of what they are taking; with the 
proliferation of NPS this risk has become ever present. The inability to routinely 
detect these substances in a treatment setting means the real extent of NPS in 
these sub-populations is unknown. Urine analysis has the advantage of being less 
invasive than blood and yields a high volume sample. The window of detection in 
urine is longer than in blood, especially when metabolites are also monitored, for 
example, studies found that pyrazolam and delorazepam (metabolite of 
diclazepam as well as a drug in its own right) can both be detected in urine up to 
six days after a single administration of pyrazolam and diclazepam. (Moosmann et 
al., 2013b; Moosmann, Bisel and Auwärter, 2014) This longer window of detection 
is useful for testing in populations where abstinence from drugs is particularly 
important, such as workplace drug testing, in offenders or in patients where drug 
use may be especially damaging, such as benzodiazepine use in individuals with 
severe mental health disorders. Urine samples have to be collected under the right 
conditions such as direct observation as they can be easy to substitute for a drug-
free sample or to adulterate by diluting.  
This chapter describes the targeted testing of designer benzodiazepines in two at-
risk populations, Scottish Drug Court participants and Forensic Psychiatric 
patients. 
5.1.1. Scottish Drug Court participants 
The Scottish Drug Court (SDC) is a service that aims to reduce drug misuse, and 
the offences associated with drug misuse, such as theft, to fund a drug habit. The 
court orders a Drug Treatment and Testing Order (DTTO) as an alternative to 
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prison and imposes an obligation to be treated for drug abuse and to commit to 
change criminal behaviour. (NHS Greater Glasgow and Clyde) The Scottish Drug 
Court (SDC) treats a weekly average of 75 individuals under a DTTO. 
Drug testing is routinely undertaken by the Drug Court to ensure abstinence from 
illicit drug use as part of sentencing and treatment. A urinary immunoassay 
dipstick test (Alere ® Drug Screen Urine Test Strip) is employed, which covers the 
most commonly abused drug groups including benzodiazepines, opiates, 
cannabis, cocaine and amphetamines, however it is not designed to test for, and 
does not include, NPS.(Alere Toxicology Point of Care Cut offs) The immunoassay 
results obtained by the drug court were not shared with the author and therefore 
were not available to compare with this studies results.  
5.1.2. Forensic Directorate psychiatric patients 
Approximately 70% of patients treated by NHS Greater Glasgow and Clyde 
Forensic Directorate (NHS GGC FD) have a primary diagnosis of schizophrenia 
although many have co-morbidity with a range of diagnoses‘ combined with a 
history of illicit drug use and alcohol abuse. Most patients are detained under 
either the Mental Health (Care and Treatment) Scotland Act (2003) or the Criminal 
Procedure (Scotland) Act 1995. It is a condition of the patient‘s suspension of 
detention or condition of discharge that they must not use drugs and alcohol. 
5.2. Aim 
To evaluate the use of benzodiazepines including designer benzodiazepines in 
individual treatment programmes under the jurisdiction of the SDC system, and 
how this compares to self-assessment questionnaires; and also in patients 
undergoing treatment by the NHS GGC FD. Hypothesis: The samples from 
individuals from the SDC and patients from NHS GGC FD will have a higer 
frequency of positive results for benzodiazepines than noted on their 
questionnaires.  
5.3. Ethical considerations 
The SDC work was considered as ‗service development‘ and as such NHS ethical 
approval was not deemed necessary. Ethical approval was sought and granted 
from the University of Glasgow, College of Medical, Veterinary & Life Sciences 
Research Ethics Committee (application number 200140101), (see appendix 11.2)  
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Ethical approval for the Forensic Directorate cohort was sought and granted from 
the NHS Greater Glasgow and Clyde, West of Scotland Research Ethics Service 
(WoSRES) (Application number 15/WS/0263), (see appendix 11.3)  
5.4. Method and materials 
5.4.1. Materials 
The materials used are detailed in section 4.3.1 of chapter 4. 
5.4.2. Extraction Method 
Urine samples were extracted using the LLE extraction method detailed in section 
4.5.1.3 of chapter 4. 
5.4.3. Instrumentation and method  
The extracts were analysed using the LC-MS/MS method detailed in section 4.3.4 
of chapter 4. This method was employed as a qualitative method with cut-off 
concentrations. Table 51 details the analytes included in the method. The cut-off 
used for this method was 0.015 mg/L (15 ng/mL) as this concentration was tested 
for the matrix effects and recovery (see section 4.4.2.3).  
Table 51: Benzodiazepine compounds included in the LC-MS/MS method 
Prescribed Benzodiazepines Designer Benzodiazepines 
Diazepam and metabolites 
(desmethyldiazepam, oxazepam and 
temazepam) 
Diclazepam and metabolites 
(delorazepam, lorazepam and 
lormetazepam) 
Chlordiazepoxide and metabolites 
(desmethyldiazepam and oxazepam) 
Etizolam* 
Alprazolam* 
Nitrazepam Phenazepam* 
 3-Hydroxyphenazepam  
 Flubromazolam 
Pyrazolam 
Clonazolam 
Deschloroetizolam 
Meclonazepam 
Nifoxipam 
Metizolam 
*As explained in section 1.5.1 in chapter 1, these are considered designer benzodiazepines for simplicity  
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5.4.4. Sample collection 
5.4.4.1. Scottish Drug Court samples 
Sample collection was carried out over one week each month (except December) 
between August 2015 and February 2016. Every participant who attended the 
Drug Court for urine testing was offered the opportunity to take part in the study. 
Participants were over 21 years of age, a history of problem drug use and a 
criminal record. The nurse in charge of the collection of their mandatory urine 
sample approached the participant and provided them with the study information 
sheet and the consent form (see appendices 11.3 and 11.4). Participants were 
reassured that the results of the analysis were anonymised and were not used in 
any legal proceedings or shown to the Sheriff overseeing the Court. The Nurse 
Team Leader was the only person with access to the signed consent form, which 
could be linked to the questionnaire (see appendix 1.8) and urine sample, this 
traceability was maintained as an individual could decide to withdraw from the 
study at any time. The schematic in Figure 48 was used to explain the process in 
the ethics application. 
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Figure 48: Flow chart describing the SDC sample process 
 
The samples were refrigerated (2-8°C) after donation then taken to Forensic 
Medicine and Science (FMS) at the University of Glasgow. The Drug Court did not 
have a freezer, as they do not usually store any biological samples. The samples 
were frozen immediately at −20°C on receipt at FMS until they were analysed. The 
samples collected usually contained at least 10 mL of unpreserved urine or more.  
The samples were labelled ―DC 01‖ to ―DC 73‖ and linked to their questionnaire 
using this numerical system. It was possible for individuals to give more than one 
sample on different weeks however it was not possible to link this or know where 
or if this occurred.  
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5.4.5. Data handling and statistical analysis  
Once results had been generated in the Analyst software, they were copied onto a 
Microsoft® Excel® (version 14.7.3) spreadsheet and batch checked by a second 
toxicologist before any calculations were performed. The results copied include the 
peak areas of the analyte and the internal standard, the calculated values of the 
calibration standards, samples and QCs in mg/L and the datapath information. 
Microsoft® Excel® was then used to generate the charts and descriptive statistics 
within the results section. All personal data was kept anonymised. The 
anonymised questionnaire data was entered into a Microsoft® Excel® 
spreadsheet and kept on a secure drive to protect the data.  
 
5.4.5.1.  Forensic Directorate psychiatric samples 
Urine samples were collected from January 2016 to November 2016 in FD 
facilities as part of the standard drug testing procedure. Participation is this study 
was voluntary. Participants were provided with an information sheet and a consent 
form (see appendices 11.5 and 11.6). NHS biomedical scientists carried out the 
initial testing procedure which includes splitting the collected urine sample into two 
separate aliquots; one is retained for independent testing if required whilst the 
other is used for the initial drug screen. The initial immunoassay drug screen was 
conducted using an automated system called an Abbott Architect analyser. This 
testing system has a benzodiazepine cut-off of 200 ng/mL. (Abbott Architect, 
Benzodiazepine Manufacturer Kit Insert, 2018) No dip stick tests were used for 
these samples. Positive screened samples were confirmed at the same laboratory, 
and the remainder of the sample was then sent to FMS for the additional testing. 
Each urine sample was collected in 6 mL white-topped vacuette tubes, which 
contained no preservative. On average the samples contained 4 mL of urine. 
Positive screens were confirmed by GC-MS in the Queen Elizabeth University 
Hospital and were noted on the form sent to FMS. All anonymised samples and 
paperwork were transported to FMS by courier. Samples were labelled ―FP 01‖ to 
―FP 95‖ and linked to their consent form using this numerical system. 
All samples were stored at −20°C on receipt at FMS until they were analysed. The 
storage conditions prior to this are not known.  
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5.5. Results and discussion 
5.5.1. Scottish Drug Court results 
Urine samples were collected from 73 individuals in total under the supervision 
and treatment of a DTTO through the SDC system in Glasgow. A Drug Court 
nurse collected the samples as part of their mandatory drug testing, no additional 
sample was collected from the donor for this study. The samples were collected in 
25 mL universal vials containing no preservative. Participants also completed a 
questionnaire about their licit and illicit drug use. Table 52 displays the collection 
dates. 
Table 52: SDC collection weeks for urine samples 
Week beginning Samples collected 
31/08/2015 DC01-DC25 
28/09/2015 DC26-DC47 
26/10/2015 DC48-DC51 
23/11/2015 DC52-DC57 
18/01/2016 DC58-DC67 
15/02/2016 DC68-DC73 
 
5.5.1.1. Questionnaire responses 
Some basic demographic information was obtained from the questionnaire (see 
Appendix 11.8) responses. There were 64 samples from males, 4 from females 
and 5 samples with no sex detailed. According to the Drug Court nurse this is in 
keeping with the drug court system treating more men than women in general. The 
age range spanned from 24 to 65 years old. It is important to note that over the 
six-month collection period the same individual was able to participate more than 
once so 73 samples does not necessarily mean 73 different individuals. It was 
unknown if this had occurred, as the data was kept anonymised. 
The participants were provided with a space to complete a questionnaire with 
regards to their drug use using free text opposed to a tick box therefore they used 
their own terms to report it. Every respondent mentioned that they had taken at 
least one drug in the week prior. Most participants named 2 drugs on their 
questionnaire (n=25). The graph in Figure 49 shows how many drugs participants 
mentioned.  
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Figure 49: SDC number of drugs mentioned per questionnaire by participant 
 
From the 73 questionnaires,‖diazepam‖ or ‖benzodiazepines‖ were mentioned 14 
times (19%). Both were treated as one drug in this instance. There was no 
mention of any designer benzodiazepines or any brand name associated with 
them e.g. chillax. Figure 50 displays the non-benzodiazepine drugs mentioned by 
the participants in their questionnaire. 
 
Figure 50: SDC non-benzodiazepine drugs mentioned in the questionnaires 
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According to a report published in June 2018 by the Information Services Division 
(ISD) heroin was the most reported illicit drug to the Scottish Drug Misuse 
Database (SDMD) in the month prior to their assessment at 52%, followed by 
cannabis at 32%, diazepam at 29% and cocaine/crack at 19%. The SDMD gathers 
data from individuals reporting to drug treatment services; the SDMD aim is to 
monitor drug use, identify trends and feedback to treatment services, therefore it 
deals with the same population as this study. Figure 51 displays the drugs 
reported to the SDMD over the years. (Information Services Division, Scottish 
Misuse Database, Overview of initial assessments for specialist drug treatment 
2016/2017, 2018) 
 
 Figure 51: SDMD illicit drugs use reported over a 10 year period 
(reproduced with permission from Public Health Scotland) 
OST stands for Opioid Substituted Therapy. The data from 2012-2014 is missing 
due to data quality and completeness issues. (Information Services Division, 
Scottish Misuse Database, Overview of initial assessments for specialist drug 
treatment 2016/2017, 2018) 
It should be noted that the methadone use reported in Figure 51 is illicit 
methadone use. The questionnaire used in this study asked for all drug use and 
they recorded their prescribed methadone use. The most common non-
benzodiazepine drug mentioned in this study was methadone, which is only a 
small portion in the SDMD findings, heroin is the third most mentioned in this study 
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compared to first. Perhaps the participants in this study did not hesitate to mention 
of methadone as they were prescribed it but were more reserved about discussing 
heroin as this is breaking their DTTO. Both found cannabis to be the second most 
reported drug.  
5.5.1.2. Scottish Drug Court laboratory results 
The SDC urine samples were positive for 9 different benzodiazepine analytes. 
Table 53 displays the number of positive urine samples for the benzodiazepine 
drugs tested. All other samples were negative for the benzodiazepines specified in 
Table 51. Concentrations are not reported, as this was a qualitative study.  
Due to the complex nature of the benzodiazepine class of drugs, care must be 
taken when interpreting benzodiazepines detected in urine. Benzodiazepines often 
metabolise, or break down, to other active benzodiazepine drugs, e.g. diclazepam 
forms delorazepam, lorazepam and lormetazepam in the body. In addition to being 
active metabolites, these substances are drugs in their own right, and some can 
be formed from more than one parent drug e.g. delorazepam is a metabolite of 
both diclazepam and cloxazolam (not licensed for use in the UK, prescribed in 
Italy). (Manchester et al., 2018; Moosmann, Bisel and Auwärter, 2014) 
Diazepam is the most prescribed benzodiazepine worldwide and metabolises to 
three other active drugs, desmethyldiazepam, oxazepam and temazepam. 
Desmethyldiazepam is also a metabolite of six other benzodiazepine drugs. 
Diazepam and its metabolites were the most detected benzodiazepines in this 
study.  
Table 53: SDC number of urine samples positive for benzodiazepines 
Analyte No. of Positives 
Diazepam 15 
Desmethyldiazepam 34 
Temazepam 35 
Oxazepam 40 
Delorazepam 2 
Lorazepam 5 
Lormetazepam 2 
Etizolam 1 
Metizolam 1 
The results showed 2 positives for delorazepam indicating diclazepam use, 
(Moosmann, Bisel and Auwärter, 2014) DC 41 and DC 72, see Table 54. In 
addition sample DC 41 was positive for a further 2 diclazepam metabolites 
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(lorazepam and lormetazepam). Lorazepam and lormetazepam are clinical drugs 
in Scotland however not commonly prescribed, especially compared to 
benzodiazepines such as diazepam, see section 1.3 in chapter 1. The combination 
of the drugs together also adds weight that they are the product of diclazepam 
metabolism rather than lorazepam and lormetazepam consumption. Sample DC 
41 was collected from a 30-year-old male, his questionnaire does not mention any 
benzodiazepines; it states he had only taken methadone in the week prior to 
sample collection. It is reasonable to conclude that DC 72 and DC 41 have used 
diclazepam as they are positive for more than one of its metabolites. Diclazepam 
metabolism is discussed in section 1 .7 of chapter 1. The questionnaires for DC 
41, DC 72 and DC 49 state they are all male and they had only taken methadone 
in the week prior to sample collection. DC 41 and DC 49 are positive for diazepam 
metabolites but not diazepam itself, which is not unusual in urine samples. (Temte 
et al., 2018) DC 64 and DC 65 are positive for lorazepam only, which may be from 
the use of prescribed lorazepam, although this was not stated, or the use of 
diclazepam. DC 64 is a 36-year-old male who stated he had taken diazepam from 
a dealer as well as methadone and cannabis in the week prior to his sample 
collection. DC 65 is a 65-year-old male who states he had taken heroin and 
methadone in the week prior to his sample collection.  
Table 54: NHS GDDC urine samples positive for diclazepam metabolites 
Sample number Age Sex Drug mentioned 
on questionnaire 
Toxicology findings 
DC 41 30 M Methadone Delorazepam 
Lorazepam 
Lormetazepam 
Oxazepam 
Temazepam 
Desmethyldiazepam 
DC 49 34 M Methadone Lorazepam 
Lormetazepam 
Oxazepam 
Temazepam 
Desmethyldiazepam 
DC 72 51 M Methadone Delorazepam 
Lorazepam 
Oxazepam 
Temazepam 
Desmethyldiazepam 
Diazepam 
Sample DC 53 was positive for both etizolam and metizolam, see section 5.5.1.3 
for an investigation into the metizolam positive samples. 
Sample DC 53 was also positive for diazepam and all three metabolites. Sample 
DC 53 was collected from a 36-year-old male who stated in his questionnaire that 
he had taken ‗benzodiazepines‘ in the form of 5 x 5mg street diazepam he had 
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purchased from a dealer. He states he took these the day before attending the 
Drug Court to provide his urine sample. DC 53 was the only sample positive for 
etizolam. This is unusual as etizolam has been shown to be a very popular drug in 
Scotland however no metabolites for etizolam were in the method and this will 
reduce detection. The half-life of etizolam is 3 to 7 hours (Høiseth, Tuv and 
Karinen, 2016) and is much shorter than diazepam and diclazepam (20-50 and 42 
hours respectively) so therefore etizolam has a shorter window of detection 
compared to diazepam and diclazepam.  
It is reasonable to speculate that all of the positive results for oxazepam, 
temazepam and desmethyldiazepam came from diazepam use as these are the 
major diazepam urinary metabolites and as discussed in 1.3 of chapter 1 
diazepam is much more available than oxazepam. (Temte et al., 2018) The 15 
positives for diazepam are also positive for all three diazepam metabolites.  
In total there were 40 (55%) samples positive for benzodiazepines, all 40 were 
positive for more than one analyte tested. This is higher than the reported use on 
the questionnaires. As the result of the dip stick tests were never reported to the 
author, it is not possible to compare the results of this analysis to the dip stick 
results. This study shows that benzodiazepine use is common in this population 
and it is possible that individuals may be using designer benzodiazepines either in 
an attempt to evade detection by the immunoassay tests used in mandatory drug 
testing or inadvertently due to illicitly made ―valium‖ tablets. (Kirby, 2016) The 
ability to evade detection is a concern for the healthcare workers in these settings 
however in this study the samples in which designer benzodiazepines detected 
were all positive for diazepam and therefore would test positive by immunoassay 
leaving this question not fully answered. The study is also voluntary and thereby 
users may have not agreed to take part if they had recently used designer 
benzodiazepines. The use of benzodiazepines is common amongst opioid users 
as they can be used to enhance the high or to self-medicate during withdrawals or 
insomnia. (Jones, Mogali and Comer, 2012) 
5.5.1.3. Metizolam investigation 
Metizolam appeared on the NPS market in 2015. (EMCDDA, Europol, EMCDDA-
Europol 2015 Annual Report on the Implementation of Council Decision 
2005/387/JHA, 2016) It is an analog of etizolam and differs only structurally in that 
it has one less methyl group, see Figure 52.  
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Figure 52:Chemical structure of etizolam and metizolam 
 
Due to the lack of published research it is difficult to determine the source of 
metizolam in the urine samples; the individual may have ingested both etizolam 
and metizolam or metizolam may be a degradation product of etizolam however it 
is unknown what would be causing this if this was the case. All metizolam 
positives in this study were also positive for etizolam. All urine samples were 
treated in the same way with the same solutions therefore if pH changes or 
etizolam breaking down to metizolam in the instrument is occurring, why has this 
only been seen in some samples and not in others, which were also positive for 
etizolam. A study into the metabolism of metizolam found that less than one 
percent (0.3%) of the parent compound was found in urine unchanged but was still 
detectable up to 46 hours in urine. (Kintz et al., 2017) With such a small 
percentage found in urine it seemed unlikely the metizolam detected in this study 
was from metizolam use. To investigate the source of metizolam sample DC 53 
was re-extracted along with a further 7 urine samples from a previous study that 
were also positive for both etizolam and metizolam. These samples were ran on 
the method described in section 4.3.4 chapter 4 but in addition the theoretical 
metizolam metabolite MRMs described in Kintz et al, 2017 were monitored. (Kintz 
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et al., 2017) There was no certified reference standard available for this 
metabolite. It is expected that the LLE used was capable of extracting the 
theoretical metabolites as LLE is a broad extraction technique and is adequate for 
all the other drugs in the method however testing this using a certified reference 
standard is required to prove this. The parameters used to screen for the 
theoretical metizolam metabolite are displayed in Table 55. In addition to this 
experiment, etizolam in reconstitution solution at concentrations 1 mg/L and 10 
mg/L were injected down the LC-MS/MS urine method in order to determine if 
etizolam is losing a methyl group due to the temperature in the ion source. 
Table 55: Theoretical metizolam metabolite MRMs 
Q1 Q3 
345.058 327.043 
345.058 291.038 
345.058 276.013 
According to Kintz et al, these transitions are of the main hydroxylated metabolite 
of metizolam.  
The samples screened negative for the metizolam metabolite therefore it is likely 
the metizolam detected in these urine samples is from the metabolism or 
degradation of etizolam rather than consumption of metizolam. The results from 
the 10 mg/L etizolam injection are shown in Figure 53, the etizolam peak can be 
seen at the top panel, the middle and bottom panels are the metizolam QT and QL 
windows, the lack of response of metizolam excludes the possibility of in-source 
etizolam degradation. 
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Figure 53: Chromatogram of a 10-mg/L etizolam injection and the lack of 
metizolam response 
 
 An article by Zawilska and Wojcieszak identified metizolam as a metabolite of 
etizolam (Zawilska and Wojcieszak, 2019) however give no further details. A 
Japanese study investigated the contributed of the cytochrome P450 isoforms in 
the in vitro metabolism of benzodiazepines including etizolam. (Niwa et al., 2005) 
They concluded that CYP3A4 had the highest activity in etizolam metabolism 
however they also noted a minor contribution from CYP2C18 and an even lesser 
contribution from CYP2C19. Another study found that genetic polymorphisms of 
CYP2C19 could lead to variations in etizolam metabolism. (Fukasawa et al., 2005) 
CYP3A4 is the predominant CYP in diazepam metabolism and is one of the 
enzymes responsible for the hydroxylation of diazepam to temazepam; (Niwa et 
al., 2005) this is therefore the isoform responsible for the formation of alpha-
hydroxyetizolam in etizolam metabolism. CYP2C18 was not detected in diazepam 
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metabolism however CYP2C19 was and is known to catalyse the demethylation to 
desmethyldiazepam (Niwa et al., 2005) however this is best described as N-
demethylation and therefore is not a mechanism in which metizolam can be 
produced from etizolam as the methyl group is absent from a carbon atom and not 
a nitrogen atom, see Figure 52 for the chemical structure comparison. By 
considering the metabolism of better-known benzodiazepines such as diazepam 
there does not appear to be a pathway that explains metizolam as a metabolite of 
etizolam. Another explanation for metizolam production is from the manufacture of 
etizolam possibly creating a metizolam by-product, this may explain why it is seen 
in some etizolam positive samples but not all as there are multiple ways to 
synthesise drugs. This is an unconfirmed theory due to the lack of literature on 
etizolam metabolism and metizolam in general.  
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5.5.2. Forensic Directorate psychiatric results 
Urine samples were collected from 95 patients from January 2016 to November 
2016 in NHS GGC FD facilities as part of the standard drug testing procedure. 
5.5.2.1. Questionnaire responses 
Each sample received had a corresponding form, which detailed the results of the 
immunoassay test, the drugs the patient was prescribed and the results of 
confirmation testing. Figure 54 shows the prescribed drugs that were mentioned 
on more than one occasion on the form submitted with each sample. Other drugs 
only mentioned once included amisulpride, clonazepam, quetiapine, propranolol, 
venlafaxine and haloperidol. Unlike the drug court cohort it was ensured that an 
individual did not donate twice to this study so the 95 samples were collected from 
95 individuals. Only one form mentioned the prescribed use of benzodiazepines. 
This was the form with sample FP 73, it states the individual had 2 mg of 
diazepam approximately one week ago.  
 
Figure 54: NHS GGC FD drugs mentioned on study forms 
 
Table 56 displays the samples, which gave a positive immunoassay test. All other 
samples gave a negative response to all drug groups included in the 
immunoassay screen. Individuals being treated by NHS GCC FD are not given 
prior warning that they would be drug tested and the testing is done at random 
however they are aware that they are subject to random drug and alcohol testing. 
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Table 56: Screen results on the FD form submitted to FMS 
Sample 
Number 
A
m
p
h
e
ta
m
in
e
s
 
B
e
n
z
o
d
ia
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e
p
in
e
s
 
C
o
c
a
in
e
 
C
a
n
n
a
b
is
 
M
e
th
a
d
o
n
e
 
O
p
ia
te
s
 
Prescribed 
Drug 
detected by 
GC/MS 
13 N N N N P N Methadone - 
22 N N N N P N Methadone, olanzapine - 
49 N N N N N P 
Lansoprazole,aspirin, 
lamotrigine,clozapine 
Codeine 
50 N N N N N P None stated 
Codeine and 
morphine 
68 N N N N N P None stated 
Codeine and 
morphine 
74 N N N N N P None stated 
Codeine and 
morphine 
85 N N N N N P Co-codamol 
Codeine and 
morphine 
90 N N N N N P Co-codamol 
Codeine and 
morphine 
92 N N P N N N None stated - 
N = Negative response, P = Positive response. 
5.5.2.2. Forensic Directorate psychiatric laboratory results 
All urine samples were found to be negative for the compounds listed in Table 51, 
however oxazepam was detected at a concentration of <15 ng/mL (15 ng/mL cut-
off was used) for FP073. According to the form, this individual had taken 2 mg of 
diazepam approximately one week ago however the initial urine immunoassay 
screening test had indicated a negative result. The immunoassay uses an 
oxazepam cut-off concentration of 200 ng/mL; (Abbott Architect, Benzodiazepine 
Manufacturer Kit Insert, 2018) so it is to be expected that this concentration would 
not have been detected. Due to the anonymised nature of the information provided 
it is not known if this patient was given this diazepam for a clinical reason or not or 
if they were in a low/medium or community setting. Consent was sought for every 
sample and therefore those likely to give a positive result may not have provided a 
sample. The apparent absence of benzodiazepines in this population is an 
 
 
142 
encouraging result as these drugs are not recommended in this group of 
individuals as mentioned in chapter 1 section 1.3, they may exacerbate symptoms 
and have a higher abuse potential than in some other populations. 
5.6. Conclusion 
This study found that diazepam was being commonly used in the sub-set of the 
SDC cohort tested but designer benzodiazepines were only detected in four 
samples. This gives a snapshot of the benzodiazepine use in these individuals 
during a six-month period however the voluntary requirement in this study could 
skew the results. There were more positive samples than noted on the 
questionnaires therefore proving the hypothesis correct for this population. 
The forensic psychiatry (NHS GGC FD) results showed a population who do not 
appear to be using benzodiazepines; it is possible their treatment may be 
restricting their access to these drugs. It is thought that prescribing 
benzodiazepines to patients with a severe mental health diagnosis may 
exacerbate their condition and they are more at risk of abusing benzodiazepines 
than individuals who do not suffer from these conditions. Therefore it is unlikely 
that there would be many patients prescribed diazepam and other 
benzodiazepines. (Brunette et al., 2003) There no positive samples therefore 
proving the hypothesis incorrect for this population. 
5.6.1. Limitations 
The individuals who took part in both studies gave consent as part of the ethical 
considerations. The author is not privy to how many individuals declined to be part 
of the study; it is possible those more likely to give a positive result did not consent 
to the additional testing. There was no reward offered to take part in this study. 
The individuals are required to attend the Drug Court by appointment and 
therefore it is possible that they were careful about their drug use in the couple of 
days prior to their appointment. With these considerations it is possible that the 
positives found in study are an underestimate of the benzodiazepine use in both 
populations. The patients in the forensic psychiatry cohort are tested for drugs and 
alcohol randomly with less prior warning however they are aware that they are 
subject to random testing. The immunoassay results for the SDC were not 
available for comparison and therefore no conclusion can be drawn on their use 
and level of success. It would be expected that the analytes detected in this study 
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would also give a positive results as traditional benzodiazepines immunoassays 
have demonstrated cross-reactivity with some of the designer benzodiazepines, 
see Chapter 2. Future studies in populations such as the SDC so should ensure 
access to immunoassay results in order to compare their results to the 
confirmatory results.  
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6. Scottish Prison Service samples 
6.1. Introduction 
The Scottish Prison Service (SPS) carries out the Addiction Prevalence Testing 
(APT) annually in all 15 Scottish Prisons. This involves all individuals being 
admitted to or liberated from one of these prisons in the designated testing month 
to undergo a urine drug test. Participation in the APT is voluntary. (Drug Misuse 
and Treatment in Scottish Prisons, 2019) 
The analysis carried out is a point-of-care test, which includes a broad range of 
drug groups: cannabis, benzodiazepines, opiates, methadone, amphetamine(s), 
methamphetamine(s), barbiturates, cocaine, buprenorphine and some prisons 
included tramadol. This test is an immunoassay; the principle of immunoassay is 
explained in chapter 2. There is no available information on the brand of the test 
used. 
The Scottish Prison Study 2015 was carried out by all of the 15 prisons in 
Scotland, this was an anonymous survey, and all prisoners were invited to take 
part in. There was a response rate of 55%. 80% of the respondents were 
convicted, whilst the rest were untried at the time of the survey. 92% of 
respondents were male with the average age being 33 years old. In this survey, 
43% admitted they had used illegal drugs while in prison and 24% stated they had 
used drugs in prison within the last month. Of those who used drugs within the last 
month 39% stated they used benzodiazepines.(Carnie and Broderick, 2015) The 
Scottish Prison Study 2015 and the SPS APT suggest that benzodiazepine use is 
an issue in custody settings and therefore designer benzodiazepines should be 
investigated in a prison setting. 
6.2. Aim 
The aim of this study was to determine the extent of benzodiazepine use including 
designer benzodiazepines in individuals being admitted to and liberated from SPS 
facilities during November 2015. Hypothesis: The individuals admitted to prison 
will give more positive results for benzodiazepines than those being liberated.   
6.3. Ethical considerations 
NHS Ethical Approval was sought and granted from the NHS West of Scotland 
Research Ethics Committee under reference WS/15/0207. See Appendix 11.9. 
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6.4. Method and materials 
6.4.1. Materials 
The materials used are detailed in section 4.3.1 of chapter 4. 
6.4.2. Extraction method 
Urine samples were extracted using the LLE extraction method detailed in section 
4.5.1.3 of chapter 4. 
6.4.3. Instrumentation and method  
The extracts were analysed using the LC-MS/MS method detailed in section 4.3.4 
of chapter 4. This method was employed as a qualitative method with cut-off 
concentrations. The cut-off used for this method was 15 ng/mL. Table 51 details 
the analytes included in the method, this is the same panel used in chapter 5.  
6.4.4. Sample collection 
Unpreserved urine samples were collected from 7 out of 15 SPS facilities; HMP 
Addiewell, HMP Barlinnie, HMP Cornton Vale, HMP Edinburgh, HMP Greenock, 
HMP Low Moss and HMP Perth as part of the APT procedure.  
Individual consent was obtained before the remaining urine sample was sent to 
FMS by courier for additional testing regardless of a positive or negative SPS APT 
result. There were no personal details pertaining to the individual on the tube of 
the urine sample, the only detail was a sticker, which said either ‗Admission‘ or 
‗Liberation‘.  
6.4.5. Data handling and statistical analysis 
Once results had been generated in the Analyst software, they were copied onto a 
Microsoft® Excel® (version 14.7.3) spreadsheet and batch checked by a second 
toxicologist before any calculations were performed. The results copied include the 
peak areas of the analyte and the internal standard, the calculated values of the 
calibration standards, samples and QCs in mg/L and the datapath information. 
Microsoft® Excel® was then used to generate the charts and descriptive statistics 
within the results section. The spreadsheets were kept on a secure drive to protect 
the data.  
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6.5. Results and discussion 
725 urine samples were received from the seven prisons that took part. The SPS 
publish weekly figures showing the population of Scotland‘s prisons. (Scottish Prison 
Service) The Scottish Prison population on the last week of November 2015 (the APT 
collection month) for over 21 year olds was 7,187. Females made up 5% of the 
Scottish Prison population on that week. 725 samples represents around 10% of 
the Scottish prisoner population, however the samples received were prisoners in 
transit, either entering or leaving the prison system and not the general prison 
population. The number of admission and liberation samples from each prison is 
summarised in Table 57.  
Table 57: Admission / Liberation breakdown for the prison urine samples tested in 
this study 
Facility 
No. Admission 
Samples 
No. Liberation 
Samples 
Total no. of samples 
HMP Addiewell 69 34 109* 
HMP Barlinnie 109 63 173* 
HMP Cornton Vale 62 25 87 
HMP Edinburgh 27 35 62 
HMP Greenock 6 20 26 
HMP Low Moss 19 40 60* 
HMP Perth 138 70 208 
Total 430 287 725* 
*Six samples from HMP Addiewell and one each from HMP Barlinnie and HMP Low Moss were 
not labelled as admission or liberation and could not be identified as either. 
6.5.1. SPS results vs this study results  
SPS reported the most common drug group detected was cannabis followed by 
benzodiazepines in the admission samples. Buprenorphine was the most 
commonly detected drug in the liberation samples.(Addiction Prevalence 
Testing for Performance Measurement Purposes 2015-16 (November 
2015) 2016) Table 58 shows the results of the SPS testing for each drug group. 
They tested 1,579 samples overall.  
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Table 58: Result for the urine samples (n=1,579) of SPS APT  
  % of positive samples 
Drug Admission Liberation 
  
 
  
Cannabis 52 8 
Benzodiazepines 35 6 
Opiates 25 8 
Methadone 6 3 
Amphetamine(s) 3 0 
Methamphetamines 2 1 
Barbiturates  0 0 
Cocaine 15 0 
Buprenorphine 7 12 
Tramadol* 4 1 
*Tramadol was tested in 7 out of the 15 prisons therefore does not give a true prevalence. 
Table 58 displays the data across all 15 prisons; this is more prisons than tested 
for in this custody study therefore the results are not directly comparable. 
However, Figure 55 shows the results produced for the SPS APT for 
benzodiazepines for the 7 prisons included within the study presented in this 
chapter.  
 
Figure 55: SPS APT results for benzodiazepines in the 7 prisons featured in this 
study. 
 
The charts in Figures 56 and 57 show the number of positive results obtained by 
this study side-by-side with the SPS APT results. Only two prisons gave a higher 
incidence of positives in the SPS results, HMP Low Moss and HMP Barlinnie for 
admission samples. The liberation results in Figure 53 show that in all prisons this 
study found a higher incidence of positive results apart from HMP Addiewell, which 
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had the same number of positives. However the liberation samples overall gave a 
very low number of positives. It also should be noted that SPS tested a higher 
number of samples than this study, and not all samples collected were provided to 
FMS. SPS tested 986 samples from these 7 prisons, of these 725 were available 
for this study. These results suggest positive samples have been missed by the 
immunoassay testing kit used by the prisons and potentially underestimate how 
many have been missed as the SPS tested more samples than this study. Chapter 
2 demonstrates how six benzodiazepines were successfully detected by the  
Immunalysis® Benzodiazepine ELISA kit however this was a laboratory based kit 
and not a point of care test. The test used by the prison was never detailed to the 
author therefore its cross-reactivity was not tested. This means it is not known if 
these samples have evaded detection due to cross-reactivity or the limit of 
detection. This further emphases the requirement for confirmation testing and why 
presumptive testing cannot be solely relied upon.  
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Figure 56: SPS APT results vs this prison study results in admission samples 
 
Figure 57: SPS APT results vs this prison study results in liberation samples 
 
Table 59 shows the number of samples that tested positive for at least one 
benzodiazepine for admission, liberation and unlabelled samples for each prison. 
HMP Greenock which is a small prison designed to hold 249 prisoners only 
submitted 26 samples for this study. HMP Barlinnie, which is a larger facility and 
receives an average of 8,000 prisoner admissions each year sent 173 samples to 
this study. Interestingly HMP Cornton Vale, Scotland‘s female prison had the 
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highest percentage of positives for benzodiazepines overall. 
Table 59: Number of positive urine samples for one or more benzodiazepine for 
this prison study 
Facility No. of positive samples % of positive samples Total no. of samples 
HMP Addiewell 46 42% 109 
HMP Barlinnie 80 46% 173 
HMP Cornton Vale 49 56% 87 
HMP Edinburgh 9 15% 62 
HMP Greenock 3 12% 26 
HMP Low Moss 20 33% 60 
HMP Perth 83 40% 208 
Total 290 40% 725 
 
This study found that overall the 40% of the samples were positive for 
benzodiazepines, this is 5% more than the APT result however they did test 15 
prisons compared to the 7 detailed here so it is not directly comparable.  
6.5.2. Individual analyte results  
There were six benzodiazepines that were negative in all samples in this dataset; 
these were alprazolam, deschloroetizolam, flubromazolam, clonazolam, 
meclonazepam and nifoxipam, however, no metabolites for these drugs were 
included in the analytical method used. Approximately 20% of alprazolam taken 
orally is excreted in urine unchanged so there is a detection window to some 
degree. (Fraser, Bryan and Isner, 1991) The nitrobenzodiazepines - clonazolam, 
meclonazolam and nifoxipam are likely to extensively metabolise and require the 
inclusion of metabolites in methods for urine detection. (Meyer et al., 2016) 
Deschloroetizolam has found to be detectable in blood but not in urine and 
therefore also requires metabolites in urine analysis for successful detection. (El 
Balkhi et al., 2017) Table 60 provides a summary of all positive findings and prevalence 
in the sample set. 
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Table 60: Summary of benzodiazepine urine positives for this prison study 
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HMP 
Addiewell 
43 39 38 22 11 8 8 2 3 - - 1 1 1 1 - 
HMP 
Barlinnie 
74 69 65 44 23 21 20 6 6 2 1 1 1 - - 1 
HMP Cornton 
Vale 
49 45 41 28 8 7 5 3 1 - 1 2 1 - - - 
HMP 
Edinburgh 
9 8 6 5 - - - - 1 - - - - - - - 
HMP 
Greenock 
3 3 3 1 - - - - - - - - - - - - 
HMP Low 
Moss 
20 18 17 12 6 5 3 - 2 - - - - - - - 
HMP Perth 83 76 72 41 11 3 5 11 8 5 4 1 - - - - 
Total no. of 
admission 
positives 
237 225 210 139 54 41 39 20 18 7 5 5 3 1 1 1 
Total no. of 
liberation 
positives 
38 28 27 9 3 2 1 2 2 0 1 0 0 0 0 0 
Total no. of 
unlabelled 
6 5 5 5 2 1 1 0 1 0 0 0 0 0 0 0 
Total Overall 281 258 242 153 59 44 41 22 21 7 6 5 3 1 1 1 
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6.5.3. Diazepam 
Diazepam is the most prescribed benzodiazepine worldwide and metabolises to 
three other active drugs, desmethyldiazepam (nordiazepam) and temazepam, 
which both then metabolise to oxazepam. Desmethyldiazepam is also a metabolite 
of six other benzodiazepine drugs (chlordiazepoxide, clorazepate, halazepam, 
medazepam, prazepam and tetrazepam). (Ator and Griffiths, 1997)  
 
Figure 58: Diazepam and metabolite urine positive results for this prison study 
 
Oxazepam was the analyte with the most number of positive samples in all 
prisons; this is unsurprising as it is the metabolite with the longest detection 
window from diazepam use. (Luk et al., 2014; Lennestål et al., 2008)  It is likely the 
LC-MS/MS method cut-off of 15 ng/mL is lower than the cut-off used for the prison 
immunoassay, therefore more positives will be detected. Figure 58 shows the 
difference in the number of positives from admissions compared to liberations - 
this difference is more pronounced especially for HMP Perth, HMP Barlinnie and 
HMP Cornton Vale. Figure 59 shows the same data but displayed as a percentage 
positive, this allows the positivity rate between the prisons to be compared more 
easily. Figure 59 shows that HMP Cornton Vale has the highest rate of positivity 
for the diazepam metabolites. The graph in Figure 59 does not contain the 
samples which were not labelled. The one unlabelled sample from HMP Barlinnie 
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was positive for oxazepam and five out of the six HMP Addiewell unlabelled 
samples were positive for oxazepam, temazepam and desmethyldiazepam.  
An oxazepam positive in urine indicates use of diazepam, temazepam or 
oxazepam. The oxazepam-only positive samples are likely to be from diazepam 
use, although use of other benzodiazepines cannot be excluded. 
 
Figure 59: Diazepam and metabolite urine positive results for this study by 
percentage 
 
Oxazepam was present without any other metabolites in four samples from HMP 
Addiwell, four samples from HMP Barlinnie, four samples from HMP Cornton Vale, 
one sample from HMP Edinburgh, two samples from HMP Low Moss and seven 
samples from HMP Perth. This equates to 8% of the oxazepam positive-samples 
with no other diazepam metabolites detected. Oxazepam is prescribed for the 
treatment of anxiety and insomnia, in Scotland but it is not common - in 2015/16 
oxazepam was dispensed 8,936 times versus the 874,810 times diazepam was 
dispensed. (Information Services Division Scotland, 2016) One HMP Barlinnie 
sample was positive for oxazepam and desmethyldiazepam which is likely to show 
use of chlordiazepoxide due to the absence of temazepam. 
It is reasonable to speculate that all of the positive results for oxazepam, 
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temazepam and desmethyldiazepam came from diazepam use. Many samples are 
positive for the diazepam metabolites but not diazepam itself, which is not unusual 
in urine samples. (Luk et al., 2014)  
6.5.4. Diclazepam  
Diclazepam has been observed amongst Scottish fatalities in the past six years 
and in drug seizures. (Scotland, 2016) It is not always clear if users seek 
diclazepam specifically or they are unknowingly consuming it in ‗street Valium‘ 
pills.(Scotland, 2016) Diclazepam metabolites were the most common analytes 
detected after the diazepam metabolites. Table 61 displays the number of 
diclazepam and metabolites positives. Diclazepam is metabolised to delorazepam 
and lormetazepam, which are then both metabolised to lorazepam, which is turned 
into a glucuronide for excretion, see Figure 11. One sample may be counted 
several times within Table 61 depending on how many metabolites were positive 
within that sample. Samples from HMP Edinburgh and HMP Greenock were all 
negative for diclazepam and metabolites and therefore Table 61 only shows the 
results of five prisons.  
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Table 61: Diclazepam and metabolites urine positive results for this prison study 
Prison Analyte 
No. of 
admission 
positives 
No. of 
liberation 
positives 
No. of 
unlabelled 
positives 
Total No. of 
positives 
HMP 
Addiewell 
Lorazepam 9 0 2 11 
Delorazepam 7 0 1 8 
Lormetazepam 7 0 1 8 
Diclazepam 0 0 0 0 
HMP 
Barlinnie 
Lorazepam 23 0 0 23 
Delorazepam 21 0 0 21 
Lormetazepam 19 1 0 20 
Diclazepam 1 0 0 1 
 
HMP 
Cornton Vale 
 
Lorazepam 8 0 0 8 
Delorazepam 7 0 0 7 
Lormetazepam 5 0 0 5 
Diclazepam 0 0 
0 
 
0 
HMP  
Low Moss 
Lorazepam 4 2 0 6 
Delorazepam 3 2 0 5 
Lormetazepam 3 0 0 3 
Diclazepam 0 0 0 0 
 
HMP  
Perth 
 
Lorazepam 10 1 0 11 
Delorazepam 3 0 0 3 
Lormetazepam 5 0 0 5 
Diclazepam 0 0 0 0 
 
Lorazepam was detected without any other diclazepam metabolites in some 
samples (n =1 - HMP Low Moss, n = 1 - HMP Cornton Vale, n = 2 - HMP 
Barlinnie, n = 3 - HMP Addiewell, n = 8 - HMP Perth). This equates to 25% of 
lorazepam positive-samples with no other diclazepam metabolites detected. 
Lormetazepam was detected on its own in one liberation sample from HMP 
Barlinnie and one admission sample from HMP Perth. All positive samples for 
diclazepam and its metabolites were in admission samples with the exception of 
two unlabelled samples from HMP Addiewell, one sample previously mentioned 
from HMP Barlinnie, one sample from HMP Perth and two from HMP Low Moss. 
Admission samples have a higher positivity rate just as the diazepam results 
showed. 
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Lorazepam-only positives can be a result of diclazepam, lormetazepam or 
lorazepam use. Both lorazepam (used in the treatment of psychosis) and 
lormetazepam (used in the treatment of insomnia) are prescribed in Scotland. 
Lorazepam is not commonly prescribed and was dispensed 97,857 times in 
2015/16 year period compared to the 874,810 times diazepam was 
dispensed.(Information Services Division Scotland, 2016) Lormetazepam is even 
less common and was dispensed 3,541 times in that one-year period. 
Delorazepam (also a drug in its own right) is a metabolite of both diclazepam and 
cloxazolam. It is not licensed for use in the UK and is not included in the British 
National Formulary (BNF).(British Medical Association ) Cloxazolam is also not 
prescribed in the UK. Delorazepam was always detected along with other 
diclazepam metabolites in this study. This makes delorazepam the most suitable 
metabolite for targeting diclazepam use in urine sample; it is less likely to have 
come from another source like lorazepam.  
6.5.5. Other designer benzodiazepines 
Etizolam was the second most common designer benzodiazepine (following 
diclazepam) found in this dataset with 22 positives detected overall (7.6% of the 
positive samples, 3% overall). Figure 60 displays the number of other designer 
benzodiazepine urine positives excluding diclazepam. Figure 61 displays the 
designer benzodiazepine urine positive excluding diclazepam broken down by 
prison. HMP Perth had the most etizolam positives at 11; they were all found in 
admission samples. HMP Barlinnie had two liberation samples that were positive 
for etizolam (3% of HMP Barlinnie liberation samples) one of these samples was 
also positive for 3-hydroxyphenazepam. 3-hydroxyphenazepam is also a drug not 
just a metabolite therefore its presence may indicate 3-hydroxyphenazepam 
consumption and not phenazepam use, the six phenazepam positive samples 
were all also positive for 3-hydroxyphenazepam. One study found phenazepam 
was detected in samples fortified with 3-hydroxyphenazepam only, likely due to 
thermal instability (Crichton et al., 2015) therefore determining the source of this, from 
phenazepam or 3-hydroxyphenazepam consumption is particularly difficult. The 
samples in this study were collected in November 2015 and 3-
hydroxyphenazepam was reported to the EMCDDA in 2016. (EMCDDA., 2015) 
This suggests phenazepam metabolism is the more likely explanation for 3-
hydroxyphenazepam detection however consumption is cannot be ruled out. 
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Metizolam was positive in seven admission samples overall. All metizolam positive 
samples were also positive for etizolam. As previously described in Chapter 5, 
Section 5.5.1.3 metizolam positives could be the result of etizolam use rather than 
metizolam itself.  
 
Figure 60: Designer benzodiazepine prison urine sample positives-excluding 
diclazepam 
 
 
Figure 61: Designer benzodiazepine urine sample positives by prison-excluding 
diclazepam 
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6.5.6. Poly-drug use  
Figure 62 shows the number of benzodiazepines present in positive samples. The 
majority (73%) of positive samples had one drug present. This chart has been 
made with the assumption that oxazepam, temazepam and desmethyldiazepam 
have come from diazepam use, and therefore one drug has been consumed. It 
was also assumed that samples positive for delorazepam, lorazepam and 
lormetazepam were from diclazepam consumption. A sample positive for both 
etizolam and metizolam has been counted as consumption of etizolam only, and 
3-hydroxyphenazepam and phenazepam together has been counted as 
consumption of phenazepam only. It is therefore possible that the values used to 
create this chart are an underestimate.  
 
Figure 62: Poly-Benzodiazepine use within positive prison urine samples 
 
6.6. Conclusion 
Overall this data shows that the majority (60%) of participants in this study were 
negative for all benzodiazepines tested. Diazepam metabolites were the most 
commonly detected for all prisons; particularly in admission samples. It is not 
possible to know if these positives were the result of prescribed diazepam use, 
due to the anonymised nature of the study. Diclazepam use was mostly detected 
amongst admission samples; HMP Barlinnie had the highest number of 
diclazepam metabolite positives with 21% of admission samples. Other designer 
benzodiazepines did not have as high a presence overall, at 3% for etizolam, the 
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second most common designer benzodiazepine. The vast majority (73%) of 
positive samples for designer benzodiazepines showed use of one 
benzodiazepine drug. 
Benzodiazepine use is occurring in the Scottish prison system. This data shows 
that the admission samples have a greater incidence of positives than the 
liberation samples. It suggests that individuals are going into prison whilst using 
benzodiazepines but are likely to come out of prison having abstained from 
benzodiazepine use. This may indicate that benzodiazepines are difficult to obtain 
in prison but it should also be noted that more admission samples were tested and 
consent was required to be included in this study. 
6.6.1. Limitations 
Due to the need to obtain consent for this study, this may not be a true 
representation of the use of benzodiazepines within the prison population. There is 
the possibility of collection bias and that those who knew they had been taken 
drugs may have refused to participate. This also only gives data on individuals 
entering or leaving the prisons so therefore cannot show benzodiazepine use 
amongst the general prison population. It would also be useful to know if the 
individuals providing the samples were prescribed any benzodiazepines in order to 
determine if the results are truly illicit use of a drug. Random urine sampling for 
drugs would give a more comprehensive overview of the illicit drugs being 
consumed while in prison.  
 
 
160 
7. Designer benzodiazepines in post-mortem blood samples 
7.1. Introduction 
There are few articles within the scientific literature that have explored the 
concentrations of designer benzodiazepines in human tissue (Høiseth, Tuv and 
Karinen, 2016; Moosmann et al., 2013a; Moosmann et al., 2013b; Moosmann, 
Bisel and Auwärter, 2014; Crichton et al., 2015) and even fewer that have 
considered these drugs in post-mortem samples. (Shearer et al., 2015; Lehmann 
et al., 2019; Heide et al., 2020; Crichton et al., 2015; Mei et al., 2019) Diclazepam 
and pyrazolam post-mortem blood concentrations are discussed in one study for a 
single case. (Lehmann et al., 2019) The most comparable study to this one in the 
literature is a Norwegian article that examined designer benzodiazepine in living 
offenders as well as in post-mortem blood. (Heide et al., 2020) This article 
revealed diclazepam to be the most commonly detected designer benzodiazepine 
in both populations. In the post-mortem data diclazepam was detected 13 times in 
6,500 and etizolam was only detected twice. (Heide et al., 2020) The study has the 
advantage of a large dataset however the rate of positive cases in the post-
mortem blood is low and is much lower than in Scotland, however the study does 
not include any metabolites in their method which would potentially increase their 
positivity rate. They include lorazepam analysis but this was detected as part of 
their routine investigation as its own drug and not included because it is a 
diclazepam metabolite. There was also the disadvantage of no causes of deaths 
included within the study. These PM studies have been summarised in section 
1.10 of chapter 1. The DRD data discussed in section 1.9.1 of chapter 1 shows 
how common etizolams presence is in Scotland, however this is not the only illicit 
benzodiazepine in circulation over the last few years. Diclazepam, pyrazolam and 
flubromazepam were reported to the EMCDDA not long after etizolam and 
therefore became drugs of interest in this study. It is important to understand if the 
individuals in Scotland who are dying are taking these drugs, in DRDs as well as 
other non-drug related deaths. Collating this data will provide concentration 
ranges, which can be consulted by toxicologists and pathologists to aid their 
interpretations.  
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7.1.1. Post-mortem toxicology in Scotland 
Scotland is split into three Scottish Fatalities Investigation Units (SFIU) named 
SFIU North, SFIU East and SFIU West. Figure 63 shows the geographical area 
each unit covers. The East and West area serves around 3 million out of the 5.4 
million Scottish population. (Shearer et al., 2015) 
 
 
Figure 63: The areas of Scotland divided by the three Scottish Fatalities 
Investigation Units. 
 (reproduced with permission under the Open Government License 
http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/) 
 
The Forensic Toxicology Service (FTS), which is part of Forensic Medicine and 
Science (FMS) at the University of Glasgow, carries out the post-mortem 
toxicology testing for SFIU West and SFIU East and the Tayside area of SFIU 
North. Since 2015 the FTS has analysed more than 3,000 cases for post-mortem 
toxicology per year, this is approximately 90% of the Scottish post-mortem 
toxicology casework.  
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7.1.2. Aim 
The aim of this study was to review all post-mortem casework positive for the 
designer benzodiazepines, diclazepam and two of its metabolites (delorazepam 
and lormetazepam), flubromazepam and pyrazolam from 2014 to 2018. Data 
collated included drug concentrations, other drugs present, the circumstances 
surrounding the death and the recorded cause of death. This information will give 
toxicologists a clearer idea of how to interpret the concentrations encountered in 
post-mortem casework. This, in turn could assist pathologists in understanding if 
the drug has contributed to the cause of death or not.  
7.1.3.  Ethical considerations 
Ethical approval was sought and granted from the University of Glasgow Medical, 
Veterinary and Life Sciences Ethics Committee under reference 200180192.  (See 
Appendix 11.10). 
7.2. Method  
7.2.1. Method and extraction 
Blood samples were extracted using the SPE extraction method detailed in 
Section 3.3.5 of chapter 3 as part of the post-mortem toxicological investigation. 
The instrumentation and analytical method used in this study is described in 
section 3.3.4 in chapter 3. This designer benzodiazepine method included 
diclazepam and two of its metabolites (delorazepam and lormetazepam), 
flubromazepam and pyrazolam. These were the designer benzodiazepines that 
directly followed etizolam and had been reported to the EMCDDA when the 
method was created.  
7.2.2. Data Collection 
An in-house database containing information on all cases submitted for analysis to 
FTS was used to identify the designer benzodiazepines positive cases between 
January 2013 and December 2018. This gave an approximate six-year time 
period. Due to the number and variety of cases received during this time period, 
not every case was analysed for the designer benzodiazepines. On receipt, all 
cases are reviewed and case circumstances, such as items found at the scene or 
statements from witnesses, and the volume of sample available were used to 
decide if testing was appropriate. Therefore the number of positive cases found is 
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likely to be an underestimation of the true prevalence in the casework received by 
FTS. Phenazepam has been tested for since 2012 and etizolam from 2013 for 
cases received to FTS, these will not be detailed in this PM study. Diclazepam, 
flubromazepam and pyrazolam were tested for in cases deemed appropriate by 
the pathologist or the toxicologist since 2014. From September 2018 all drug 
related deaths were tested for designer benzodiazepines. The results of the 
routine benzodiazepine analysis prompted the analysis for the designer 
benzodiazepines in some cases for example a positive lorazepam may indicate a 
diclazepam positive case. Every effort was made to ensure cases were not missed 
for designer benzodiazepine analysis but it is still a possibility.  
The positive cases identified were examined to extract the following information: 
1. Basic demographics. This included the age, sex and SFIU region. 
2. Toxicological findings. This included the post-mortem femoral blood 
concentrations of diclazepam and metabolites (delorazepam and lormetazepam), 
flubromazepam and pyrazolam as well as the presence of other drugs. 
3. Cause of death. This is the cause of death including contributory factors and the 
categories of death (e.g drug-related, unascertained). 
7.2.3. Data handling and statistical analysis 
Once results had been generated by the in-house database, they were copied 
onto a Microsoft® Excel® (version 14.7.3) spreadsheet and checked by a second 
toxicologist before any calculations were performed. Microsoft® Excel® was then 
used to generate the descriptive statistics where necessary in addition to the 
percentiles for the diclazepam blood concentration data and to conduct a paired 
two sample t-test to determine if there was a statistical difference between the 
concentration included or excluded in the cause of death for pyrazolam and 
flubromazepam positive cases. The spreadsheets were saved on a secure drive to 
protect the data. 
7.3. Results and discussion 
Over the six-year period examined, 1691 cases were analysed using the SPE, LC-
MS/MS method (see section 3.3.4 of chapter 3) including diclazepam and its two 
metabolites, flubromazepam and pyrazolam. There was a total of 369 cases 
positive for the designer benzodiazepines tested in blood (22% overall), 354 of 
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these were diclazepam positive (21% overall). A case positive for delorazepam is 
counted as a diclazepam positive as delorazepam is the major metabolite, there 
were 126 instances of delorazepam positive cases which were negative for 
diclazepam and lormetazepam. These cases may have also been positive for 
lorazepam, which was detected in a separate analytical method.  
The 369 total positive cases included 18 flubromazepam positive cases (1% of all 
cases analysed), 7 of which were also diclazepam positive cases and four were 
positive for pyrazolam. The 369 total positive cases also included 9 pyrazolam 
positive cases (0.5% of all cases analysed), of which 1 was also diclazepam 
positive. 
7.3.1. Diclazepam results 
Figure 64 shows the number of cases positive for diclazepam and diclazepam 
metabolites in post-mortem blood from 2013 to 2018. Diclazepam positives 
peaked in the year 2016, they were positive in 49% of post-mortem cases 
analysed for designer benzodiazepines. Table 62 shows the percentage of 
diclazepam positive cases in the FTS post-mortem casework from 2013 to 2018. 
There was a dramatic dip in diclazepam positives in 2017 despite an increase in 
the number of cases analysed. This appears to be the direct impact of the 
Psychoactive Substances Act 2016, which came into force in May 2016. 
Interestingly, a 2019 study that monitored self-reporting of NPS use in the 
admissions to a London hospital found that there was no decrease after the Act 
came into force. (Webb et al., 2019) However, drugs like synthetic cannabinoids and 
cathinones are popular in admissions to this emergency department. (Webb et al., 2019) 
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Figure 64: Diclazepam positive cases in FTS post-mortem blood casework 
casework over a six-year period (2013-2018) 
 
Table 62: Percentage of diclazepam positive cases in FTS post-mortem casework 
 
Year Number of post-mortem 
toxicology cases 
Number of cases 
analysed for designer 
benzodiazepines 
% of analysed 
cases positive 
2013 2563 1 100 
2014 2991 50 22 
2015 3181 64 59 
2016 3367 337 49 
2017 3407 413 15 
2018 3703 826 9 
 
7.3.1.1. Demographics 
This dataset found there were more males positive for diclazepam in post-mortem 
cases than females. The difference in male to female positive cases was 
particularly noticeable in 2016; when there was more than double the number of 
males compared to females, see Figure 65. The ―Drug-related deaths in Scotland 
in 2018‖ report produced by the National Records of Scotland found that males 
made up 72% of drug related deaths. (National Records of Scotland, 2019) 
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Figure 65: Sex of diclazepam positive cases in FTS post-mortem casework over a 
6-year period (2013-2018) 
 
The mean age found in this study remained consistent for the cases from 2014 to 
2018, (range, 18-75 years old). The median age was 41 years old for both male 
and female. The number of cases positive for diclazepam in each age range is 
presented in Figure 66. There was only one case from December 2013 and this 
individual was 22 years old.  
 
Figure 66:The range of ages for male and female in diclazepam positive post-
mortem cases cases over a 5-year period (2014-2018) 
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The ―National Records of Scotland, Drug-related deaths in Scotland in 2018‖ 
report found that the two age groups encompassing the 25 to 44 year olds had the 
largest number of DRDs. Figure 67 shows the rates for each age group over an 
18-year period. (National Records of Scotland, 2019) 
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Figure 67: Drug-related death rates rates over an 18-year period (2000-2018) by 
age group  
(reproduced with permission under the Open Government License 
http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/) 
 
7.3.1.2. Toxicological findings 
Figure 68 displays the range of concentrations detected, and shows that 
diclazepam is more likely to be detected at the lower end of the concentration 
range. The mean and median concentrations of the diclazepam positive cases are 
displayed in Table 63. The LLOQ for this method was 0.005 mg/L; a positive 
sample was one that gave a peak area ratio of 50% or above the peak area ratio 
of the LLOQ. The ULOQ was 0.20 mg/L, for most cases sample dilution was 
carried out to give a quantitative value if required, however >0.20 is used for the 
purposes of this chart.  
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Figure 68: The range of diclazepam and metabolite post-mortem femoral blood 
concentrations detected over a 6-year period (2013-2018) 
 
Lormetazepam is also likely to be detected at the lower end of concentration 
range, (range, 0.005 – 0.020 mg/L for all three analytes). Lormetazepam is an 
active metabolite that is then further metabolised to lorazepam, which is also 
active; see section 1.7 of chapter 1. Delorazepam is the active metabolite that is 
most likely to be detected over a wider range of concentrations according to this 
dataset. A study by Moosmann et al (Moosmann, Bisel and Auwärter, 2014) 
demonstrated that diclazepam has an elimination half-life of around 42 hours and 
the metabolites delorazepam and lormetazepam could be detected in urine for up 
to 6 days and 11 days, respectively. This study also carried out a self-
administration experiment; a 43 year old ingested a 1 mg diclazepam tablet. The 
study found that the peak serum concentration for diclazepam was 0.003 mg/L 
and was reached after 3 hours, delorazepam was 0.002 mg/L and was reached 
after 36 hours, lormetazepam was 0.0003 mg/L and was reached after 6 hours. 
(Moosmann, Bisel and Auwärter, 2014) These concentrations are low compared to 
the average found in the post-mortem blood in this study however this is a single 
dose of 1 mg compared to potentially heavy consumption of the drug.  
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Table 63: Diclazepam and metabolites femoral blood concentration range and 
median in post-mortem cases over a 6-year period (2013-2018).  
Analyte 
Minimum 
(mg/L) 
Lower 
quartilte 
(mg/L) 
Median 
(mg/L) 
Upper 
quartile 
(mg/L) 
Maximum 
(mg/L) 
Diclazepam 
(n=212) 
0.005 0.011 0.017 0.033 0.400 
Delorazepam 
(n=339) 
0.005 0.020 0.043 0.098 1.500 
Lormetazepam 
(n=144) 
0.004 0.006 0.010 0.019 0.180 
 
The study by Høiseth et al, which described designer benzodiazepine 
concentrations in living offenders of various crimes, found an 18-year-old male 
with a diclazepam blood concentration of 0.057 mg/L who was described to be 
―considerably impaired.‖ There were no other drugs detected in this individual‘s 
blood. This was the highest concentration of diclazepam found in that study of 15 
positive cases; the median concentration was 0.013 mg/L.(Høiseth, Tuv and 
Karinen, 2016) This is close to the median concentration for diclazepam in this 
study (0.017 mg/L).  
A study from Australia (Partridge et al., 2018), described a 23-year-old male who 
was found dead at home, he had a history of illicit drug use and had a post-
mortem blood concentration of 0.07 mg/L for diclazepam and 0.01 mg/L for 
flubromazepam in addition to the synthetic opioid U-47700, the hallucinogen 2,5–
dimethoxy-4-chloroamphetamine (also known as DOC), methyl amphetamine, 
amphetamine, lorazepam (not stated if the authors considered this a diclazepam 
metabolite or from additional use of lorazepam) and etizolam. The cause of death 
was given as ―aspiration (of gastric contents into airways and lungs) due to mixed 
drug toxicity.‖ (Partridge et al., 2018)  
Only eight cases in this study gave a diclazepam concentration in the range >0.06 
– 0.08 mg/L (see Figure 68), therefore 0.07 mg/L is considered a moderately high 
diclazepam concentration in the context of this study.  
Heide et al detected 13 diclazepam cases in post-mortem blood that had a median 
concentration of 0.0032 mg/L, range 0.0018 – 0.032 mg/L. This median is below 
the LLOQ of this study. The results of the Heide et al study are towards the low 
end of the concentration range used in this study, perhaps a more sensitive 
method would have detected more positives in this study however this study 
compensates by analysing for two metabolites which gives further evidence of 
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use. It is unfortunate Heide et al only gave diclazepam data as comparison of the 
metabolites, in particular delorazepam would have been particularly interesting as 
this has a much higher mean and median concentration than diclazepam.  
The routine toxicological analysis of the post-mortem case samples identified 
additional drugs in the samples positive for diclazepam. The most commonly found 
drugs are displayed in Figure 69; the antidepressants category in the chart 
represents amitriptyline, mirtazapine, sertraline, paroxetine, venlafaxine and 
citalopram. The antipsychotics category represents quetiapine and olanzapine. 
The 6-monoacetylmorphine (6-MAM) positive cases in the graph include post-
mortem blood and/or urine positives. The other drugs are all present in the post-
mortem blood. The author did not carry out the toxicological analysis for these 
additional drugs; the hard work of the FMS technicians must be credited for this.  
 
Figure 69: Other drugs found in diclazepam positive post-mortem cases over a 6-
year period (2013-2018) 
 
Figure 69 shows the most commonly found drugs in the diclazepam-positive 
samples were morphine and/or codeine. Morphine and/or codeine was found in 
58% of the diclazepam positive cases. The concurrent use of opioids and 
benzodiazepines prolong the high from the opioids making benzodiazepines an 
attractive drug for heroin users. (EMCDDA., 2015) The detection of morphine and 
codeine in post-mortem blood samples can be from codeine use (as morphine is a 
metabolite of codeine), morphine and codeine use or heroin use. The morphine 
and codeine ratios were not determined. The presence of 6-MAM can assist with 
interpretation as it confirms heroin use. (Baselt) One hundred and twenty 
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diclazepam positive cases also tested positive for 6-MAM in either the post-
mortem blood or urine confirming heroin use, another 59 cases were potentially 
heroin positive cases – 25 of these cases were positive for morphine and codeine 
with the remaining 34 cases positive for morphine but negative for codeine. There 
were 10 cases, which were positive for codeine only. DHC in the graph stands for 
dihydrocodeine, a prescription opioid. Other benzodiazepines, diazepam and its 
metabolite (DMD) and etizolam were also commonly detected. It was not always 
known if the user was intentionally taking diclazepam or if they were under the 
impression they were consuming diazepam or etizolam. Drug testing services 
such as the Welsh Emerging Drugs and Identification of Novel Substance 
(WEDINOS) (https://www.wedinos.org, 2016) have shown that users have 
purchased street diazepam or etizolam and have in fact been sold diclazepam. 
WEDINOS is a harm reduction service, which analyses substances submitted to 
them, this is helpful in giving in current market intelligence. Figure 70 is an 
example from the WEDINOS website showing a tablet submission they received in 
2016.  
 
Figure 70: Tablet submission from the WEDINOS website in 2016.  
(reproduced with permission from WEDINOS (https://www.wedinos.org) 
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7.3.1.3. Cause of death 
The causes of death for the diclazepam positive cases were investigated for this 
study. Figure 71 displays the diclazepam post-mortem femoral blood 
concentrations and if it was included in the cause of death or not. Cases with a 
concentration of <0.005 mg/L were excluded from this graph. 
There were 75 cases (21%) in this dataset where diclazepam was mentioned in 
any part of the cause of death, for example: 
 1a - Multiple organ failure; 1b - Hypoxic ischaemic brain damage; 1c - 
Cardiac arrest following fall; 2a - Diclazepam and alcohol intoxication 
was included as the word ―diclazepam‖ featured despite it being in 2a and far 
down the list of contributing factors.  
 1a - Buprenorphine and benzodiazepine intoxication 
was not included as ‗diclazepam‘ was not specifically named although 
benzodiazepine intoxication implies diclazepam may be implicated Other 
benzodiazepines are positive in this case. 
There were 85 cases where diclazepam was not mentioned. The graph in Figure 
71 shows there appears to be no relationship between concentration and the 
inclusion in the cause of death. There is almost even split between cases included 
and not included within the cause of death. It should be noted that there were 
several pathologists working on these cases in three separate areas of the 
country, this is likely to lead to difference of opinion and they will all interpret the 
significance of diclazepam differently. There are different categories of deaths 
included within the graph and are not all considered drug deaths, some would be 
hangings for example. The lack of published literature in this subject adds to this 
issue. The six cases clustered together at the top of the chart within the red circle 
are detailed in Table 64. These six cases stand out as they are above the main 
cluster of cases and three have diclazepam implicated in the cause of death and 
three have not. Five out of the six cases are from the SFIU West region and one 
from the SFIU East region - five different pathologists worked on these cases so 
the final cause of death decision is not being skewed by one particular 
pathologists opinion for these six cases. The details of case 3 are discussed in 
section 7.3.1.4 of this chapter.  
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Table 64: Case details for the 6 cases with the highest diclazepam concentration 
over the 6-year period (2013-2018) investigated 
 Concentration (mg/L)  
Case  Diclazepam Delorazepam Lormetazepam 
Cause of 
Death 
Sex Age Other drug findings 
1 0.15 0.69 0.07 
1a - Heroin, 
gabapentin, 
diclazepam and 
methadone 
intoxication 
F 32 
Methadone, gabapentin, 
morphine, codeine, 6-
MAM in urine 
2 0.17 1.5 0.09 
1a - 
Diclazepam, 
codeine and 
gabapentin 
intoxication 
F 38 
Paracetamol, 
gabapentin, pregabalin, 
codeine, morphine 
3 0.211 0.23 0.041 
1a -Methadone, 
alcohol and 
diclazepam 
intoxication 
M 43 
Alcohol,methadone, 
mirtazapine,THC and 
metabolite, diazepam 
and metabolite 
See 7.3.1.4 
4 0.147 0.38 0.024 
1a - Heroin, 
methadone and 
benzodiazepine 
intoxication 
M 29 
Alcohol, DMD, 
morphine, codeine, 6-
MAM in blood and urine 
5 0.14 Present Present 
1a Multi-drug 
toxicity 
M 40 
Cocaine metabolite-
benzolyecogonine, 
mirtazapine, morphine, 
gabapentin and 
etizolam 
6 0.089 0.11 0.02 
1a Multi-drug 
toxicity 
M 26 
Low alcohol in blood, 
diazepam and 
metabolites, citalopram, 
paracetamol, THC and 
metabolite, morphine, 
codeine and 6-MAM in 
blood and urine 
 
All six cases are drug related and cases 4 to 6 may not specifically name 
diclazepam but they do acknowledge combined drug use as the mechanism 
leading to the death. 
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Figure 71: Diclazepam concentrations and role in cause of death 
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Each cause of death in this dataset was categorised into ten categories. The 
categories are shown in Table 65. The author was responsible for categorising these 
based on the words used in the cause of death. If a drug or intoxication was 
mentioned in any part of the cause of death then it was included in the drug 
related/intoxication category. If drugs and alcohol was mentioned this was counted as 
drug-related/intoxication and not ―alcohol related.‖ The alcohol related category was 
for when alcohol only was mentioned with no other substances. The death fell into the 
category of ―natural‖ when no intoxication was mentioned and no additional trauma 
was a factor. Examples of natural deaths included in this study‘s categories were 
epilepsy, cirrhosis of the liver with no mention of alcohol or other substances and 
cardiac causes of death. Natural death is often a complex category for pathologists 
and there can be inconsistencies in how different pathologists would report a death 
with a combination of trauma and natural disease. (Roberts, Gorodkin and Benbow, 
2000) Categories ―drowning‖ and ―immersion in water‖ are separate as immersion in 
water suggests there is no proof of drowning and death could have occurred due to 
another mechanism such as hypothermia. A system for categorising deaths where 
drugs are detected in the post-mortem blood was devised by Druid and Holmgren, 
this split the deaths into three groups designated as A, B and C. (Druid and 
Holmgren, 1997) Group A is a single drug intoxication death; this is not an expected 
scenario with benzodiazepines due to their relative safe nature when used alone. 
Group B is death by intoxication with one or more substances and/or alcohol and 
group C deaths are unrelated to the drug(s) detected within the post-mortem blood 
e.g. hanging. The categories in Table 65 are broken further down but mostly fall into 
group C.  
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Table 65: Cause of death categories used in this study 
Drug related/intoxication 
Natural 
Stab wounds 
Hanging /asphyxia 
Unascertained 
RTA (including pedestrian) 
Alcohol related 
Drowning 
Immersion in water 
Fire 
The vast majority of diclazepam positive cases fell into the drug-related/intoxication 
category (83%) when the cause of death was considered in this way or group B using 
the Druid and Holmgren system. Figure 72 displays the cause of death when spilt into 
the categories in Table 65. Heroin was named in the cause of death in 25% of 
diclazepam positive cases. There are six cases, which have been excluded from the 
cause of death data for the diclazepam cases, as the author was unable to confirm 
the official cause of death.  
The mechanism of death can be complex and multifaceted especially in drug users, 
this data does show that diclazepam is present in drug deaths but its significance is 
not entirely clear. The poly-drug use makes this difficult as well as the health issues 
drug users are at high risk of exposure to.  
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Figure 72: Cause of death categories for diclazepam positive cases over a 6-year 
period (2013-2018) 
 
7.3.1.4.  Case example 
The highest diclazepam post-mortem femoral blood concentration detected in this 
study was in the case of a 43-year-old man who had a hepatitis C infection as well as 
a history of substance abuse. He told his doctor that he used cannabis and diazepam 
every night before bed. At the time of his death he was prescribed methadone, 
mirtazapine, levothyroxine (used in the treatment of hypothyroidism), omeprazole 
(used to decrease stomach acid) and amitriptyline. He was found face down in his 
bed with decomposition changes particularly to his skin and eyes. A search of the 
area found cannabis, dihydrocodeine tablets along with ―street valium‖ consisting of 
over 100 blue tablets containing the marking ―NT ‖ and some yellow tablets with a 
―MSJ‖ marking. NTZ markings on blue tablets have been confirmed to contain 
etizolam in Scotland. (Scotland, 2016) However this may not represent what every 
blue ―NT ‖ tablet contains. The toxicological analysis revealed the following in the 
blood: 
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 Alcohol – 111 mg/100 mL 
 Methadone – 0.71 mg/L 
 Mirtazapine – 0.29 mg/L 
 Diclazepam – 0.211 mg/L 
 Delorazepam – 0.225 mg/L 
 Lormetazepam – 0.041 mg/L 
 Lorazepam – 0.01 mg/L 
 THC and metabolite present 
 Diazepam and desmethyldiazepam - <0.10 mg/L for both 
 
Mirtazapine is known to cause drowsiness, alcohol and use of benzodiazepines is not 
recommended when mirtazapine is prescribed due to the excessive sedation that 
may occur. (Hartmann, 1999) The pathologist concluded that the moderate alcohol 
concentration in combination with methadone and diclazepam led to dangerous 
sedation and respiratory depression causing this man‘s death. They noted that the 
low concentration of diazepam and metabolite may also have contributed to the 
sedative effect, but were unlikely to be a major contributory factor in causing death. 
The cause of death was given as: 1a: Methadone, alcohol and diclazepam 
intoxication.  
7.3.2. Flubromazepam results 
Flubromazepam was detected in 18 post-mortem cases over the six-year period 
included in this study. One positive was a case where only liver had been received 
and is therefore excluded from some results given. There were no flubromazepam 
positives detected in 2013 or 2018. Most flubromazepam positives were detected in 
2017 (n=8) followed by 2016 (n=7).  
7.3.2.1. Demographics 
There were 15 males and 3 females that gave positive flubromazepam positive 
results in post-mortem cases in the six years examined. The mean age of this group 
was 37-years old (range, 28-51 years old). The mean age for males was 39-years old 
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and 32-years old for females. The number of cases positive for flubromazepam in 
each age range is presented in Figure 73. 
 
Figure 73: The range of ages for males and females in flubromazepam positive cases 
over a 6-year period (2013-2018) 
 
7.3.2.2. Toxicological findings 
The mean and median concentration in the post-mortem femoral blood was 0.74 
mg/L and 0.66 mg/L for flubromazepam, respectively. Figure 74 shows the range of 
flubromazepam post-mortem blood concentrations detected; the graph shows that in 
most cases flubromazepam was above 0.20 mg/L. A more appropriate calibration 
range should be considered for the quantification of flubromazepam. A self-
administration study found that the peak serum concentration was 0.078 mg/L six 
hours after the ingestion of a 4 mg capsule by a 43-year-old male. (Moosmann et al., 
2013a) 
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Figure 74: The range of flubromazepam concentrations detected 
 
Pyrazolam was also detected in four of the flubromazepam positive post-mortem 
cases; diclazepam was detected in four cases and delorazepam was detected in 
seven cases. This demonstrates that the users of flubromazepam often took other 
designer benzodiazepines. The study by Høiseth et al collated concentrations in living 
offenders and they found 24 positive flubromazepam cases. These cases had a 
median blood concentration of 0.055 mg/L; the lowest concentration detected was 
0.0047 mg/L and the maximum was 1.2 mg/L. (Høiseth, Tuv and Karinen, 2016) The 
FTS post-mortem data gathered in this study shows four cases with concentrations 
higher than 1.0 mg/L, see Figure 74. Høiseth et al noted that a 37-year-old male who 
had a flubromazepam blood concentration of 0.60 mg/L with no other drugs detected 
was ―mildly impaired.‖ (Høiseth, Tuv and Karinen, 2016) An article published in 2018 
by Koch et al described a lethal case of U-47700 and flubromazepam intoxication. 
(Koch et al., 2018) U-47700 is a synthetic opioid and is considered an NPS. (Koch et 
al., 2018) A 24-year-old male was hospitalised after consuming both U-47700 and 
flubromazepam, his flubromazepam serum concentration was 0.83 mg/L 42 minutes 
after hospital admission, this fell to 0.28 mg/L in serum three days later. Six days after 
hospital admission the patient died after life support was removed. (Koch et al., 2018) 
Six cases in the FTS post-mortem flubromazepam positive dataset in this study were 
above 0.80 mg/L, see Figure 74. U-47700 alone could have possibly caused death 
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however the combination of these two drugs is very dangerous. As drug distribution 
can vary widely between blood and serum, concentrations in these sample types are 
not always comparable. (Launiainen and Ojanperä, 2014) 
There were three flubromazepam positive cases, that were also positive for 
flubromazolam, see section 1.5.1 in chapter 1 for the structural difference of these 
two compounds. The first case was from 2015 and was 33 year old male who had the 
following post-mortem blood concentrations: 
 Flubromazolam - 0.27 mg/L 
 Flubromazepam - 1.6 mg/L 
 Lorazepam - <0.005 mg/L 
 Delorazepam – 0.021 mg/L 
 Alcohol – 25 mg/100 mL 
The cause of death was given as 1a: Mixed benzodiazepine (flubromazepam, 
flubromazolam, delorazepam, lorazepam) and alcohol toxicity.  
A case from Poland published by Łukasik-Głębocka et al (Łukasik-Głębocka et al., 
2016) described a 27-year-old male who had a variety of serious symptoms including 
deep coma and acute respiratory failure. Analysis of his serum sample detected 
flubromazolam at a concentration of 0.059 mg/L, this serum sample was thought to 
have been drawn around 19 hours after a 3 mg dose. No other drugs were detected. 
The patient survived due to the medical intervention he received. (Łukasik-Głębocka 
et al., 2016) 
The other two FTS flubromazepam and flubromazolam-positive cases both had a 
concentration of <0.005 mg/L for both flubromazolam and flubromazepam in post-
mortem blood. One case was a 24-year-old female; the cause of death was 
concluded as 1a Amitriptyline and venlafaxine intoxication. The other case was a 44-
year-old male; the cause of death was concluded as 1a Ischaemic heart disease; 1b 
Cardiac enlargement and coronary artery atheroma. 
The concentrations documented in the articles by Koch et al (Koch et al., 2018) and 
Łukasik-Głębocka et al (Łukasik-Głębocka et al., 2016) suggest that the 
flubromazepam and flubromazolam concentrations found in the 2015 case described 
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in this study are particularly high, however this is a comparison of blood and serum 
concentrations, which as stated before cannot be reliably compared due to the widely 
varying distribution of drugs between sample types. Comparing ante-mortem and 
post-mortem concentrations also cannot be reliably compared due to factors such as 
post-mortem redistribution.  
7.3.2.3. Cause of death 
The cause of death attributed to the flubromazepam positive cases were investigated 
for this study. There were 7 cases in which flubromazepam was mentioned in the 
cause of death. The flubromazepam post-mortem blood concentrations and cause of 
deaths are shown in Table 66. These fall into group B using the Druid and Holmgren 
system.  
Table 66: Flubromazepam post-mortem femoral blood concentrations in cases where 
flubromazepam is mentioned in cause of death 
Flubromazepam 
(mg/L) 
Cause of death 
1.60 1a-Mixed Benzodiazepine (Flubromazepam, Flubromazolam, 
Delorazepam, Lorazepam) and Alcohol Toxicity 
 
1.30 1a-Dihydrocodeine, Flubromazepam, Pyrazolam and Hydrocodone toxicity 
 
2.30 1a-Methdone, flubromazepam and gabapentin intoxication 
 
0.85 1a-Heroin, morphine, etizolam and flubromazepam intoxication 
 
1.10 1a-Morphine and flubromazepam intoxication 
 
0.42 1a-Flubromazepam, alcohol intoxication and cocaine 
 
0.01 1a-Heroin, gabapentin, methadone, etizolam and flubromazepam 
intoxication; 
2- ischaemic heart disease with cardiac enlargement 
 
The cases where flubromazepam was included in the cause of death has a mean 
concentration of 1.08 mg/L and a median of 1.10 mg/L which is higher than the 
overall mean and median which was 0.74 mg/L and 0.66 mg/L respectively.  
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Table 67: Flubromazepam post-mortem femoral blood concentrations in cases where 
flubromazepam is not mentioned in cause of death 
Flubromazepam 
(mg/L) 
Cause of death 
0.80 
1a-Heroin and benzodiazepine toxicity 
 
0.69 
1a-Tramadol and venlafaxine intoxication 
 
0.663 
1a-Unascertained 
 
<0.005 
1a-Amitriptyline and venlafaxine intoxication 
 
0.46 
1a-Hanging 
 
<0.005 
1a-Ischaemic heart disease; 1b Cardiac enlargement and coronary 
artery atheroma 
 
0.013 
1a- Ischaemic heart disease and possible drug toxicity 
2-Fatty degeneration of the liver 
 
0.029 
1a-Dihydrocodeine, tramadol, morphine, gabapentin and 
benzodiazepine intoxication 
 
0.59 
1a-Methadone, morphine and benzodiazepine intoxication 
 
<0.005 
1a Drowning 
2a Alcohol and multi-drug toxicity 
2b Epilepsy 
 
Table 67 displays the flubromazepam-positive cases where flubromazepam was not 
included in the cause of death. The cases where flubromazepam was not included in 
the cause of death have a mean concentration of 0.59 mg/L and a median of 0.59 
mg/L which is lower than the overall mean and median of 0.74 mg/L and 0.66 mg/L 
respectively however this is a small dataset and there is no significant difference in 
the concentrations included in the cause of death compared to the concentrations not 
included (p-value=0.06).  
The same categories of death were applied to the post-mortem flubromazepam cases 
as detailed in 7.3.1.3. Figure 75 shows the categories of death of the flubromazepam 
positive cases. The vast majority of flubromazepam positive cases fell into the drug-
related/intoxication category (76%) (Group B using the Druid and Holmgren system) 
when the cause of death was considered in this way. There were only three 
flubromazepam positive cases that included heroin in the cause of death.  
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Figure 75: Cause of death categories for flubromazepam positive cases over a 6-year 
period (2013-2018) 
 
7.3.2.4. Case example 
The highest flubromazepam concentration detected in this study was in the case of a 
51-year-old man who had a history of schizophrenia, depression and drug abuse. He 
was known to use heroin and ―street valium.‖ He was prescribed methadone, 
sertraline and the antipsychotic drug pericyazine, at the time of his death. He was 
found slumped and unresponsive on his bed with post-mortem staining to his face. 
The previous night he was witnessed consuming around 30 ―street valium‖ tablets 
and 20 gabapentin tablets. The police search of the area found a small empty 
polythene bag, which they noted might have contained drugs. It is not known if any 
forensic testing was carried out on any residue from the polythene bag. The 
toxicological analysis detected the following in the post-mortem femoral blood: 
 Methadone - 1.3 mg/L 
 Sertraline - 0.27 mg/L 
 Gabapentin - 18 mg/L 
 Flubromazepam - 2.3 mg/L 
 Pyrazolam - <0.005 mg/L 
 Diazepam - <0.05 mg/L, Desmethyldiazepam – 0.07 mg/L 
Drug 
related/intoxic
ation, 13 
Natural, 2 
Hanging 
/asphyxia, 1 
Unascertained
, 1 
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The pathologist determined this case to be a drug-related death with the low 
concentrations of diazepam and metabolite and pyrazolam as well as the therapeutic 
concentration of the sertraline possibly having a cumulative effect with the high 
concentration of methadone, flubromazepam and moderate concentration of 
gabapentin. The cause of death was concluded as 1a: Methadone, flubromazepam 
and gabapentin intoxication. 
7.3.3. Pyrazolam results 
Pyrazolam was detected in 9 post-mortem femoral blood cases over the six-year 
period examined. Like flubromazepam there were no pyrazolam positives detected in 
2013 or 2018. Most pyrazolam positives were detected in 2016 (n=4) followed by 
2017 (n=3). According to anecdotal reports pyrazolam has low sedation effects and 
has a low recreational value in general. (Manchester et al., 2018) This may explain 
why there are a low number of positives in the post-mortem femoral blood, as it may 
be a less attractive drug to the Scottish drug users than other benzodiazepines.  
7.3.3.1. Demographics 
There were 7 males and 2 females, who were positive for pyrazolam in the six years 
examined. The mean age of this group was 28 years old (range, 20 to 51-years old).  
7.3.3.2. Toxicological findings 
The mean and median concentrations in the post-mortem blood were 0.209 mg/L and 
0.033 mg/L for pyrazolam, respectively. Figure 76 shows the range of pyrazolam 
concentrations detected; the graph shows how the pyrazolam concentration was 
below 0.050 mg/L in most cases. There is one case with a concentration of 1.1 mg/L, 
which has skewed the mean concentration, and therefore the median concentration is 
a more appropriate reflection of the concentrations found in this dataset. A self-
administration study found a peak serum concentration was 0.051 mg/L three hours 
after the ingestion of a two 0.5 mg tablets. (Moosmann et al., 2013b) The study by 
Høiseth et al. collated concentrations in living offenders and they found 1 positive 
pyrazolam case, which had a blood concentration of 0.074 mg/L. (Høiseth, Tuv and 
Karinen, 2016) An article published in 2018 noted that pyrazolam had been detected 
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in urine samples in 33 instances from 2012 to 2016 in individuals presenting as 
intoxicated to Swedish emergency departments, no concentration data was included 
in the article. (Bäckberg et al., 2019) 
 
 
Figure 76: The range of pyrazolam concentrations detected in post-mortem femoral 
blood samples over a 6-year period (2013-2018) 
 
Flubromazepam was also detected in six of the pyrazolam positive post-mortem 
cases; diclazepam was detected in one case. 
7.3.3.3. Cause of death 
The causes of death attributed to the pyrazolam-positive cases were investigated for 
this study. There were 3 cases in which pyrazolam was mentioned in the cause of 
death. The pyrazolam post-mortem blood concentrations and causes of death are 
shown in Table 68. 
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Table 68: Pyrazolam post-mortem femoral blood concentrations in cases where 
pyrazolam is mentioned in cause of death 
Pyrazolam 
(mg/L) 
Cause of death 
0.070 
1a-Ethylphenidate, methoxphenidine, morphine, pyrazolam and etizolam 
intoxication 
 
1.100 
1a-Dihydrocodeine, Flubromazepam, Pyrazolam and Hydrocodone toxicity 
 
0.012 
1a-Heroin, gabapentin, etizolam, pyrazolam, flubromazolam intoxication 
 
 
The cases where pyrazolam is included in the cause of death has a mean 
concentration of 0.39 mg/L and a median of 0.070 mg/L which is higher than the 
overall mean and median which were 0.209 mg/L and 0.033 mg/L, respectively.  
Table 69: Pyrazolam post-mortem femoral blood concentrations in cases where 
pyrazolam is not mentioned in cause of death 
Pyrazolam 
(mg/L) 
Cause of death 
0.028 
1a-Heroin and methadone intoxication 
 
0.037 
1a-Morphine and alcohol intoxication 
 
<0.005 
1a-Ischaemic heart disease 
1b-Cardiac enlargement and coronary artery atheroma 
 
0.008 
1a-Multi-drug toxicity 
2-Anomalous origin of the coronary arteries 
 
<0.005 
1a-Methdone, flubromazepam and gabapentin intoxication 
 
<0.005 
1a-Heroin, morphine, etizolam and flubromazepam intoxication 
 
 
Table 69 displays the pyrazolam-positive cases where pyrazolam was not included in 
the cause of death. The cases where pyrazolam was not included in the cause of 
death have a mean concentration of 0.028 mg/L and a median of 0.028mg/L, which is 
lower than the overall mean, and median that were 0.209 mg/L and 0.033 mg/L, 
respectively. This is a very small dataset that is skewed by the 1.1 mg/L result. There 
was no significant difference found in the concentrations included in the cause of 
death compared to the concentrations not included (p-value =0.39).  
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The same categories of death were applied to the post-mortem pyrazolam cases as 
detailed in section 7.3.1.3 Every case except one of the pyrazolam-positive cases fell 
into the drug-related/intoxication category (89%) (Group B using the Druid and 
Holmgren system) when the cause of death was considered in this way. There were 
three pyrazolam positive cases that included heroin in the cause of death.  
 
7.3.3.4. Case example 
This case was a 30-year-old male who was found slumped on his bed in a state of 
advanced decomposition. He had a syringe in his leg and a bag of citric acid in his 
hand. He was not prescribed any medication at the time of his death but had 
previously admitted addiction to heroin, ―street diazepam‖, alcohol and ecstasy to his 
doctor. A search of the area found uncapped needles, burnt spoons, brown powder, 
burnt foil and empty ―legal high‖ packets. The packets appeared to be pyrazolam, as 
well as deschloroetizolam and clonazolam. The toxicological analysis revealed the 
following in the post-mortem femoral blood: 
 Alcohol – 155 mg/100 mL 
 Morphine – 0.21 mg/L 
 Pyrazolam – 0.037 mg/L 
Chest blood was also submitted and was positive for morphine, codeine and 
pyrazolam. Deschloroetizolam and clonazolam were included in the analysis, and 
were found to be negative in both chest and femoral blood.   
The pathologist in this case did not include pyrazolam in the cause of death, which 
was concluded as 1a: Morphine and alcohol intoxication.   
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7.3.4. Other benzodiazepines in post-mortem samples 
7.3.4.1. Etizolam 
The most prevalent designer benzodiazepine in the post-mortem cases submitted to 
FTS is etizolam; from October 2013 to December 2017 it was detected in 993 cases 
(7.3%). Etizolam in post-mortem cases will not be explored any further in this study. 
7.3.4.2. Alprazolam 
There have been 232 alprazolam-positive cases from 2016 to 2018 in the post-
mortem cases submitted to FTS. The mean age in these cases was 39 years with 
77% of cases being male (n=178) and 23% female (n=54). During this time period, 
not every case submitted to FTS was analysed for alprazolam. The inclusion of 
alprazolam is dependent on the case circumstances, for example if it is mentioned in 
the police death report. Alprazolam may also be picked up within another analysis, 
such as an interfering peak with a different benzodiazepine method or a library 
spectrum match within the basic drug GC-MS analysis. Therefore true prevalence 
cannot be fully determined from this data.  
Figure 78 shows the number of cases where alprazolam was detected in post-mortem 
blood from 2013 to 2018. 
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Figure 77:Alprazolam positive cases in FTS post-mortem casework 
 
Figure 77 shows an increase in alprazolam in post-mortem cases over the last three 
years, which is in contrast to diclazepam, which has decreased since 2016.  
The mean concentration of alprazolam in this dataset was 0.179 mg/L. A Swedish 
study published in 2013 compared the alprazolam concentrations found in post-
mortem samples with those found in impaired drivers. (Jones and Holmgren, 2013) 
They discovered the mean concentration detected in deaths attributed to drug 
intoxication was 0.10 mg/L with the range 0.02 - 1.6 mg/L. The mean concentration in 
other causes of death was 0.08 mg/L with the range 0.02 - 0.9 mg/L. Interestingly the 
concentrations in blood from impaired drivers were very similar to those found in the 
post-mortem samples. The mean concentration in impaired drivers was 0.08 mg/L 
with the range 0.02 - 3.9 mg/L. (Jones, Mogali and Comer, 2012) This may be 
explained by users developing tolerance which commonly occurs with 
benzodiazepine use, this in turn results in increased dosage. (Ashton, 2005) 
Tolerance is thought to occur when the GABA receptor becomes desensitised to the 
repeated use of benzodiazepines leading to dependence. Severe withdrawal 
symptoms occur when a dependent user reduces their dose or stops taking 
benzodiazepines.  
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7.3.4.3. Designer benzodiazepines in 2019 post-mortem samples 
In the first eight months of 2019 there were 25 delorazepam positive cases, 14 of 
which have also tested positive for diclazepam and 8 for lormetazepam. It appears 
that diclazepam is steadily becoming less prevalent in post-mortem samples in 
Scotland; this could be due to lack of availability as a consequence of the 
Psychoactive Substances Act 2016 and the availability or preference for other drugs 
such as etizolam. The typical concentrations found in the 2019 positive samples have 
remained consistent with those of the previous six years. Table 70 displays the mean 
and median concentrations for the 2019 cases.  
Table 70: Diclazepam and metabolites mean and median post-mortem femoral blood 
concentrations in 2019 post-mortem cases 
 Diclazepam Delorazepam Lormetazepam 
Mean concentration (mg/L) 0.026 0.106 0.015 
Median concentration (mg/L) 0.017 0.028 0.006 
 
One positive case of flubromazolam was detected in 2019 however the deceased 
was found heavily decomposed at the start of the year so the drug could have been 
ingested at the end of 2018. This case was a 34-year-old male who had a history of 
drug abuse. As the blood sample provided was central blood the concentrations of 
drugs found were not interpreted. Central blood tends to give inaccurate, usually 
elevated concentrations of drugs due to post-mortem redistribution. (Pounder and 
Jones, 1990) Morphine and codeine were detected in the central blood in addition to 
cyproheptadine, which is an antihistamine. The EMCCDA received a report from 
Ireland suggesting that cyproheptadine may be in fake Xanax tablets (alprazolam). 
(European Monitoring Centre for Drug and Drug Addiction, European Database on 
New Drugs.) The urine sample in this case was positive for 6-monoacetylmorphine 
and alcohol.  
7.4. Conclusion 
This study gives some idea of the typical concentrations seen in the post-mortem 
blood of users of flubromazepam, pyrazolam and diclazepam in particular. This study 
has shown that designer benzodiazepines are present in drug related deaths and are 
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found in combination with other drugs. Due to poly-drug use it is difficult to assess the 
significance of designer benzodiazepines in an individuals‘ death, but it is very likely it 
has a cumulative effect when combined with other CNS depressants. Over the six-
year period examined, diclazepam suddenly became a very popular drug in the drug-
using population in Scotland (especially in 2016), but is now steadily in decline and is 
being replaced with the likes of alprazolam. Flubromazepam, pyrazolam and 
flubromazolam had a small part to play in the designer benzodiazepine using 
population but never reached the popularity of etizolam and diclazepam.  
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8. Conclusions 
The abuse of benzodiazepines has been a problem in Scotland for decades. The 
introduction of designer benzodiazepines from 2010 onwards exacerbated this; it led 
to issues such as how these newly abused drugs contribute to a drug related cause of 
death, how treatment services deal with the users and users being unaware of what 
benzodiazepines they are taking. This is especially dangerous as benzodiazepine 
users often take ―supratherapeutic‖ doses. This work investigated the use of designer 
benzodiazepines as well as traditional prescription benzodiazepines in sub-
populations in Scotland. 
This work has shown the Immunalysis® Benzodiazepine ELISA kit can positively 
identify phenazepam, etizolam, diclazepam, delorazepam, pyrazolam and 
flubromazepam in blood. This is vital to know for a routine forensic toxicology 
laboratory as it can reduce the number of samples required for confirmation and 
quantitation. Positive samples are therefore not likely to be missed at the screening 
step but there is a lack specificity to help analyse what particular benzodiazepine(s) is 
present. PM samples are often decomposed which may have a deleterious effect on 
drug detection. 
A quantitative LC-MS/MS, SPE method for the detection of diclazepam and two of its 
metabolites (delorazepam and lormetazepam) plus flubromazepam and pyrazolam 
was validated. The method was fit for purpose. The concentration range (0.005-0.20 
mg/L) selected for these drugs in blood gave acceptable linearity. The method is 
specific and selective and demonstrated no carryover at the concentrations tested. 
Bias and precision were acceptable. Matrix effects were found to be acceptable for all 
analytes and within the ±25% criterion for %ME and <15% for precision. Recovery 
and process efficiency was suitable for diclazepam and delorazepam, it was 
suboptimal for lormetazepam, pyrazolam and flubromazepam however the LOD of 2 
ng/mL was sufficient for these analytes. All analytes were stable in the autosampler 
up to 48 hours at 16-24 °C. 
 A qualitative LC-MS/MS, LLE method to detect 22 benzodiazepines compounds in 
urine was developed and validated. This method was fit for purpose, it had a limit of 
detection range of 2 ng/mL - 6 ng/mL, an acceptable range of matrix effects and 
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recovery was acceptable with the exception of pyrazolam recovery. The method is 
specific and demonstrated no carryover at the concentration tested. All analytes were 
stable in the autosampler up to 36 hours at 16-24 °C.  
The quantitative LC-MS/MS, SPE method was used to analyse 1691 post-mortem 
blood samples over a six-year period. There was a total of 369 cases positive for 
designer benzodiazepines in blood (22% overall), 354 of these were diclazepam 
positive (21% overall).  
The 369 total positive cases also included 18 flubromazepam positive cases (1% of 
all cases analysed), 7 of which were also diclazepam positive cases and 4 were 
positive for pyrazolam.  
The 369 total positive cases also included 9 pyrazolam positive cases (0.5% of all 
cases analysed), 1 of which was also diclazepam positive.  
This study also provided information on the typical concentrations seen in the post-
mortem femoral blood of users of flubromazepam, pyrazolam and diclazepam.  
Diclazepam was detected in 212 cases and gave a median concentration of 0.017 
mg/L (n=157, 0.005 – 0.211 mg/L). Delorazepam was detected in 339 cases and 
gave a median concentration of 0.043 mg/L (n=311, 0.005 – 1.50 mg/L). 
Lormetazepam was detected in 144 cases and gave a median concentration of 0.010 
mg/L (n=85, 0.005 – 0.18 mg/L).  
The findings in this study answered a gap in the knowledge regarding post-mortem 
blood concentrations of diclazepam and two of its metabolites. It showed that 
delorazepam was detected at higher blood concentrations than diclazepam and 
lormetazepam, and gave the longest window of detection in post-mortem femoral 
blood. This study has shown that these analytes are present in drug related deaths 
and are found in combination with other drugs. Due to poly-drug use it is difficult to 
assess the significance of designer benzodiazepines in an individuals‘ death, but it is 
very likely it has a cumulative effect when combined with other CNS depressants. 
This data can be utilised as a reference for toxicologists and pathologists when 
interpreting the presence of these drugs and their metabolites in post-mortem cases. 
It is most probably due to the lack of knowledge of these drugs that this study found 
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there was no relationship between the drug concentration and the inclusion in the 
cause of death. Different pathologists assigning the cause of death over the caseload 
also adds to inconsistencies. This dataset found there were more males positive for 
diclazepam in post-mortem cases than females and the mean age found in this study 
remains consistent for the cases from 2014 to 2018, (range, 18-75 years old). The 
mean age for males was 40-years old and 41-years old for females. This is in-line 
with the drug-related death statistics, most DRDs in Scotland are individuals between 
25-44 years old and 75% are male. The diclazepam dataset displayed an increasing 
trend in popularity, which reached its peak in 2016; the PSA ended the high street 
and online availability and while diclazepam did not disappear its‘ presence in PM 
cases declined from 2016.  
Flubromazepam and pyrazolam were also detected in PM cases and the blood 
concentrations will also provide a good resource in aiding toxicological interpretation, 
however they were detected on a much smaller scale than diclazepam. 
Flubromazepam was detected in 18 cases and gave a median concentration of 0.66 
mg/L (n=15, 0.01 – 2.30 mg/L). Pyrazolam was detected in 9 cases and gave a 
median concentration of 0.033 mg/L (n=6, 0.008 – 1.10 mg/L). The flubromazepam 
blood concentrations were much higher than diclazepam and perhaps a more 
appropriate calibration range should be applied to their analysis. The demographics 
for these two drugs are also in agreement with the drug-related death statistics. The 
concentrations of flubromazepam are higher than most of the concentrations reported 
in the literature, however there is not a great deal of studies in which to compare. It 
may be the case that the high doses (‗supratherapeutic‖) that Scottish 
benzodiazepine users are reported to take accounts for this. Pyrazolam was only 
detected in 9 post-mortem cases over the six-year period examined suggesting it is 
not a popular drug of abuse in Scotland. One explanation for this is that pyrazolam is 
anecdotally reported to have low recreational value and low sedation making it an 
unlikely choice amongst Scottish drug users.  
The secondary aim of this research was to determine if individuals from high-risk 
populations are using benzodiazepines. These cohorts provided unpreserved urine 
samples for analysis and were tested for 22 analytes to provide a more 
comprehensive result. The qualitative LC-MS/MS, LLE urine method was used to 
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analyse 73 individuals under a DTTO from the Scottish Drug Court, 95 patients 
receiving forensic psychiatry treatment from the NHS GGC FD and 725 samples from 
individuals being admitted or liberated from SPS facilities. The SDC and FD cohorts 
were found to be largely compliant with the conditions imposed upon them, concerns 
that their testing method was not detecting designer benzodiazepines could not be 
fully answered as no designer benzodiazepines other than 3 instances of diclazepam 
metabolites and 1 instance of etizolam and metizolam in the SDC cohort were found. 
These four samples were also positive for diazepam metabolites so would have 
tested positive in the SDC screen. This study found that diazepam was being 
commonly used in the SDC. The forensic psychiatry results showed a population who 
did not appear to be using benzodiazepines.  
The third urine sample population evaluated was the SPS samples. The SPS study 
showed the majority (59%) of participants were negative for all benzodiazepines 
tested. Diazepam and/or its metabolites (n=281) were the most commonly detected 
followed by diclazepam and/or its metabolites (n=59) then etizolam (n=22), 3-
hydroxyphenazepam (n=21), metizolam (n=7), phenazepam (n=6) then pyrazolam 
(n=1) and flubromazepam (n=1). HMP Barlinnie had the highest number of 
diclazepam metabolite positives - 21% of admission samples. Other designer 
benzodiazepines did not have a high presence overall, at 3% for etizolam, the second 
most common designer benzodiazepine after diclazepam. The vast majority (73%) of 
positive SPS samples for designer benzodiazepines showed use of one 
benzodiazepine drug. Admission SPS samples were more likely to be positive than 
liberation samples suggesting there is general abstinence of benzodiazepine use 
while in prison however the participation in this study was voluntary and this can skew 
the results. Despite this, this SPS study detected more positive samples than prison 
APT scheme that tested more samples overall. This emphasises why confirmation 
techniques are required and that a screening method should not be relied upon to 
provide an accurate assessment.  
This research contains limitations and cannot be thought of as true prevalence 
studies as consent was required for the urine samples to be tested and the SDC and 
NHS GGC FD patients were aware of their test date. Therefore they could have 
 
 
198 
abstained from drug use prior to sampling. The SPS samples provide a snapshot but 
are not indicative of the general static inmate population.  
Benzodiazepine urine analysis interpretation can be particularly complex, many 
metabolise to other benzodiazepines that are also parent drugs. In some instances 
the source of the analyte detected is not known, as there may be a number of 
possibilities. A particular challenge in this study was the source of 3-
hydroxyphenazepam and metizolam especially since there is a lack of literature 
pertaining to both of their metabolism. There is sufficient evidence to argue that it is 
likely the 3-hydroxyphenazepam detected in the SPS samples is from phenazepam 
metabolism and not 3-hydroxyphenazepam consumption as the samples were 
collected before 3-hydroxyphenazepam had been reported as a designer 
benzodiazepine to the EMCDDA. Metizolam was reported in 2015 to the EMCDDA, 
the same year as the SPS study and after most of the SDC were collected. The 
source of the metizolam in some urine samples is unknown however metabolism from 
etizolam and in-source degradation from etizolam was ruled out. The absence of 
some metabolites, in particular alpha-hydroxyetizolam, was a limitation for the urine 
method used. However, the metabolism of most designer benzodiazepines is not well 
documented in the literature due to their novelty. For this same reason commercially 
available certified reference standards were not readily available at the time of the 
urine method development. Inclusion of diazepam and diclazepam metabolites within 
the method took priority over the less popular designer benzodiazepines.  
Overall this research provides valuable information on the scale of benzodiazepine 
use in different populations, how popular a drug is and how this trend changes, as 
well as the typical designer benzodiazepine blood concentrations found in post-
mortem cases which will ultimately aid the forensic toxicologists and forensic 
pathologists when interpreting concentrations found in their cases. 
  
 
 
199 
9. Further work 
The ever-changing drug market means that routine analytical methods should be 
frequently reviewed and new compounds added for monitoring as required. This 
study has shown that users, inadvertently or not, have moved towards other 
benzodiazepines such as alprazolam when it was previously not being abused in 
Scotland. The dynamic nature of the drug market is a challenge for a laboratory to 
keep up to date and this can be practically difficult, utilising a screening method for a 
number of compounds makes this task slightly easier and negates the need to 
frequently quantitatively revalidate. 
The methods detailed in this work could be improved upon; the addition of 
metabolites when they became available from reference standard suppliers would be 
beneficial and would give a wider time frame of detection. The addition of alpha-
hydroxyetizolam to the urine method would be the most significant initial change and 
would likely identify some past use previously missed. The extraction methods could 
also be optimised or further developed in order to improve recovery. Pyrazolam in 
particular would benefit from a stability investigation and the use of acetonitrile in the 
solutions might improve the recovery. A thorough investigation into the presence of 
metizolam to determine its source within the positive samples should be carried out; 
the further monitoring of etizolam positives in urine samples and the ratios in which 
these are found may provide evidence of metizolam being produced from etizolam 
synthesis rather than metizolam consumption. The lack of information regarding 
metizolams metabolism hinders this as well as being unable to source the metabolites 
as a certified reference material.  
Extending the cohorts to include work place testing or other patients under different 
forms of treatment would give additional valuable information on the scale of use. 
This could also reveal more trend information and chart any peaks and troughs in 
popularity. Testing every post-mortem case even as a screen would also give more 
complete data in terms of prevalence. This could then be confirmed quantitatively to 
add to the post-mortem blood typical concentration data. An investigation into the 
presence of lorazepam and its concentrations in blood for diclazepam positive cases 
should be carried out and would further add to the post-mortem data. In addition, 
repeating the projects with the same cohorts such as with the SPS or Scottish Drug 
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Court would be very interesting as it would give a direct comparison and could 
demonstrate if there has been a change in benzodiazepine drug trends.  
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